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Activin A is a member of the TGF-β superfamily, a family of structurally related growth factors that 
have been implicated in embryogenesis, homeostasis, and cancer. All members consist of pro- and 
mature domains which are post translationally cleaved. Upon signalling the pro-domain dissociates 
from the mature growth factor. Signalling in this family requires a type I and a type II receptor. Though 
there are over thirty growth factors, there are only seven type I and five type II receptors resulting in 
promiscuity between ligands and receptors. In order to fully elucidate the roles of these proteins and 
develop therapeutics, specific inhibitors must be generated. 
In this thesis, I targeted activin A to achieve specificity. I first targeted mature activin A through the 
use of XChem, conducting a fragment screen against mature activin A crystals. I describe the 
identification of twelve fragment hits that bind in the putative type I receptor binding site and the 
validation and optimisation of one of these fragments. 
I then used the structure of the pro-mature complex of activin A to design and generate a series of 
GB1- fused peptides based on the α1-helix-loop-α2-helix motif of the pro-domain. I determined the 
α1-helix-loop epitope to be key for interactions with the mature domain, before investigating the 
effect of truncation and mutation on this epitope. I then determined the potency of the fusion GB1-
H1LH2 as an inhibitor of activin A signalling (IC50 = 4.4 μM). I further optimised GB1-H1LH2 through 
dimerization resulting in a large increase in inhibitor potency (IC50 = 71.5 nM). Lastly, I screened this 
dimeric inhibitor against several TGF-β family members to determine it specifically inhibits both activin 
A and activin B. 
To conclude, I discuss the findings of this thesis before considering how this methodology could be 
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1.1 Cell Signalling 
The term “cell signalling” can be defined as the transmission of information either within or between 
cells. It is often initiated by a stimulus (the information), either internal or external to the cell, and 
results in a biological response. The process in which the information is transmitted, from detection 
of the stimulus to the response, is through a series of mechanical or biomolecular events that include 
interactions between proteins, enzymatic processing of substrate, chemical modification of a 
biomolecule, or interactions between proteins and DNA. Cell signalling can be categorised into five 
broad categories: intracrine, juxtracrine, autocrine, paracrine, and endocrine.  
Intracrine refers to signalling that is initiated in and remains within a single cell. Initiation is commonly 
caused by one of the other categories of signalling through modulation of membrane receptors or 
concentration changes of molecules of interest in the cell. Conversely, juxtracrine signalling occurs 
between two immediately proximal cells and often requires direct contact between cell surface 
proteins/ glycosides or the use of cell junctions. Autocrine, paracrine and endocrine signalling all 
require secretion of a signalling molecule that then induces signalling either in the cell from which it 
was secreted (autocrine); a cell in the local environment of the secreting cell (paracrine); or a cell 
distant to the site of secretion, using  the circulatory system to travel there (endocrine). As cellular 
signalling directs and determines all aspects of a living system, the interplay between these signalling 
methods is thus responsible for underpinning the complexity of life.  
Cell growth, proliferation, differentiation and apoptosis are four important biological responses that 
are controlled by cell signalling. Misregulation of these responses in metazoans is the classical 
phenotype of cancer, thus making tight regulation vital. Growth factors are a group of signalling 
molecules that regulate these four processes. They can be cytokines or hormones and are usually 
secreted from the cell, acting in autocrine, paracrine, or endocrine manner. Important families include 
the fibroblast growth factor (FGF) family, the epidermal growth factor (EGF) family, the vascular 
endothelial growth factor (VEGF) family ,and the transforming growth factor beta (TGF-β) family. In 
this thesis, I will be looking at the TGF-β family, specifically focussing on one of its members – activin 
A. 
1.2 The TGF-β Superfamily and Activin A 
The TGF-β superfamily is a family of extracellular growth factors that play vital roles in an organism’s 
development and homeostasis, especially in embryogenesis, growth, and repair mechanisms.1 Highly 
conserved across metazoans,2 mature TGF-β growth factors can signal in both autocrine and paracrine 
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manners, through the formation of heteromeric complexes with TGF-β family receptors on the cell 
surface. Formation of the growth factor-receptor complex then triggers a phosphorylation cascade 
that can produce a diverse range of cellular responses. In humans over 30 members of the family have 
been identified, including the eponymous proteins, bone morphogenic proteins (BMPs), growth 
differentiation factors (GDFs), anti-müllerian hormone, nodal, and the activins.3 These proteins all 
have high structural and sequence similarity with the majority being disulfide linked dimers and 
consisting of an “active” signalling mature domain and an “inactive” pro-domain (mature domain 
pairwise identity >30% across the whole family).4 These domains are post translationally cleaved but 
with the majority of growth factors, remain in association until signalling where the pro-domain 
dissociates allowing the mature domain to interact with cell surface receptors. In contrast to the 
number of growth factors there are only 12 identified TGF-β receptors in humans – seven type I and 
five type II.5 Signalling requires formation of a heteromeric ligand-type I-type II complex and thus this 
results in high ligand promiscuity with multiple growth factors signalling through the same receptors 
(sometimes in different combinations) but inducing different cellular responses. 
One well studied member of the superfamily is activin A. Originally isolated by Vale et al. in 1986 from 
porcine ovarian follicular fluid, it was initially identified as having the direct opposite effect to related 
protein inhibin A, stimulating the secretion of follicle stimulating hormone (FSH) from culture anterior 
pituitary cells.6 Homologues were subsequently identified in several species, including humans. Since 
then activin A signalling has since been found to have a variety of biological functions, including in 
muscle homeostasis, inflammation and wound healing as well as being implicated in several forms of 
cancer and in the disease Fibrodysplasia Ossificans Progressiva (FOP).7–10 Activin A is a homodimer of 
inhibin-βA subunits that has many typical of features of the TGF-β family. Due to its role in disease and 
its effects on cell differentiation, specific inhibition of activin is desirable. However,  this has often 
been difficult to achieve due to the high structural and sequence similarity with other TGF- β 
superfamily members and the ligand promiscuity of the receptors. In this thesis I will be looking at 
ways in which to generate specific inhibitors of activin A signalling. 
1.3 The Cellular Signalling of the TGF-β Superfamily 
Activin A has been implicated in a diverse range of physiological and pathological processes. Before 
looking at these processes however, the signalling of activin A must be understood. Being a member 
of the TGF-β superfamily, activin A signalling shares many features with that of the signalling of other 
family members. Therefore, I will first look at the wider signalling pathway of the TGF-β family as a 
whole, focussing on each component in detail. 
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1.3.1 The Canonical TGF-β Signalling Pathway 
Unlike the FGF, EGF, and VEGF families, the TGF-βs do not primarily signal through a receptor tyrosine 
kinase pathway, but rather have their own unique serine / threonine receptor kinase pathway.1,11,12 
The canonical mechanism for TGF-β family signalling is through a phosphorylation cascade that 
activates Smad proteins and causes them to induce transcription. In total, four receptors are required 
for signalling to occur, two type I receptors and two type IIs. In the basal state it is not known if these 
receptors exist alone or as pre-formed complexes, however FKBP12 binds to the type I receptor, 
inactivating its kinase domain preventing signalling from occurring.13 An external stimulus causes 
dissociation of the pro-domains from a TGF- β pro-mature complex. The mature TGF-β ligand can then 
form heteromeric complex with the extracellular domains of two type I and two type II receptors. 
Formation of this complex causes FKBP12 to dissociate from the receptor, which in turn leads to the 
constitutively active kinase domain of the type II receptors to phosphorylate the glycine / serine rich 
(GS) region of the type I receptors. This activates the kinase domain of the type I receptors which then 
recruits regulatory-Smad proteins (R-Smads) and phosphorylates them. Two phosphorylated R-Smads 
then typically hetero-oligomerize with Smad4 before translocating to the nucleus, where the complex 
interacts with other transcription factors and DNA. This triggers transcription and causes a cellular 




Figure 1: The cellular signalling of activin A. The canonical mechanism of TGF-β family signalling shown here 
using activin A as the example. Thus, the type I, type II receptors and R-Smads shown are ALK4, ActRIIA/B, and 
Smad2/3 respectively. 
1.3.2 The TGF-β Receptors 
All TGF-β ligands signal through the formation of a heteromeric complex consisting of two 
autonomous pairs with two type I and two type II receptors.14–16 In total there are only seven type I 
receptors (ALK1-7) and five type II (ActRIIA, ActRIIB, TGFβRII, BMPR2, and AMHR2) meaning multiple 
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ligands share the same receptors and receptor combinations. Within the TGF-β family there are two 
broad subgroups into which the receptors and ligands can be divided based on receptor ligand 
interactions and their subsequent downstream SMAD phosphorylation cascades – one containing 
ActRIIA/B and ALK4/5/7 activated by the activins, GDFs 8 and 11, and nodal and the other containing 
BMPRII and ALK1/2/3/6 activated by the BMPs and the other GDFs.3,5 Though this rule holds true in 
the majority of cases there are numerous exceptions. Both BMP2 and BMP4 signal through BMPRII 
and ActRIIA/B, and activin A has been observed to signal through ALK2 in FOP.10,17 Unlike most other 
members of the family, TGF-β1/2/3 only signal through the type II receptor TGFβRII. However this can 
result in the formation of signalling complexes with either ALK1 and ALK5 resulting in two different 
Smad phosphorylation pathways and mixed Smad complexes.18 Additionally, AMH signals through a 
unique type II receptor – AMHRII. It is thought in this case that the type I receptor can be ALK2/3/6 as 
interactions are observed between AMH and all type Is.19,20 AMH only signals through the same Smad 
pathway as the BMPs. 
The type I and type II receptors have the same general features, consisting of an extracellular domain, 
transmembrane helix, and intracellular kinase domain. Type I receptors also have an additional GS 
region which is phosphorylated by the type II receptors during signalling. One of the key regulators of 
this phosphorylation is FKBP12. FKBP12 inhibits type I receptor in the basal state. It binds proximal to 
the GS region, causing a section of the GS region to disrupt the kinase domain resulting in an inactive 
conformation being adopted.21 FKBP12 does not prevent association of type II receptors to the type II 
receptors however it does prevent phosphorylation of the type I receptors by the type II, suggesting 
it has a role in preventing signalling in the absence of ligand.13 It is unclear exactly how FKBP12 
dissociates from the type I receptor however it is likely to come from the formation of the ligand – 
type I – type II receptor complex. Dissociation of FKBP12 allows for phosphorylation of the GS region 
of the type I receptor by the type II receptor, activating the type I receptor kinase domain and thus 
leading to signalling. 
Regulation of the kinase activity of the type II receptor is governed by the phosphorylation state of 
several key residues in the cytoplasmic region of the protein. Phosphorylation has been shown to be 
required on serine residue S213 and S409 for signalling to occur, with phosphorylation of S213 
occurring through intramolecular autophosphorylation whereas as phosphorylation of S409 can occur 
through both inter and intra molecular autophosphorylation and is enhanced by receptor 
dimerization. In addition to the two serine residues, phosphorylation of three tyrosine residues (Y259, 
Y336, and Y424) has been shown to be vital, with their loss resulting in a reduction in signalling.22 By 
contrast the autophosphorylation of residue S416 results in inhibition of signalling, with Luo et al. 
showing mutation to alanine results in a hyperactive receptor. A given receptor may be 
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phosphorylated on either S409 or S416 but not both allowing for the dynamic regulation of receptor 
activity and thus signalling.23  
Two modes of ligand binding exist, with the mechanism being determined by the growth factors 
affinity for a specific receptor. The first is a cooperative mechanism where the growth factor binds the 
type II receptors creating a binding interface to which the type I can bind. In this mechanism, direct 
contacts are formed between the extracellular domain of the type I receptor and the extracellular 
domain of the type II receptor plus the growth factor, thus binding of the growth factor to the type I 
receptor is significantly stronger in the presence of the type II. As such, ligands that use this mechanism 
have a high affinity for the type II receptor and a low affinity for the type I. This is characteristic of the 
eponymous TGF-βs.24,25 In the second mechanism, the growth factor binds to the type I and type II 
receptors in independent events, and the extracellular domains do not form direct contacts with each 
other.26,27 This is typical of the BMPs which unlike the TGF-βs usually have the type I receptors as their 
high affinity receptors.28,29 It has been suggested that this second method is due to the existence of 
pre-formed homodimeric receptor complexes of BMP receptors on the cell surface resulting in an 
increased affinity due to an avidity effect.88,91 The complexation of the receptors at the cell surface 
has important implications for signalling. In the case of the TGF-β family there are two possible modes 
of receptor assembly – either they exist as pre-formed complexes at the cell surface or they form 
complexes in the presence of ligand. There is currently conflicting evidence as to which of these 
mechanisms is the case with a number of studies observing different results for the same receptors. 
For the TGF-β receptors ALK5 and TβRII, Gilboa et al. observed  both form homodimeric complexes in 
the endoplasmic reticulum and that these homodimers were preserved at the cell surface.30 However, 
this was not the case with ALK5–TβRII complexes which were only detected at low levels.31 In the case 
of the BMP receptors, it has been observed that preformed heterodimeric and homodimeric receptor 
complexes exist on the surface of the cell and both these complexes are significantly enhanced in the 
presence of ligand.32 One thing important to note is that these studies used overexpression of the 
receptors in question. In contrast Zhang et al. used fluorescence microscopy to observe that at low 
expression levels, TβRII exists as monomers in the cell membrane, only dimerising upon the addition 
of ligand.33 The same group also observed the similar results when looking at ALK5.34 A fluorescence 
based method was also used to observe that TβRII was trafficked to the cell surface as a monomer.35 
This conflicting evidence for receptor assembly may be due to the differing techniques but also the 
cell lines used. Different cell lines are known to have differing levels of receptors.36 In these studies, 
with Gilboa et al. using L6 and COS7 cells and Zhang et al. using HeLa and MCF7 cells. Therefore, it 
may be the case that the existence of pre-formed complexes depends on cellular expression and thus 
the cell line. 
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Receptor promiscuity is well described in the TGF-β family.37 As there are only seven type I and five 
type II receptors, it follows that multiple different ligands must be able to signal through the same 
receptors and even receptor combinations. There are a number of mechanisms that exist by which 
cells can direct signalling. These include differences in ligand affinities, such that certain ligand 
receptor complexes are only formed at high concentrations of the ligand; differences in ligand 
processing, such that mature ligands are only available for signalling under certain conditions; and the 
involvement of co-receptors either in an agonistic or antagonistic manner.38–41 In addition, cells can 
direct signalling through differences in receptor expression levels between tissues and certain 
receptor complexes being favoured such that though a TGF-β ligand may be able to interact with one 
of the receptors in a complex, it cannot interact with the complex due to its inability to interact with 
the other receptor.17,36 Thus signalling can be directed to produce a diverse range of responses in 
different tissues.  
1.3.3 The Smad Proteins 
In the canonical TGF-β signalling pathway, the Smads are the main substrates for the type I receptors. 
There are eight Smad proteins in total, five regulatory (Smad1, Smad2, Smad3, Smad5, and Smad8), 
two inhibitory (Smad6 and Smad7), and one common Smad (Smad4). Similar to that observed with 
the growth factors and receptors, different R-Smads are only phosphorylated by specific type I 
receptors – with ALK1/2/3/6 phosphorylating Smad1/5/8 and ALK4/5/7 phosphorylating Smad2/3.42 
They all share a common architecture consisting of an N-terminal MH1 domain, a linker region, and a 
C-terminal MH2 domain. Both domains can interact with various transcription factors and MH1 can 
directly interact with DNA,43 however it is the MH2 domain that interacts with type I receptors. 
Association to type I receptors is governed by the “basic patch”, a region in the MH2 domain 
containing a high number of positively charged residues that binds to the phosphorylated GS region 
of the activated receptor. Phosphorylation then occurs at the C-terminus of the MH2 domain, on an 
SSXS motif where X is a valine or methionine reside.44 The phosphorylated SSXS then interacts 
intramolecularly with the basic patch, causing the Smad protein to dissociate from the receptor.45 In 
the case of Smad2 this can be aided by SARA which binds to both the type I receptor and Smad2.46 
Receptor specificity is determined by a combination of the MH2 domain and the receptor kinase 
domain with the sequence of two loops, the L3 loop of the Smad and the L45 loop of the receptor 
kinase domain, being vital to determining receptor-Smad interactions. The identity of the X in the SSXS 
motif has also been identified as playing a crucial role in the generating specificity.47,48 
The I-Smads, Smad6 and Smad7, act as intracellular inhibitors of TGF-β signalling. Smad6 preferentially 
inhibits BMP signalling whereas Smad7 is more ubiquitous inhibiting both ligands from the BMP and 
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TGF-β / activin pathways.49,50 The architecture of the I-Smad proteins is similar to that of the R-Smads 
however there are some key differences. Like all Smads, I-Smads consist of a MH1 domain, linker 
region and MH2 domain however the MH1 domains are poorly conserved with that of the R-Smads. 
By contrast their MH2 domains are highly conserved with the R-Smads though they lack an SSXS motif 
at the C-terminus of their MH2 domains. This means though their basic patch can interact with the 
type I receptors they cannot be phosphorylated, thus cannot dissociate resulting in the formation of 
a non-signalling complex. Additional mechanisms of inhibition also exist through interactions with 
Smad4, interactions with the R-Smads and targeting the receptors for degradation.51–53 
Smad4 is distinct from the other Smad proteins. Like the I-Smads, it lacks a SSXS motif for 
phosphorylation however it does not inhibit signalling. Rather its role is to oligomerise with the R-
Smads to facilitate translocation to the nucleus.54 In an unstimulated cell there is constant shuttling of 
the Smads between the nucleus and cytoplasm however both the R-Smads and Smad4 are primarily 
cytoplasmic.55 Upon signalling, Smad4 forms a heterotrimeric complex with two phosphorylated R-
Smads through its MH2 domain. This complex then translocates to the nucleus where it is retained 
and accumlates.56 The accumulation is due to the import rate of these complexes being four times 
higher than their export rate.57 Once in the nucleus, these complexes can either bind to DNA or 
interact with other transcription factors to induce a cellular response. It is only upon 
dephosphorylation does the complex dissociate and both the R-Smads and Smad4 are exported.58 
SARA (Smad Anchor for receptor activation) is a protein that can facilitate Smad signalling through 
aiding the localisation of R-Smads to the type I receptors.46 It consists of a FYVE zinc finger domain 
that allows it to localise to the cell membrane, a Smad binding domain, a PP1c binding domain, and a 
C-terminal type I receptor binding region. The Smad binding domain has been shown to interact with 
Smad2 and Smad3 through their MH2 domains, however due to the high conservation between the 
Smad MH2 domains, interactions with the other Smads may be possible. SARA preferentially binds 
unphosphorylated Smads, presenting them to the type I receptor for phosphorylation. Upon 
phosphorylation, the Smads then dissociate from SARA allowing them to translocate to the nucleus. 
Interestingly, it appears that SARA is not required for TGF-β signalling in most cases. In COS7 cells, 
Goto et al. demonstrated that although SARA was required for Smad2 dependent signalling it was not 
for Smad3.59 Additionally in HeLa cells and B lymphocytes, Bakkebø et al. observed that SARA was not 
required for phosphorylation of any of the Smads.60 Therefore it is likely SARA plays more of an aiding 
role, facilitating TGF-β signalling however its full role is yet to be fully elucidated.  
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1.3.4 Non-Smad Mediated TGF-β Signalling 
Signalling through the Smad pathway is the canonical signalling mechanism for the TGF-β superfamily, 
however it is not the only pathway through which signalling can occur. TGF-β ligands have been 
reported to signal through a number of additional pathways and I will now look at how TGF-β signalling 
occurs through these pathways.61 
The non-Smad signalling of the TGF-β can occur through three primary mechanisms: phosphorylation 
of non-Smad proteins by the TGF-β receptors; interactions between Smads and non-Smad pathway 
proteins such that the Smad pathway is perturbed; and interactions between Smads and non-Smad 
pathway proteins such that the non-Smad pathway is perturbed. In the case of receptor 
phosphorylation, both the type I and type II receptors can phosphorylate non-Smad pathway proteins. 
Ozdamar et al. observed that TGF-β can interact with the Rho GTPase pathway through 
phosphorylation of the protein Par6 by the type II receptor leading to degradation of Rho A and 
disassembly of the cytoskeleton.62 Furthermore, Src has been shown to phosphorylate the TFβRII on 
Y284 allowing for recruitment of Grb2 and Shc allowing for initiation of the Erk pathway.63 The Erk 
pathway can also be initiated by the type I receptors through activated type I receptors directly 
phosphorylating Shc allowing it to recruit Grb2 and Sos initiating the signalling cascade.64 Another 
interaction of the type I receptors with a non-Smad pathway is that of the Akt pathway. However, in 
this case it is the Akt pathway that interacts with the receptor through localising USP4, a 
deubiquitylating enzyme, to the cell membrane. This results in a reduction in type I receptor 
degradation thus increasing the effective concentration of type I receptor on the cell surface.65 
The amount of cross talk between the Smad and non-Smad pathways is often significant and this can 
be highly important in determining biological outcome. Interactions between Smads and non-Smads 
usually results in a modulation in their transcriptional activity, either upregulating or downregulating 
expression. Kretzschmar et al. demonstrated that for Smad 1, modulation by the Erk pathway results 
in a downregulation in Smad transcriptional activity due to a reduction in nuclear accumulation.66 This 
is due to the presence of a number of serine residues in the linker region of the R-Smads that can be 
phosphorylated by Erk pathway kinases. A similar phosphorylation pattern was observed on Smad2 
by Erk which resulted in an increase in the duration of Smad2 induced transcription.67 Interestingly as 
TGF-β can itself activate the Erk pathway, it may therefore be the case that TGF-β can modulate its 
own Smad signalling through non-Smad pathways.  In addition to the modification of Smads, 
modulation of other pathways by the Smads has also been reported. The Smad3-Smad4 complex has 
been observed to interact with the regulatory subunit of protein kinase A resulting in the release of 
its catalytic domain independent of cAMP concentrations.68 Furthermore, an indirect modulation has 
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been observed for the Jnk and p38 pathways where one mechanism of TGF-β activation involves Smad 
signalling inducing expression of proteins that can trigger these pathways.69  
Synergism between the Smad and non-Smad pathways is often important in determining a signalling 
outcome. In the embryogenesis of chickens, BMP5 signals through the Smad and p38 pathway to 
mediate limb development.70 Furthermore, the Smad, Erk, and Notch pathways have been shown to 
work together to promote the epithelial-mesenchymal transition of cells.71,72 In the case of activin A, 
its synergism with FGF pathway in mesoderm induction and maintaining the pluripotency of stem cells 
has been reported.73,74 All these factors combined mean the true TGF-β signalling network in cells is 
highly complex with many factors and proteins interplaying to produce a specific response. 
1.3.5 The Cellular Signalling of Activin A 
The canonical and non-canonical signalling of activin A follows the generic mechanisms described 
above with the pro-domains dissociating through an unknown mechanism followed by formation of a 
heteromeric signalling complex and a phosphorylation cascade through the Smad proteins (Figure 1). 
However, there are some features that differentiate activin A signalling from that of other TGF-β family 
members. Canonically activin A signals through three of the twelve TGF-β receptors in most 
circumstances – the type II receptors ActRIIA and ActRIIB and the type I receptor ALK4. Of these 
receptors, activin has a high affinity for the type II receptors and a low affinity for ALK4.14,75 
Mechanistically this means it is likely activin binds to type II receptors first to form a complex which 
then binds to the type I receptor, however this signalling complex appears to be unstable. Attisano et 
al. demonstrated that when metabolically labelled ALK4 is added to activin A-ActRIIB complex only a 
small amount of the ternary complex forms, indicating a low affinity of activin A-ActRIIB for ALK4.14 
Therefore, this suggests formation of the ternary complex only occurs transiently however the process 
may be aided in vivo by close spatial proximity of the type I and II receptors. It is currently unknown 
whether the mechanism through which activin A binds to its receptors occurs through the cooperative 
mechanism typical of TGF-βs or through the independent events mechanism typical of the BMPs, 
though the latter may be more likely. Goebel et al. determined the structure of the ternary GDF11-
ActRIIB-ALK5 complex and found that there appear to be no direct contacts between the type I and 
type II receptors.76 As activin A is highly similar to GDF11 and signals through the same Smad signalling 
pathway, it is therefore likely activin A binds its receptors through this mechanism. 
Due to the interaction with ALK4, it is conventionally thought of that activin only signals through the 
Smad 2/3 pathway. However additional activin signalling has been observed through ALK2 and the 
Smad 1/5/8 pathway under certain circumstances. The disease Fibrodysplasia Ossificans Progressiva 
is caused by mutations in the intracellular kinase domain of the ALK2 receptor which makes it 
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responsive to activin signalling.10 Furthermore Olsen et al. observed apoptosis triggered by activin 
through the Smad 1/5/8 in a number of myeloma cell lines.36 This indicates that activin A can interact 
with ALK2 under certain circumstances however does not usually signal through it. This is likely due to 
the interactions between BMPRII and ALK2. In the case of BMP receptors is it thought that pre-existing 
heteromeric complexes are formed on the cell surface. As ALK2 is usually a receptor for the BMP 
pathways it may be the case that the majority of ALK2 is already assembled in a complex with BMPRII 
in most cell lines, to which activin A cannot bind. In the absence of BMPRII both activin A and B 
signalling through ALK2 is massively upregulated implying that this is indeed the case. A reverse 
mechanism is also observed where activin A can inhibit BMP signalling through ActRIIA / ActRIIB due 
its higher affinity for those receptors.17 
1.3.6 Regulation of Activin A Signalling 
In order for activin A and other members of the TGF-β family to produce the diverse range of cellular 
responses observed, the cell must have mechanisms through which it can dynamically control 
signalling. In addition to regulation through morphogenic behaviour, variable expression patterns 
between cell types and the I-Smads, a number of additional mechanisms exist which can regulate 
signalling. These mechanisms can be broadly broken down into those that interact with activin A and 
those that interact with the type I and type II receptors. I will now focus on the proteins involved in 
these mechanisms and how they sequester activin A signalling. 
Follistatin is an extracellular glycoprotein that inhibits a number of TGF-β family members, including 
activin A. It exists in three isoforms – FS315, FS303, and FS288, all of which contain four domains Fs0, 
Fs1, Fs2, and Fs3. Of these domains Fs1 and 2 are crucial for activin inhibition.77 In addition, the Fs1 
domain contains a highly basic region allowing for binding of heparan sulfate.78 The main difference 
between the isoforms is at the C-terminus. FS315 contains a highly acidic tail which is lacking in the 
splice variant FS288. FS303 is a proteolytically processed form of FS315 which partially lacks the C-
terminal tail but still contains the acidic sequence. The in vivo distribution of these three isoforms 
varies dramatically, with FS288 and FS300 being primarily found in tissue and follicular fluid whereas 
FS315 is only detected in serum.79 One reason for this could be that FS288 has a greater affinity for 
cell surface proteoglycans than FS303, which in turn has a higher affinity than FS315.80 It has been 
suggested that this could be due to the acidic tail of FS315 and FS303 interacting intramolecularly with 
the basic heparan sulfate binding region, reducing the ability of the isoforms to bind surface 
proteoglycans and thus aiding transport around the body however there is currently not sufficient 
evidence for this.  
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Of the TGF-β ligands inhibited by follistatin, it appears to have the strongest affinity for activin A.81 
Activin inhibition is achieved through forming a high affinity complex with the mature growth factor 
(displacing the pro-domains from the pro-mature complex to achieve this). Follistatin shares the same 
binding site on activin A as the type II receptors and thus the receptors cannot bind and signalling is 
inhibited.77 A related protein to follistatin, FSTL3 also inhibits activin signalling in the same manner. 
FSTL3 shares very high structural similarity with follistatin and both molecules bind activin A with 
similar affinities ( Kd approximately 39 pM).82 Significant differences are found however between the 
sequences of the N-terminal region and this is thought to have an effect on specificity, with follistatin 
antagonising a greater number of TGF-β family ligands than FSTL3.80,82 Interestingly, FSTL3 has also 
been found to localise to the nucleus, though any effect nuclear FSTL3 has on activin or wider TGF-β 
family signalling is unclear.83 
The second mechanism by which activin signalling is inhibited is through inhibitors binding to its 
receptors. Inhibin A is the main example of this. Inhibin A was isolated one year before activin though 
it was first discovered in 1923 as a secreted factor from the testes that could regulate function of the 
pituitary gland.84–86 It consists of one inhibin βA subunit similar to activin A, however its second subunit 
is an inhibin α chain making inhibin A heterodimer. This allows inhibin to interact with ActRIIA and 
ActRIIB on the cell surface through its βA subunit however rather than recruit two type II receptors, 
its α chain interacts with betaglycan, a type III TGF-β receptor. Formation of this complex does not 
trigger a phosphorylation cascade as the complex is unable to recruit a type I receptor. This 
competition for type II receptors results in a reduction of available receptors on the cell surface thus 
resulting in a reduction in activin A signalling.87 
Similar to inhibin, it is thought that activin C may also compete with activin A for receptor binding. Of 
the five activin dimers observed in humans (activin A, activin B, activin AB, activin C, and activin E), 
activin C and E are the least well described with their biological function being poorly known. However, 
work by Gold et al. suggests that the activin C (a homodimer of inhibin βc chains) has an inhibitory 
role on activin A signalling, specifically in the liver and sex organs, likely through competition for 
receptors. However the mechanism for this is still poorly defined.88 
Betaglycan is one example of a TGF-β co-receptor. These proteins have a variety of roles including 
binding growth factors to the cell surface creating a cellular “store”, as well as inhibiting signalling 
through disrupting the formation of an active ligand-receptors complex.89,90 For activin A betaglycan 
is an indirect inhibitor, interacting with inhibin to antagonise activin A signalling. Other co-receptors 
have also been identified that modulate activin signalling, one of which is the pseudo-receptor BAMBI. 
BAMBI is a transmembrane protein with an extracellular domain that has a high similarity to TGF-β 
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type I receptors, however lacks the intracellular kinase domain of type I receptors and thus cannot 
trigger a phosphorylation cascade.91 This means BAMBI acts as a decoy for type I receptors on the cell 
surface interacting with the activin A-ActRIIA/B complex to curtail signalling. Similar to BAMBI, the cell 
surface protein cripto also has the ability to antagonise activin A signalling through disrupting the 
ability of the activin A-type II receptor complex to recruit ALK4. Interestingly cripto has the opposite 
effect on the TGF-β ligand nodal which cannot signal without the presence of cripto. Both activin and 
nodal signal through the Smad 2/3 pathway, therefore cripto may provide a mechanism to prevent 
cross over between the signalling of these two ligands.41,92 
1.4 The Structural Features of the TGF-β Superfamily and Activin A 
The TGF-β family ligands are typified by the large degree of structural and sequence similarity between 
members. In this section, I will focus on what the key structural and biochemical features of the ligands 
are and how they define the interactions between the mature growth factors, their pro-domains and 
type I and type II receptors. I will specifically focus on the key features of activin A and how this relates 
to its observed behaviour in vivo. 
TGF-β family proteins are synthesised as large precursors containing an N-terminal signal peptide, a 
poorly conserved pro-domain that is not actively involved in signalling, and an active highly conserved 
mature domain (pairwise identity across the whole family, pro-domains = approximately 15 %, mature 
domains = >30 %).4 Upon expression, these precursors translocate to the endoplasmic reticulum 
where they assemble and dimerize. During assembly, domain swapping occurs for some members of 
the family with the pro-domain of one subunit interacting with the mature domain of the other 
subunit to adopt the correct dimeric conformation. However, this is not expected to be the case 
always.93 Dimerization is typically stabilised through the formation of a disulfide bond between the 
mature domains. Most products of this dimerization are homodimers however heterodimers do occur, 
including TGF-β1.2 and activin AB. After dimerization, the pro-TGF-β ligand is cleaved by golgi-
associated furin-like proteases, cleaving between the pro- and mature domains.94 However, this  does 
not cause the pro-domains to dissociate and they remain in complex with the mature growth factor. 
The pro-mature complex is then secreted from the cell where it either binds to the extracellular matrix 
or surface proteins and is stored ready for use or enters circulation.95–97 
Extracellular pro-mature TGF-β complexes are either secreted in an “active” or “latent” form 
depending on whether they require additional processing to induce signalling. This additional 
processing usually takes the form of a second protease cleavage step that cleaves somewhere in the 
pro-domain allowing the mature domain to be released from the complex.98 In the case of ligands that 
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form latent complexes, it is often the case that a ligands pro-domain can inhibit the mature domains 
signalling with high efficacy. This is the case for the TGF-βs, myostatin and GDF11.39,99,100 By contrast 
ligands that fall into the active category require no additional processing after secretion and include 
BMP9 and activin A.40,101 Inhibition of signalling by the pro-peptide for these proteins may also occur, 
albeit at significantly higher concentrations of pro-domain than those required for latent growth 
factors.  
Numerous structures exist of TGF-β ligands, either as pro- and mature ligands, in complex with 
inhibitors, or as part of a complex with receptors. They have a “butterfly like” dimeric structure with 
each monomer having a convex and concave face.37 Monomers can be broken down into regions 
named after the human arm. The pro-domains consist of a forearm region containing an α1-helix-
loop-α2-helix motif that forms the majority of contacts with the mature domain, and a globular 
shoulder region that sits atop the mature dimer. The mature domains consisting of a wrist helix and a 
short and long finger region made up of two pairs of twisting anti-parallel β-sheets (Figure 2).102 A high 
percentage of residues in mature domains of family members are cysteines (5.0-6.3 %) and these 
intricately link each chain through a series of inter- and intramolecular disulfide bonds forming a 
cysteine knot. Due to the similar architecture and sequence identity, receptor binding sites appear to 
be preserved across the family with type II receptors binding at the fingertip region on the convex face 
and type I receptors binding to a pocket located at the dimer interface on the concave face.27 This 
pocket is highly hydrophobic in nature and exists between the wrist helix of one monomer and the 
finger region of the other. Activin A follows all these typical features. It is a 426 residue protein 
consisting of a 20 amino acid signal peptide, a 290 amino acid pro-domain and a 115 amino acid 
mature domain. The structures of both the pro- and mature forms of activin A are known, as well as 
the pro-mature complex, the activin-follistatin complex, and the activin-ActRIIB complex.77,103,104 One 
peculiarity of these structures is the large degree of flexibility about the dimerization cysteine. In each 
of the structures this angle is different and can vary anywhere between 108° in the pro-mature 
complex (PDB ID: 5HLZ) to 57° in the structure of activin A with ActRIIB (PDB ID: 1NYS). This may have 
some biological relevance, with Greenwald et al. suggesting this change in conformation is crucial for 




Figure 2: Topology of pro-TGF-β family ligands. Here the structure of the pro-activin A is shown as an example  
(left) with a schematic (right) where the different regions of the ligand are labelled. The pro-domains are shown 
in pink and the mature domains in yellow and grey. For clarity, one pro-domain has been made transparent. 
The role of pro-domains in the TGF-β family is highly important. Though not thought to be actively 
involved in signalling, it aids in dimerization, assembly and interactions with the extracellular 
matrix.95,96,105 Furthermore it helps to keep the mature growth factor soluble in solution through the 
binding of the forearm region to the mature dimer which buries the hydrophobic residues of the 
mature domains within the structure of the protein.104,106 In addition to pro-activin A, there are 
currently three other members of the TGF-β family for which the structure of the pro-form is known 
– TGF-β1, BMP 9 and myostatin (Figure 3).102,107,108 Comparison of the four structures reveals a number 
of key similarities. Three of the four pro-domains start with a highly hydrophobic helix (α1-helix) 
followed by a latency lasso (loop) that wraps around the mature domain and then a second helix (α2-
helix) (the N-terminal region of BMP9 is poorly defined however an additional α-helix occupies the 
site occupied by the α1-helix in the other three structures). The lasso region contains a high number 
of prolines (approximately 33 % in most family members), adding rigidity to the region and allowing it 
to encircle the mature domain in a so-called “straitjacket”. After the second -helix, a variable linker 
connects this “straitjacket” region to the shoulder region. This region has a similar fold in all TGF-β 
members but there is no overall preserved structure. Three of the four structures, pro-TGF-β1, pro-
myostatin, and pro-activin A, all show a domain swapped topology with the pro-domain of one subunit 
interacting primarily with the mature domain, however it is unclear if this is the case for pro-BMP9.93 
Furin cleavage between the pro- and mature domains appears not to significantly affect the overall 
25 
 
structure with no significant changes being observed between the X-ray structures of pro-activin A 
and the activin A pro-mature complex.104 
 
Figure 3: Pro- structures of the TGF-β family. A figure showing the available structures of  pro-TGF-β family 
members. Here, the mature domains are shown in a surface representation whereas the pro-domains are shown 
with a cartoon representation. 
There are however major differences. There appears to be no overall trend as to whether a particular 
ligand will be a latent or active complex. Pro-Activin A, myostatin and BMP 9 all appear to adopt an 
“open arm” “V-like” conformation whereas TGF-β1 adopts a “closed arm” disulfide linked 
conformation (though Mi et al. suggest interconversion between “open arm” and “closed arm” 
conformations may be possible).107 Interactions between pro-domains varies between structures as 
well. In TGF-β1, extensive hydrophobic interactions exist in addition to the inter pro-domain disulfide, 
whereas in pro-activin A interactions appear to come mainly through two additional helices (α3-helix) 
that also appear to interact with the base of the finger regions. In myostatin and BMP 9 there appear 
to be no major interactions between the pro-domains. Therefore, the overall poor conservation 
between pro-domains when compared to the mature domains appears to have a major impact on the 
tertiary structure of the pro-ligand. 
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1.5 The Pathology and Physiology of Activin A 
Now I have covered the main structural features of activin A and how activin A signalling occurs, I will 
now look at the role of activin A in physiology and disease. The biology of activin A is diverse and has 
been implicated in many physiological and pathological processes. In this section chapter I will focus 
on a number of these processes, especially those that are therapeutically or commercially important. 
 
1.5.1 Activin A in Development and Stem Cell Biology  
The role of activin A in development is complex. Homozygous knockout mice lacking either inhibin βA 
or βB genes both yielded viable pups, though those lacking the inhibin βA showed craniofacial defects 
and died within 24 hours of birth.109 However, maternal activin A is present from an early stage in 
mammalian embryogenesis in both the oocyte, fallopian tube and womb which may account for 
survival till birth.110,111 Furthermore, the expression of activin A or homologues has been detected in 
several tissues of developing mammals, including the sex organs, the brain and the kidneys.112–115 The 
role of activin A in the initial stages of embryogenesis is deeply entwined with that of another TGF-β 
family ligand, nodal.116 Like activin A, nodal is detected early on in development (pSmad 2/3 detected 
from 4-egg stage in mice, expression of both detected from blastocyst stage) and both proteins signal 
through the same receptors (ActRIIA/B and ALK4) and Smad 2/3 pathway, making it difficult to discern 
which protein is performing which role. However, due to the role of cripto, it is likely activin A signalling 
is suppressed as nodal signalling increases.41 Incidentally, disruption of nodal gene expression in 
mouse embryos has been shown to result in significant abnormalities including lack of mesoderm 
formation and patterning abnormalilites.117,118 However, it has been observed that both proteins can 
produce similar phenotypic results in stem cells and early animal models, including maintaining 
pluripotency and driving mesoderm formation.119–121 
In stem cell technologies, activin A is often used as a surrogate for nodal due to the more widespread 
availability of activin A.122 It has been demonstrated that activin A can maintain human embryonic 
stem cells in a pluripotent state without the need for feeder layers and can be used to maintain 
pluripotency in induced pluripotent stem cells as well.123,124 Mechanistically, activin maintains 
pluripotency through triggering expression of a number of transcription factors that suppress 
differentiation including Oct4, Sox2 and Nanog.125 In addition, a second mechanism for maintaining 
pluripotency may exist where activin acts in concert with other growth factors to suppress BMP 
signalling. BMP4 has been shown to initiate differentiation of human embryonic stem cells to the 
trophoblast, thus by suppressing their signalling pluripotency is maintained.126  
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The key to controlling pluripotency and proliferative potential is activin concentration. At low 
concentrations of activin A (0.12 – 1.2 nM), pluripotency is maintained. However once activin A levels 
increase pluripotency and proliferative potential are lost.123 This is due to the morphogenic nature of 
activin A, with cells undergoing differential gene expression depending on the concentration of activin 
A to which they are exposed.127 Thus, responses and cell fate at different concentrations of activin A 
will be different. This, along with the method of culturing, additives used, and the time point at which 
activin A is either added or removed determines the product of activin A induced differentiation.128 
Activin has been reported to drive the formation of the definitive endoderm in stem cells and 
differentiation into a number of cell types under the influence of activin has been reported including 
both endoderm and mesoderm cells.129,130 Therefore by tightly controlling these factors activin can be 
used to determine the fate of stem cells in a desired manner. 
1.5.2 Activin A in Inflammation and Wound Repair 
Activin is one of the first cytokines released in acute inflammation.131 Its behaviour is observed to be 
biphasic, with initial increase in serum levels followed by a drop and another increase. The source of 
activin A involved in the first phase is likely to be release from the extracellular matrix to which activin 
A is known to bind, however currently there is insufficient evidence for this.95 The second increase in 
activin A levels is due to an increase in expression that is mainly driven by the Toll-like receptor 
pathway and Toll-like receptor 4.8 After 4-5 hours, activin levels reduce and the amount of follistatin 
increases suppressing activin signalling.  
Once present, the role of activin A in inflammation and injury is contradictory and depends on the 
tissue in question. The levels of activin A at a site of inflammation appear to correlate with the 
magnitude of an immune response, and activin A has been shown to trigger and suppress the levels 
of inflammatory cytokines depending on the cell type.132–134 In addition, activin A can both aid and 
impede regeneration. In the liver, activin A appears to have an inhibitory effect on regeneration after 
a partial hepatectomy.135 Furthermore, it has been observed that activin A can increase liver fibrosis 
and induce hepatocyte apoptosis.136,137 In inflammatory bowel disease, activin A is expressed at 
significantly higher levels in the intestine and inhibits epithelial cell proliferation impeding the healing 
process.138,139 However in the case of external wounding of the epidermis, increased activin A levels 
improve the speed of recovery. Activin expression is triggered upon injury to the epidermis and 
increases the level of granulation tissue and rate of wound repair but also scarring. By contrast, 
inhibition of activin through overexpression of follistatin results in a slower repair rate, with lower 
scarring and increased resolution between granulation and surrounding tissue.140–142 Therefore 
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modulation of activin activity could be an important therapeutic target for aiding repair and 
regeneration and minimising scarring. 
The anti-inflammatory role of activin A has been described in a number of instances. In the brain 
activin A has been shown to have a neuroprotective role, increasing survival of and protecting neurons 
from neurotoxic damage.143 Furthermore, activin A has been observed to inhibit inflammatory 
cytokine release in angina patients.144 Interestingly the opposite effect is observed in healthy patients 
where activin triggers an inflammatory response. One source of the anti-inflammatory effects of 
activin likely comes from its ability to antagonise interleukin-6 signalling.145,146 As interleukins are key 
regulators of the immune system ultimately this results in suppression of the immune response. 
However, it is important to note this is just one of many of the complex interactions between activin 
A and other inflammatory cytokines and a full description of the interplay between these molecules 
is yet to be described. 
1.5.3 Activin A in Muscle Homeostasis 
Activin A is an important factor in the development and homeostasis of muscle tissue. It acts in concert 
with myostatin, another member of the TGF-β family, to inhibit muscle growth, suppressing muscle 
fibre hypertrophy.147 This allows an organism to control its muscle mass and fat metabolism, 
preventing an uncontrolled increase in the amount of skeletal muscle. Like activin A, myostatin is also 
inhibited by the extracellular protein follistatin.148 As such, increased follistatin levels have been 
associated with an increase in skeletal muscle mass.149 In healthy individuals, inhibition of activin and 
myostatin with follistatin helps to maintain muscle homeostasis however if this balance is altered a 
large increase in muscle mass can ensue. Schuelke et al. reports the case of a myostatin deficient boy 
who exhibited a highly muscular phenotype due to a loss of function mutation in the myostatin 
gene.150 Furthermore, several breeds of cattle possess mutations that lower or eliminate myostatin 
activity.151 As such they exhibit a significantly more muscular phenotype than other animals.  
Activin A has also been implicated in the muscle wastage associated with cancer cachexia. In mouse 
models, mice overexpression activin A resulted in a significant decrease in muscle mass relative to 
their starting mass however this change was reversible upon suppression of activin signalling.152 In 
humans, high levels of circulating activin A have been associated with cachexia in cancer patients, with 
patients displaying over a 40% increase in activin A levels when compared to non-cachectic patients. 
Interestingly, this study found that myostatin levels were decreased by over 35% in cachectic 
patients.153 Activin A and myostatin are often implicated as acting in concert to negatively regulate 
muscle growth however in the case of cachexia it appears that activin A plays a more prominent role. 
29 
 
The general conclusion from a number of mice studies has been that although activin A contributes to 
muscle development and homeostasis, it is a secondary player when compared to myostatin (GDF8). 
147,154,155 However, this may not be the case across mammalia, as shown by Latres et al. who studied 
the effect of specific inhibition of different TGF-β family members.7 It was observed that in mice, 
specific inhibition of myostatin and activin A both individually caused an increase in muscle mass with 
myostatin causing a greater increase than activin A. However, when the same experiment was 
performed in cynomolgus monkeys, specific inhibition of myostatin produced little effect on muscle 
mass when compared with activin A. They further investigated serum levels of mice, monkeys, and 
humans to see how they differ and found that activin A levels in humans and monkeys were 3-4-fold 
higher than those found in mice whereas myostatin levels are 5-18-fold lower. Therefore, targeting 
activin A specifically may result in a greater increase in muscle mass in humans rather than targeting 
myostatin.  
Targeting activin A as a treatment for muscular dystrophy is one possible therapeutic application of 
activin A inhibition. Though it is not the causative agent of muscle atrophy inhibition of activin may 
lead to an increase in muscle mass and muscle hypertrophy, thus combating the disease indirectly. 
Clinical trials that inhibit activin A for this purpose have already shown some success with Campbell 
reporting treatment of Duchenne muscular dystrophy patients with the multi-TGF-β ligand inhibitor 
ACE-031 (ActRIIB-ECD-IgG1 fusion) resulted in an increase in the distance of patients completing a six-
minute walk test even 2-4 weeks after treatment was stopped. However, it is important to note 
treatment was discontinued after the second dosage due to concerns about the potential side effects 
of inhibiting multiple TGF-β ligands. Therefore a similar approach with a more specific inhibitor is 
desirable.156 
1.5.4  Activin A and Cancer 
The role of activin A in cancer biology is complex. In healthy individuals, activin A acts as a tumour 
suppressor,157,158 however in cancer it has been implicated as having both oncogenic and anti-
oncogenic properties depending on the cellular context. Numerous cancers have been associated with 
either elevated or suppressed signalling, including breast, prostate, ovarian, lung, and colorectal, and 
oncogenic signalling can occur through both activin’s canonical and non-canonical signalling 
pathways.159–164 As such, it is important to take into account many factors when looking into the role 
of activin A in a specific cancer. 
The complex nature of activin A ’s cancer biology can be demonstrated in breast cancer. Bashir et al. 
used qPCR and immunohistological analysis to demonstrated that activin A expression is highly 
upregulated in the tumour cells of advanced breast cancer patients compared to normal tissue 
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samples (11-fold increase) and an increase in pSmad2/3 is also observed (3-fold increase in pSmad2 
detected, 2-fold in pSmad3).159 When applied to the cell line MDA-MB-231, this in turn promoted 
anchorage independent cell growth, induced epithelial-mesenchymal transition of cancer cells, and 
promoted cell migration and invasion of cancer cells – all key steps in cancer metastasis. By contrast, 
in a different breast cancer cell line (T47D) Burdette et al. report that activin acts as a tumour 
suppressor, inhibiting cell proliferation promoting cell cycle arrest.165 The story is equally complex in 
prostate cancer where activin is observed to inhibit cell growth prostate cancer yet appears to 
promote prostate cancer metastasis.160,166,167 This suggests that the role of activin A in cancer depends 
on the specific cancer in question, the stage of cancer, and even the cell type involved. Therefore, 
inhibition of activin may result in tumour suppression in one patient whereas in another it may 
increase tumorigenesis and metastasis.  
The presence of hormonal factors appears to have a large effect on activin’s role in cancer cells. In 
prostate cancer it has been observed that the presence of androgens can eliminate the anti-
proliferative effects of activin A.168 In addition activin contributed towards androgen production which 
is one of the key drivers of castration resistant prostate cancer (androgens levels also increased levels 
of activin A expression). In breast cancer a similar interplay is present, however with activin A 
supressing proliferation though inhibiting oestrogen production and oestrogen inhibiting expression 
of activin.169 Therefore it is important to consider the tumour microenvironment when analysing 
activin’s role.  
Resistance to or suppression of activin A signalling is a hallmark of some cancers. Resistance may come 
at any part of the signalling pathway and may be due to a number of factors. In certain breast cancer 
cell lines activin resistance was conferred by a reduction in expression of its receptors, thus lowering 
the total amount of activin signalling the cell undergoes.170 In addition, Gold et al. observed that the 
anti-proliferative activity of activin A in LNCaP prostate cancer cells was reduced in the presence of 
the related growth factor activin C suggesting up regulation of this growth factor could induce 
tumorigenesis in the prostate.88 This has been hypothesised to be the case with follistatin too, with 
increased follistatin levels being associated with cell proliferation in the same prostate cancer cell 
lines.171 It is also the case that mutations in activin A may alter its signalling. Tournier et al. observed 
that in an ovarian cancer patient, a mutation in the inhibin βA subunit in the tumour cells decreased 
the amount of secreted activin A relative to inhibin A.172 This  likely resulted in a reduction in activin A 
signalling and increased proliferative potential.  
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1.5.5 Activin A and Fibrodysplasia Ossificans Progressiva 
Fibrodysplasia Ossificans Progressiva (FOP) is an extremely rare autosomal dominant disease. It is 
caused by a gain-of-function mutation on chromosome 2q23-24 which often occurs spontaneously in 
the gametes prior to fertilisation.173 This region contains the ACVR1 gene which codes for the type I 
receptor ALK2, which is generally associated with BMP signalling, phosphorylating SMADS 1, 5 and 8. 
Surprisingly, in FOP patients, mutations in the intracellular GS region or kinase domain of ALK2 cause 
it to become responsive to activin A signalling. Several mutations have been reported however the 
most common by far is R206H that occurs in >95 % of FOP patients (Table 1).174,175 Incidentally, 
mutations on the same residues have also been reported in approximately 25 % of childhood cases of 
diffuse intrinsic pontine glioma, suggesting activin A may also play a role in this type of cancer too.176 
Table 1: ALK2 mutations associated with fibrodysplasia ossificans progressiva. 
Mutation Location 
P197_F198del insL GS Region 
R206H GS Region 
Q207E GS Region 
G328E Kinase Domain 
G328R Kinase Domain 
G328W Kinase Domain 
G356D Kinase Domain 
R375P Kinase Domain 
 
Any injury or inflammation to fibrous tissue in a FOP patient results in BMP-like signalling in the tissue 
due to the physiological release of activin A (which now activates ALK2). This results in the gradual 
ossification of the muscular system, resulting in the progressive immobilisation and eventual death of 
the diseased individual.177 There is currently no cure and treatment options are limited. Surgery can 
be used to remove ectopic bone, but the resulting inflammation from surgery increases bone 
formation and thus only aggravates the condition in the long run. 
The mechanism through which activin A becomes able to signal through ALK2 is at first glance unclear. 
Mutations causing FOP occur in the intracellular kinase domain of ALK2, whereas activin A is an 
extracellular growth factor interacting with the extracellular domain of the receptor only. 
Furthermore, the extracellular domains of ALK2 and ALK4 (the most common type I receptor for 
activin A) have low sequence similarity (sequence similarity = 33 %, identity = 20 %), and though activin 
A is observed to bind to ALK2, it usually does not signal through it.  
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However, Botello-Smith et al. suggests that activation occurs not due to a change in the binding 
properties of activin A or ALK2, but due to the mutations inducing leaky signalling. The key interaction 
in ALK2 that prevents ATP binding to the kinase domain in the basal state is a salt bridge blocking the 
ATP binding site. Upon activation by a type II receptor, this salt bridge is destabilised allowing ATP to 
co-ordinate and the kinase domain to phosphorylate downstream proteins. Through molecular 
dynamics simulations, this group observed that mutations associated with FOP disrupt this salt bridge 
to break due to the breakdown of an allosteric hydrogen bonding network that aids salt bridge 
formation thus activating the kinase domain in the absence of ligand and the type II receptor. 
Additionally, several mutations can also bypass inhibition by FKBP12, an interacting partner of the 
TGF-β family type I receptors that binds to the GS region and acts as a secondary mechanism to 
prevent leaky signalling.178 However, despite this ALK2 does not signal in the absence of the type II 
receptor. Bagarova et al. showed that BMP2 mediated ALK2 signalling* and ALK2R206H / ALK2Q207D 
signalling was significantly reduced in the absence of BMPRII and ActRIIA.180 Incidentally, restoration 
of these receptors resulted in the restoration of ALK2 signalling, though in the case of ALK2R206H / 
ALK2Q207D this was independent of ligand binding. It has been shown that the affinity of the type I 
receptors for the SMADs is greatly enhanced if the receptor is activated by the type II receptor.181 
Thus, this observation may explain the role of activin A in FOP, with formation of the heteromeric 
ActA-ActRIIA/B-ALK2 complex ligand-receptor complex localising ActRIIA/B to ALK2 resulting in the 
induction of signalling. 
Though this offers a good explanation as to why downstream phosphorylation occurs, it still does not 
explain why ALK2 requires binding of activin A to induce signalling if the receptor is constitutively 
active. This can be explained by the requirement of SMAD proteins. It has been shown that the affinity 
of the type I receptors for the SMADs is greatly enhanced if the receptor is activated by the type II 
receptor.180,181 Therefore, binding of activin is required to form the heteromeric ligand-receptor 
complex such that the type I receptor activation can occur and signalling be induced. 
1.6 Inhibitors of TGF-β Family Signalling 
The specific inhibition of activin A, and more generally the ligands of the TGF-β family, is highly 
desirable due to potential research and clinical applications. Numerous methods have been attempted 
to inhibit members of the TGF-β family targeting formation of ligand-receptor complexes and 
phosphorylation of the Smad proteins. In this section several of these methods will be discussed.  For 
 
* In addition to activin A, the leaky signalling of ALK2R206H makes it hypersensitive to BMP signalling. As such, 




ease, all inhibitors mentioned by name in this section are listed in Table 2. A figure indicating how the 
signalling pathway is targeted is shown in Figure 4. 
Table 2: Selected inhibitors of the TGF-β family. Where inhibitors have been reported for numerous targets, 
preference will be given to the activin  A system.  






Antibody Activin A <0.005 <0.08 Gromada et al.182 






Forvan et al.183 
ActRIIA–mFc Ligand Trap (Receptor) Activin A 0.003 0.275 Pearsall et al.184 





Activin A 0.196 0.070 Castonguay et 
al.186 
Modified ActA Ligand Trap (Pro-
domain) 
Activin A – 5 Chen et al.187 
AT propeptide Pro-domain Mutant Activin A – 2.6 Makanji et al.188 
Peptide 7 Peptide (Pro-domain) Myostatin 29.7 3500 Takayama et al.189 
Peptide 11 Stapled Peptide (Pro-
domain) 
Myostatin  260 Rentier et al.190 






Walton et al.191 
nsc119889, 
910, 911, 913, 
915 
Small Molecule TGF-β1 or 
TβRII 
– ~10000 Burmester et al.192 
NUCC-555 Small Molecule Activin A – 5300 Zhu et al.193 
Galunisertib Small Molecule ALK5 – 221 Yingling et al.194 
LDN-214117 Small Molecule ALK2  100 Mohedas et al.195 




Sakamoto et al.196 




Figure 4: Common inhibitors TGF-β family signalling. Here, a selection of common methods of inhibiting TGF-β 
family signalling are shown. The specific protein targets for each method are also listed. 
The most common target for TGF-β family inhibitors is the complexation of the ligand with its type I 
and type II receptors. By disrupting formation of this complex, the type II receptor is unable to 
phosphorylate the type I receptor thus a phosphorylation cascade cannot be triggered. The 
extracellular nature of this complex is advantageous for inhibitor development as any potential 
inhibitors would not have to cross the cell membrane. There are two main protein targets when using 
this strategy – the extracellular domains of the receptors and the growth factors themselves. 
Antibodies have been described that that use both these approaches with activin A, targeting either 
mature activin A, ActRIIA/B and ALK4.197 When compared to other methods of inhibition antibodies 
are highly specific, often binding their target with picomolar affinity, and have low off target toxicity, 
however they are commercially expensive to produce, requiring mammalian expression systems. Anti-
activin A antibodies were first described in 1996 by Funaba et al. who used fragments of activin A to 
generate polyclonal antibodies.198 The same group later used chickens to develop an antibody against 
mature activin A that could inhibit activin’s ability to stimulate FSH secretion from pituitary cells and 
suppress the development of mouse embryos.199 Since then a number of patents have been filed for 
neutralising antibodies that target activin A (Gromada et al. patent filed for antibodies with Kd values 
< 5 pM and IC50 values <80 pM).182,200 Antibodies that target activin’s receptors often target the 
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extracellular domains. Bimagrumab, an anti-ActRIIA/B antibody binds to both their extracellular 
domains with a preference for ActRIIB (ActRIIA Kd = 973 pM, ActRIIB Kd = 16 pM) through the same 
binding site as activin A and other TGF-β ligands.183 Currently, antibodies make up the vast majority of 
commercially available inhibitors of activin A. 
A similar approach to antibody inhibitors has been to develop ligand traps. These proteins are 
designed such that a dimeric Fc fragment of antibody is fused to a “trap” that can form an inactive 
complex with the ligand in question – either the extracellular domain of a receptor, an extracellular 
inhibitor such as follistatin, or a ligand’s pro-domain. While affinities of the individual binders can be 
relatively weak, dimerization through Fc part provides avidity and thus increases the apparent affinity 
for the target(s). This approach has been used for inhibition of activin A using ActRIIA, ActRIIB and 
follistatin as the traps as well as activin’s pro-domain.184–187 Both ActRIIA/B and follistatin traps have 
been shown to inhibit activin A signalling with high efficacy (ActRIIA–mFc IC50 = 275 pM, ActRIIB.hFc 
IC50 = 1.63 nM, Follistatin-288-Fc IC50 = 70.3 pM) however both have a broad ranging specificity and 
also inhibit activin B, myostatin and GDF11. However, this broad specificity has been advantageous 
when targeting muscle growth due to the complimentary roles of activin A and myostatin, with both 
ActRIIA/B (Sotatercept and Luspatercept) and follistatin (ACE-083) traps currently in clinical trials.201–
204 Pro-domain based ligand traps have an advantage over the other two classes in that due to the 
poor conservation between pro-domains, they are more likely to be specific against a given ligand. 
This was the case in Chen et al. who developed ligand traps based on the pro-domain of activin A (IC50 
= 5 nM) that had >20-fold specificity for activin A over activin B and did not inhibit myostatin or GDF11 
signalling at the concentrations tested.187 
The pro-domains of TGF-β family members represent a good starting point for developing inhibitors. 
Pro-domains bind their mature growth factors with relatively high affinity (<1 μM),104,107,189 have good 
solubility to prevent the mature growth factors from precipitating out and in some cases can actually 
inhibit signalling of the mature ligand.104,205 This is the case for activin A, whose pro-domain binds its 
mature domain with an affinity of 5 nM (as determined via biolayer interferometry). However, as pro-
activin A is processed to form an active complex, the pro-domain only appears to inhibit activin A 
signalling at high concentrations. In addition to ligand traps, a pro-domain approach for activin A has 
already  been attempted. Makanji et al. created a fusion of the α1-helix-loop-α2-helix of activin A to 
the shoulder region of TGF-β1 pro-domain (AT Propeptide).188 As the shoulder region of TGF-β1 is a 
disulfide linked dimer this resulted in a dimeric inhibitor, not dissimilar from a ligand trap, that was a 
potent inhibitor of activin A and B signalling (IC50 10.3 nM).  
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Another pro-domain based method that has been utilised to generate inhibitors is to use pro-domain 
based peptides. This approach has seen success for both myostatin and inhibin. In the case of 
myostatin, the pro-domain is a highly potent inhibitor of myostatin signalling with an IC50 value of 0.9 
nM.108 Based on this, Jiang et al. identified the region responsible for this inhibition to be in the N-
terminus between residues 42 and 115.206 Takayama et al. subsequently developed a synthetic 23 
residue high affinity minimum peptide (Kd = 29.7 nM via SPR) based on the pro-domain of mouse 
myostatin that could inhibit myostatin signalling with an IC50 value of 3.5 μM (Peptide 7).189 This 
sequence has since been identified as corresponding to the pro-domain’s α1-helix and the start of the 
loop region.108 Since then the same group has sequentially optimised this inhibitor through acetylating 
the peptide (IC50 = 1.2 μM), used SAR to mutate key residues (IC50 = 320 nM), and introduced stapling 
to the peptide (IC50 = 260 nM) (Peptide 11).190,207–209 Interestingly, Fc-peptide fusions developed by 
Ohsawa et al., similar to those reported in Takayama et al., bound not only to mature myostatin and 
GDF11 but also to the type I and type II receptors.205 This suggests interactions between the pro-
domain and receptors may play an important role in the initiation of myostatin signalling.  
A similar approach was attempted by Walton et al. who generated an inhibitory peptide for inhibin A 
and B based on the pro-domain of the inhibin α subunit (inhibin A IC50 = 255 nM, inhibin B IC50 = 150 
nM).191 This peptide was highly specific, interacting only with the inhibins, and not with either activin 
A or activin B, indicating the peptide only interacted with the α subunit of the mature inhibin dimer. 
Pepinsky et al. also attempted a peptide approach with GDF 11. Unlike myostatin and inhibin, the 
GDF11 pro-domain derived peptide did not inhibit GDF11 signalling at the concentrations used 
(though these concentrations were significantly lower than those used with the myostatin peptides 
by Takayama et al.189). Though no inhibition was observed, the minimal peptide dramatically increased 
the solubility of mature GDF 11 suggesting a potential growth factor delivery application of pro-
domain derived peptides.106 
Small molecules are the other major category of TGF-β family inhibitors. Small molecules have been 
reported that disrupt ligand-receptor complex formation. Burmester et al. conducted a high 
throughput screen against binding of TGF-β1 to solubilised TβRII which led to the identification of five 
small molecules that block this interaction (Most potent antagonist ED50 = approximately 10 μM).192 
In addition Zhu et al. used virtual high throughput in silico screening against the crystal structure of 
mature activin A to identify two inhibitors that bind in the hydrophobic pocket of putative type I 
receptor binding site, the most potent of which, NUCC-555 had an IC50 value of 5.3 μM.193 However 
the most common target for small molecule inhibitors is the kinase domains of the type I receptors. 
Targeting these kinase domains has several advantages when compared with other proteins and 
domains involved in the signalling pathway. They have an obvious binding pocket, a substrate that can 
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be used as a scaffold for inhibitor development, and many assays exist for testing kinase specificity 
thus off target toxicity can be more easily determined. Numerous inhibitors have been developed for 
the kinase domains of the type I receptors, including Galunisertib for ALK4 and ALK5, and LDN-214117 
for ALK2.195,210–214 These molecules are typically based on either a dihydropyrrolopyrazole or an 
imidazole scaffold and have a high specificity for the receptor they are targeting – even being able to 
distinguish between the different type I receptors. However, on-target toxicity if often a concern due 
to multiple ligands signalling through the same receptor.215 Despite this, the potent ALK4 / ALK5 
inhibitor Galunisertib (Ki = 86 nM, IC50 = 221 nM in cell based reporter assay) has shown success in 
clinical trials with no on-target toxicity or dose limiting event observed.194,213 
Alongside the methods already discussed, a number of novel methods of inhibition have been 
described. Harrison et al. generated mutants of mature activin A that could form a complex with 
activin A’s type II receptors but not ALK4, thus blocking the type II receptors and preventing signalling 
from being initiated. 216 In addition, Sakamoto et al. generated peptide inhibitors for the extracellular 
domain of ActRIIB through phage display.196 Interestingly several of the peptides displayed different 
ligand specificities, with one inhibiting a broad range of ligands (activin A, myostatin, GDF11, BMP9) 
that signal through ActRIIB (IC50 values = 5-12 μM) whereas another only inhibited myostatin signalling 
(IC50 value = 40 μM). The mode of binding of the peptides or the reason for this specificity however 
was not speculated on. In the larger TGF-β family, other approaches have included the use of antisense 
oligonucleotides, small molecule inhibitors that bind sequence specifically to a gene promoter, and 
upregulation of I-Smads through gene transfer.217–219 
Specificity is an important concept when designing inhibitors for the TGF-β family. Due to the 
sequence and structural similarity of the ligands and the promiscuity of the receptors, it can be difficult 
to achieve specific inhibition that doesn’t have off target effects. This is especially true when using 
inhibitors that are based on or affect either the type I or type II receptors. In two clinical trials that 
used receptor-based ligand traps to target activin A signalling, numerous side effects were observed 
including bone pain and gingival bleeding that is likely caused by inhibition of other TGF-β family 
members such as BMP9.220,221 Therefore, to minimise such effects it may be the case that targeting 
the growth factors themselves is the best approach overall. 
1.7 Aims 
The key question this thesis aimed to address is “is it possible to generate specific inhibitors for 
activin A signalling through targeting the mature activin A dimer alone?”. To answer this, the 
objectives of this thesis were as follows: 
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1) Identify and characterise fragments that bind to mature activin A (Small 
Molecule Approach) 
The identification of fragments that bind to mature activin A could be an important potential 
starting point to developing small molecule inhibitors of activin A signalling. To achieve this, I 
crystallised mature activin A as previously described by Harrington et al.77 and optimised the  
conditions for fragment soaking. I then performed a fragment screen via X-ray crystallography 
utilising the XChem platform at the Diamond Light Source to identify binding molecules. I further 
validated several of the binding molecules through X-ray crystallography and derivatised them to 
generate binders with more optimised interactions. 
2) Identify and develop peptide inhibitors based on the key sites of 
interactions between activin A’s pro-and mature domains (Peptide 
Approach) 
In order to generate inhibitors based on the pro-domain of activin A, it is important to first 
identify the key sites of interaction between the pro- and mature domains. To this end, I 
developed a series of peptide fusions containing different epitopes of the α1-helix-loop-α2-helix 
motif and used biolayer interferometry (BLI) to determine which epitopes are crucial for binding. 
I then determined the affinity of these epitopes for the mature domain using BLI and isothermal 
calorimetry (ITC) and attempted to identify the key interacting residues, before investigating the 
inhibitory properties of the peptide fusions via a Smad reporter luciferase assay. 
3) Optimise pro-domain derived peptide inhibitors through 
dimerization (Dimeric Approach) 
As the mature activin A dimer binds two pro-domains, it is possible that dimerization of any pro-
domain derived peptide inhibitor will provide a route to optimization and increased potency. As 
such, I utilised the dimerization and docking domain of the RIIα subunit of protein kinase A, and 
disulfide bonds to induce dimerization of the inhibitory peptides. Similarly to their monomeric 
counterparts, I characterised their binding properties to mature activin A via ITC, and effect on 






4) Screen pro-domain derived peptide inhibitors for specificity against 
other members of the TGF-β superfamily (Dimeric Approach) 
Due to the structural and sequence similarity of TGF-β ligands and receptor promiscuity, it is 
important to determine the specificity of any inhibitor generated in this thesis for activin A. 
Accordingly, I determined an appropriate selection of TGF-β ligands to generate a wide and 
robust screen. I then used the selected ligands in a luciferase assay to determine the effect of the 












             
Small Molecule Approach 






Small molecule drugs refer to molecules with low molecular weights (usually less than 1 kDa) that have 
therapeutic properties, usually through agonism or antagonism of signalling or activation or inhibition 
of a specific biological process. Overall, they account for over 90% of all commercially available drugs 
and have several advantages over protein-based therapeutics, namely they are cheaper, easier to 
manufacture, and usually have a longer shelf life.222,223 The identification of a hit  compound is the first 
step in generating a small molecule therapeutic agent for a target protein. In some cases, a rational 
starting point is present (such as the substrate analogue of an enzyme), however for many targets this 
is not the case. As such, large numbers of compounds are often screened against a protein to identify 
binding molecules in a high-throughput screen. The nature of these molecules is often diverse, with a 
range of molecular weights (typically between 300-1000 Da) and physicochemical properties, allowing 
for a for a wide coverage of chemical space. However, major limitations can arise from unoptimized 
fits of the molecule into the binding site, meaning interacting motifs can be overlooked due to steric 
or electrostatic repulsion of the large molecule. An alternate method that aims to overcome this 
limitation is fragment screening. In contrast to high-throughput screening, fragment screening is a 
low-throughput screen that aims to still cover a large chemical but with significantly fewer molecules. 
This is achieved through the use of smaller molecules (typically around 200 Da) that often consist of a 
one or two motifs.224 The hit rates varies from protein to protein but is often high, and multiple hits in 
a binding site are common. Motifs from these hits can then be either grown, merged, or linked 
together to create an optimised molecule for a specific binding site. As hits can be combined in 
numerous different ways, this makes the exploration of chemical space efficient despite the library 
size. Major limitations of fragment screening can arise from a high hit rate making it difficult to select 
which compound to further optimise, or weak interactions. Due to their low size and low number of 
interacting motifs, fragments usually only interact with a protein weakly making detection 
problematic. 
X-ray crystallography is one method through which fragment screening can be conducted. This is 
advantageous compared to other methods as it allows for structural information to be obtained 
allowing for identification of the binding site of a fragment the interacting residues. Additionally, it is 
more sensitive than many other screening techniques allowing for fragment binding to be more easily 
detected.225 However, crystallographic screening is time and resource intensive and requires that the 
protein of interest to be crystallisable. The crystals need to have unliganded, accessible target site,  
diffract to high resolution, and they need to be robust so as not to be destroyed upon high 
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concentration fragment soaking. Furthermore, it is still difficult to detect weakly binding fragments. 
This is because the electron density observed in maps is averaged across the entire crystal lattice. If a 
molecule binds strongly, it occupies a large percentage of sites in the crystal lattice, generating a large 
signal in electron density maps. However, if a molecule binds weakly, the ligand bound state only 
corresponds to a small percentage of states in the crystal, thus the signal is weak and difficult to 
discern from noise. Furthermore, if a ligand binds in a number of conformations, averaging will lead 
to a weak overall signal. As such these signals are often difficult to interpret or go undetected when 
analysing electron density maps. The XChem platform developed at the Diamond Light Source by 
Frank von Delft aims to overcome the problems of detecting weak fragment hits. This methodology, 
implemented in software package PanDDA, uses more sophisticated analysis of crystallographic data 
to detect weakly bound fragments. The PanDDA program aligns all “event” electron density maps 
(those obtained from fragment soaks) to the map generated from a ground state map and structure 
(in this case a map and structure of the protein without a bound ligand). It then creates an average 
electron density map from the entire data set and assigns a Background Correction Density factor to 
it. This corrected average map has a much lower signal to noise ratio than any individual map obtained 
and thus, when it is subtracted from each event map, can reveal the presence of weak density (for 
further explanation of the methodology, see Pearce et al.).226 As such it can identify weakly binding 
ligands or uncommon states that are not normally detectable. This method has already been shown 
to have success in identifying small molecule binders for several proteins including the deubiquitinase 
OTUB2, the pyrophosphatase NUDT7 and the histone deacetylase HDAC6.227,228 Therefore, I decided 
to apply this methodology to develop small molecule inhibitors of mature activin A. 
The choice of activin A as a target for small molecule screening at first glance is a challenging one. As 
activin A is an extracellular signalling protein, its primary interactions are protein-protein interactions. 
Disrupting these interactions is often difficult due to large area of interaction and lack of obvious 
binding pockets that can be targeted.229 Plus, sequence and structural similarity between the TGF-β 
family growth factors means that achieving specific binding of any small molecule will be challenging. 
However, this system does have some advantages. Firstly, the structure of mature activin A at 2.0 Å 
resolution is known, having been determined via x-ray crystallography by Harrington et al.77 Analysis 
of this structure shows the presence of a hydrophobic binding groove in the putative type I receptor 
binding site. This site was used by Zhu et al. to identify a number of small molecule binders via in silico 
screening that were subsequently developed into inhibitors (most potent IC50 = 5.3 μM).193 As this site 
is also the putative type I receptor binding site, it represents a good target site for developing 
inhibitors. In addition to this site, analysis performed by Chris Radoux (University of Cambridge, 
unpublished work) using methodology as described in Radoux et al.230 on the mature activin A 
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structure identified the presence of a potential second binding site at the dimer interface (Figure 5). 
This was through the identification of two hydrophobic hotspots close to the dimerization cysteine. 
Greenwald et al. have suggested that flexibility about the dimerization cysteine may play an important 
role in activin A signalling.103 As such, a molecule that binds here may be able to conformationally lock 
the activin A dimer, thus antagonising its signalling. These factors considered, I decided to conduct a 
fragment screen on mature activin A. 
 
Figure 5: Binding hotspots on the surface of mature activin A. Here mature activin A is shown in yellow and grey 
and the hotspots in pink. Figure adapted from work performed by Chris Radoux. 
In this section I will describe the fragment screening of mature activin A crystals using the XChem 
platform. I will describe how crystallisation conditions were optimised for fragment screening before 
identifying small molecule binders through the screening process. I will then discuss how several of 
the binding molecules were further validated via x-ray crystallography and how their in-solution 
binding was analysed via ligand-based NMR spectroscopy. 
2.2 Optimization of Crystallisation conditions for Fragment 
Screening of Mature Activin A 
In order to conduct a fragment screen on mature activin A, crystallisation conditions first needed to 
be optimised from those first described in Harrington et al. for soaking.77 Crystallisation under the 
original conditions (1.2-1.5 M (NH4)2SO4, 2-3 % PEG300, 100 mM Hepes, pH 7.4-7.8, 6 mg/mL activin 
A in 20 % acetonitrile) did not contain DMSO (the solvent most commonly used in fragment libraries). 
The addition of DMSO to crystals has been reported to result in osmotic shock in a number of systems 
which leads to degradation of the crystal. In order to minimise such a shock, the effect of DMSO on 
crystallisation was investigated. 24-well screens were set up, where the concentrations of (NH4)2SO4, 
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PEG 300, and mature activin A were varied against an increasing concentration of DMSO (100 mM 
Hepes pH 7.4 was present in all conditions). Crystals grew in most wells, with the protein first 
precipitating before crystallising from the precipitate. Nucleation was observed to increase with 
increasing concentration of (NH4)2SO4, PEG 300, DMSO and activin A. Of these, DMSO had the most 
potent effect with unsuitably small crystals being observed at concentrations higher than 2 %. The 
only condition that produced a low number of crystals of reasonable size was 1.65 M (NH4)2SO4, 4 % 
PEG 300, 100 mM Hepes pH 7.4, 2 % DMSO, 3.6 mg/mL activin A. A crystal from this condition was 
tested for diffraction properties. 
Due to the concentration of (NH4)2SO4 and presence of DMSO in the crystallisation conditions, no 
additional cryoprotectant was used when harvesting the crystal. The crystal was shot at i03 beamline 
at Diamond Light Source using X-ray wavelength of 0.9763 Å, diffracting to 2.1 Å (for crystallographic 
statistics, see Appendix 1). This is similar to the resolution observed by Harrington et al. for crystals 
that do not contain DMSO (2.0 Å)77 suggesting crystallising activin A in the presence of 2 % DMSO does 
not significantly affect diffraction quality. Analysis of the structures of DMSO-containing condition and 
original structure (PDB:2ARV) showed no significant structural differences between the two with a 
PEG molecule binding in the hydrophobic pocket thought to be the type I receptor binding site (Figure 
6). Density corresponding to DMSO was only observed at one site on the protein, in the hydrophobic 
pocket present on the other subunit where it interacted with W338 and Y403. Based on this it was 





Figure 6: The crystal structure determined for mature activin A grown in the presence of DMSO. Here the structure 
of the DMSO mature activin A is shown in green (subunit A) and white (subunit B), and the structure of mature 
activin A (PBD ID: 2ARV) is shown in yellow (subunit A) and white (subunit B) A) Structure of the DMSO mature 
activin A structure aligned to the structure of mature activin A. B) The PEG binding sites of 2ARV (left) and the 
DMSO structure (right). Here we see no significant difference between the two. C) The putative type I receptor 
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binding site unoccupied by PEG in the DMSO structure. Here we see a DMSO molecule interacting with residues 
W338 and Y403 on chain A. 
Fragment screening using the XChem platform is designed to use 96-well 3-drop Swiss CI plates. As 
such, conditions needed to be optimised from those reported above for a 96 well format. A screen 
varying (NH4)2SO4 concentration against DMSO concentration was set up in 96-well 3-drop Swiss CI 
plates. Conditions were again selected based on crystals being large and uniform with low levels of 
nucleation occurring. Generic trends were seen similar to those observed in the 24 well format, with 
increasing (NH4)2SO4 and DMSO resulting in increased nucleation. Based on visual inspection of the 
plate, a crystallisation condition of 1.55 M (NH4)2SO4, 8 % DMSO produced a single  needle-like crystal, 
measuring approximately 700 μm in the longest dimension and uniform thickness (Figure 7). Thus, 
mature activin A crystals crystallised under the following conditions were taken forward for XChem 
screening:   
 1.55 M (NH4)2SO4  
 100 mM Hepes pH 7.4 
 4 % PEG 300 
 8 % DMSO 
 3.6 mg/mL activin A in 20 % acetonitrile 
 
Figure 7: Crystallisation of mature activin A in the presence of DMSO. Crystals of mature activin A grown in the 
96 well crystal screen as described above. A) A crystal generated in the condition selected for XChem screening. 
Here we see only one large, unclustered, needle-like crystal is produced. B) crystals produced from a condition 
containing a higher concentration of (NH4)2SO4 and DMSO. Here we see many crystals that are smaller in nature 
with more clustering. 
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2.3 XChem Screening of Mature Activin A 
The first step of conducting the fragment screen was to establish the DMSO tolerance of the crystals. 
This would allow for the determination of the highest possible concentration of fragment a crystal 
could be soaked with as the library stock solutions are at concentrations of 250 mM or 500 mM 
compound in DMSO. Crystals drops were soaked with DMSO in increasing increments up to 20 %. 
Crystals were allowed to equilibrate at room temperature for 1 hour before harvesting and data 
collection. No significant increase or decrease was seen in resolution trend across the crystals 
suggesting that concentrations of up to 20 % DMSO did not affect resolution. To maximise 
concentration of fragment, initial test was done using 5-fold diluted fragments with final 
concentration of 50 or 100 mM fragment and 20% DMSO. Despite good tolerance for DMSO, in the 
presence of high concentrations of fragment a large number of crystals dissolved or lost diffraction. 
To avoid this, the soaking concentration was lower by half which resulted in no loss of crystal number 
or reduction of diffraction; most crystals diffracted to approximately 2.0-2.4 Å resolution. Thus, a 
fragment concentration of 25 mM / 50 mM was selected for the full fragment screen.  
Crystals were then screened in a similar manner with fragments from different libraries. Libraries 
were selected based on their coverage of chemical space and the ease with which derivatives and 
similar molecules could be obtained. In total 345 compounds from three libraries, were successfully 
screened: Edelris Keymical Fragments, Kidd 3D and DSPL.231,232 PanDDA requires a series of refined 
structures and associated diffraction data to perform its analysis. As such, structures of each 
successfully diffracting crystal that had higher resolution than 2.5 Å were solved and refined using 
the Dimple pipeline (part of CCP4)233 and datasets were analysed via PanDDA. Analysis of the 
datasets via PanDDA revealed that of these 345 compounds, 13 were detected in two main sites – 
the putative type I receptor binding site and the interfacial site identified by Chris Radoux ( 
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Table 3, Figure 8). Of these sites, the putative type I receptor binding site was significantly more 
favoured with 12 of the 13 compounds interacting here. Interestingly, despite being a symmetrical 
protein with two identical binding sites (be it two putative type I receptor binding sites or one 
interfacial site with two identical epitopes), binding was only observed in each case in one of the 
binding sites, likely due to accessibility in the crystal. In addition, different fragments were observed 
to bind to the same site on different chains of the dimeric protein, further validating these as 
legitimate hits. This was the case for molecules that bind to the type I receptor binding site, with three 
hits binding to one chain and nine binding to the other. As such, it may depend on the specific molecule 




Table 3: Fragment hits identified in XChem screen for mature activin along with the interacting residues for 
each fragment. TIRB refers to the putative type I receptor binding site whereas IF refers to the interfacial site.  
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Figure 8: XChem screen of mature activin A. A) The overlaid alignments of all structures obtained for fragment 
hits from the XChem screen to the DMSO structure of activin A. For clarity, the surface of the original DMSO 
structure is shown. B) The structure of all 12 fragment hits bound to mature activin A in the putative type I 
receptor binding site as identified from the XChem screen. Here the structure of each fragment fitted to the 
density is shown along the fragment fitted to the density in the binding site and fitted with a surface 
representation. C) The structure of FMOPL000578a bound to mature activin A in the interfacial site as identified 
from the XChem screen. Here the structure of each fragment fitted to the density is shown along the fragment 
fitted to the density in the binding site and fitted with a surface representation. 
The most common binding site observed for fragments was the groove in the putative type I receptor 
binding site (Figure 8B). Molecules that bound at this site were generally hydrophobic in nature, often 
containing large aromatic or aliphatic rings with few hydrogen bonding groups. As such, the nature of 
the interactions with residues in this site were usually hydrophobic, with interactions with the side 
chains of W335, W338, M401, Y403, I415, and M418 of chain A being the most common, as well as 
F368 of chain B. Incidentally, this is advantageous for inhibitor development as Harrison et al. 
identified M401, I415, and M418 as being crucial residues for mediating ALK4 binding thus by 
interacting with these residues, a molecule may inhibit signalling.216 Though not directly implicated as 
being crucial to binding by Harrison et al., residues F368 and Y403 sit in proximity to M401, I415, and 
M418 at the entrance to a binding surface containing these residues. As such, molecules that interact 
with these residues appear to block access to the binding surface and so may be able to prevent ALK4 
from binding. Incidentally, though interactions with M401, I415, and M418 are not seen for every hit, 
interactions with F368 and/ or Y403 are observed in every structure. 
Only one molecule from the entire screen was identified to bind at the dimer interface, 
FMOPL000578a (Figure 8C). This site is of interest due to the role of Activin A’s flexibility about its 
dimerization cysteine in binding to type II receptors. The structure obtained by Greenwald et al. (PDB 
ID: 1NYS) of activin A bound to two ActRIIB extracellular domains both show a reduction in the angle 
about the dimerization cysteine compared to the structure of mature activin A (58.0° vs 97.4°) (Figure 
9).103 As such, its is postulated that this change in conformation is crucial in creating an interface that 
allows they type I receptor to bind. Therefore, it is possible that a molecule that binds in the interfacial 
site may reduce the mobility of the activin A subunits, thus preventing the creation of the type I 
binding interface and allosterically inhibiting signalling.  
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Figure 9: Alignment of mature activin A and receptor bound structures. Alignment of the mature activin A 
structure to the structure of activin A (yellow / grey) bound to the extracellular domains of ActRIIB (orange) (ECDs 
of ActRIIB removed). Angles are calculated between Cα of Y403,  Cα of C390, and Cα of Y403 of the other subunit. 
In contrast to the molecules that bind in the vicinity of the type I receptor binding site, FMOPL000578a 
appears more hydrophilic, containing several hydrogen bonding groups. Indeed, the majority of 
interactions here appear to be hydrogen bonds, formed with the sidechain of S362 of chain B, as well 
as the backbone of P393 and T394 of chain A and P393 of chain B. A hydrophobic interaction does 
appear to be present between L396 of chain A and the hydrophobic face of the 6-membered ring 
though this is the only clear major hydrophobic interaction observed. This indicates that the nature of 
this pocket is significantly less hydrophobic than the type I receptor binding site. This is also reflected 
in the detection of water molecules in this site in the apo structure. Similar to the type I receptor 
binding site hits, the majority of density corresponding to the molecule is only observed in one half of 
the symmetrical binding pocket. Due to the symmetrical nature of this pocket, one possible 
optimisation route would be to take the key binding motif of the hit and develop a molecule containing 
two of these motifs joined by a linker. However due to the time constraints of the project, further 
optimisation or targeting of this binding site was not attempted.    
Of the binders identified, the four hits from the Kidd 3D library that bound in the putative type I 
receptor binding site were selected for further analysis – NM466, HLS327, SG5B8, SG6B10. This was 




2.4 Validation of Binding of NM466, HLS327, SG5B8, and SG6B10 to 
Mature Activin A via X-ray Crystallography 
In order to validate the binding of NM466, HLS327, SG5B8, and SG6B10 to mature activin A each 
molecule was screened via X-ray crystallography again. 
Before soaking, crystallisation conditions were further optimised to improve data quality. The ability 
of PEG 300 to bind to the same site as the four fragments (or the binding site on the opposite side of 
the molecule) could be problematic. Fragments may have to compete with PEG for binding which 
could lead to difficult-to-interpret density. Therefore, it was decided to attempt crystallisation in the 
absence of PEG 300. Initial attempts to crystallise activin A in the absence of PEG 300 failed, however 
microseeding with PEG 300 containing crystals facilitated crystal formation with needle like crystals, 
similar to those described previously, forming (for crystallographic statistics, see Appendix 1). Analysis 
of the structure obtained shows a key difference in the fragment binding site compared to the PEG 
300 containing structure (Figure 10). In the “PEGless” structure, W338 adopts a difference 
conformation to that seen in the PEG containing structure, with the side chain being flipped such that 
it sits adjacent to the side chain of W335 appearing to undergo π-stacking interaction. Similar to the 
non-PEG containing binding site in the DMSO structure, W338 also appears to hydrophobically interact 
with a DMSO molecule. This is in opposition to the PEG containing structure where the sidechain 
adopts a different conformation to accommodate PEG binding. As such, this residue can act as a useful 
tool for screening, as monitoring the conformation of this residue may indicate binding of a 
compound. 
 
Figure 10: The “PEGless” structure of mature activin A. The structure of the PEG binding site in the “PEG 
containing” (left) and “PEGless” (right) structures. Here, the “PEG containing structure is shown in green and 
white and the “PEGless” structure is shown in cyan and pale blue.  W338 and interacting residues are highlighted. 
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Crystals of mature activin A were soaked with 40 mM NM466, HLS327, SG5B8, and SG6B10 and 
diffraction data was collected. All four crystals diffracted with resolutions of 2.0 Å respectively (for 
crystallographic statistics, see Appendix 1). After refinement only NM466 showed the presence of a 
large unoccupied density at the molecule binding site. As chiral molecules in the Kidd 3D library exist 
as racemic mixtures, it was important to determine which of the two enantiomers were binding. As 
such, both enantiomers were fitted into the density in separate refinements. From fitting these 
molecules, it was determined that the (R)-enantiomer corresponded much better to the observed 
density than the (S)-enantiomer and thus the (R)-enantiomer is interacting with mature activin A 
(Figure 11A).  
 
Figure 11: Binding of NM466 to mature activin A. A) The structure of NM466 soaked mature activin A solved with 
the (S)- (left) and (R)- (right) enantiomers B) NM466 bound to the putative type I receptor binding site. A ribbon 
representation with the interacting residues is shown on the left whereas a surface representation is shown on 
the right. Here carbon atoms are shown in yellow and grey, oxygen atoms are coloured in red, nitrogen in blue, 
and sulfur in gold. 
NM466 utilises a compact,  folded conformation when binding to mature activin A, with the 7-
membered bi-lactam ring adopting a boat-like conformation (Figure 11B). As such the hydrophobic 
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propyl chain is positioned axially to the ring allowing for maximisation of the hydrophobic interactions 
between the molecule and activin A. The majority of the interactions are hydrophobic with NM466 
interacting hydrophobically with W335, I339, M401, Y403, I415 and M418 of chain A plus F368 and 
T371 of chain B. W338 adopts a similar conformation to that observed in the structure without PEG, 
creating the pocket to which NM466 binds. A π-stacking interaction between the phenyl ring of 
NM466 and W335 also appears to be present. Hydrophilic interactions between NM466 and mature 
activin A are significantly less common than hydrophobic ones, with only one hydrogen bonding 
interaction appearing occur. This occurs between the nitrogen of W338’s indole and the carbonyl of 
one of the amide groups of NM466 measuring 2.4 Å. Based on these observed interactions, a series of 
derivatives of NM466 where designed and synthesised in collaboration with Prof David Spring’s group 
(Department of Chemistry, University of Cambridge)  to validate binding to mature activin A and 
explore SAR. (Figure 12, Table 4). 
2.5 Screening of Derivatives of NM466 against Activin A 
A total of 10 derivatives of NM466 were soaked into activin A crystals for screening via X-ray 
diffraction. Of these, only one, TR17, showed density corresponding to the molecule binding with no 
obvious density being observed for the others. 
 
Figure 12: The generic structure of a NM466 derivative.  
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Table 4: Screened derivatives of NM466.  
Compound R1 R2 R3 R4 Observed Binding? 
NM466 Me Me Pr H Yes 
T17 Et Me Pr H Yes 
TR19 Me Ph Pr H No 
TR22 H Me Pr H No 
TR28F1 Me Me 
 
H No 
TR28F2 Me Me 
 
H No 
TR61 Me Et Pr H No 
TR75 Me H H H No 
TR78 Pr Me Pr H No 
TR80 Me Me Pr Me No 
TR81 Bu Me Pr H No 
 
TR17 differs in only one position from NM466, with an ethyl group replacing the methyl group at 
position R1. Both molecules bind in a similar manner with adopting the same conformation and 
interacting with the same residues on activin A. The binding of TR17 is slightly rotated compared to 
that of NM466 to accommodate the increased interactions between the ethyl group at R1 and M401 
and Y403 (Figure 13). The identity of R1 appears to have a large influence on binding. For molecules 
with either a methyl or ethyl group placed at position R1, binding to mature activin A was observed. 
However, for molecules with propyl or butyl groups in the same position it was not –  likely due to the 
steric clashes between mature activin A and these larger groups. Interestingly, TR22 which has a 
hydrogen atom positioned at R1 did not bind to mature activin A. This may be due to an alternate 
conformation of TR22 being more energetically favourable than the observed binding conformation 
of NM466 and TR17, thus there are a lower number of molecules in the binding conformation so 
binding is not detected. Of the other derivatives, it is likely the majority of molecules did not bind due 




Figure 13: Binding of TR17 to mature activin A. A ribbon representation with the interacting residues is shown on 
the left whereas a surface representation is shown on the right. Here carbon atoms are shown in yellow and grey, 
oxygen atoms are coloured in red, nitrogen in blue, and sulfur in gold. 
Ligand-based NMR was attempted to determine if NM466 and TR17 bound to activin A however the 
data was inconclusive (data not shown). Due to the time constraints of the project, no further 
derivatives were screened. 
2.6 Conclusions 
In this section, I have described how the crystallisation conditions of mature activin A were optimised 
for fragment soaking. I then described how a 345-fragment screen was conducted against activin A 
using the XChem platform with PanDDA analysis to identify a total of 13 binding fragments. These 
fragments bound in two distinct sites – the putative type I receptor binding site, and an interfacial site 
adjacent to the dimerization cysteine. I then took four of these compounds, NM466, HLS327, SG5B8, 
and SG6B10, forward for further validation via X-ray crystallography. From this, I only observed density 
for NM466 and  determined that the (R)-enantiomer was interacting with activin A.  Derivatives of this 
molecule were then screened via X-ray crystallography resulting in the identification of one further 
binding compound, TR17, which bound in a similar manner. Ligand-based NMR spectroscopy was then 
used to analyse the in-solution binding of NM466 and TR17 however the data was inconclusive. 
Based on these results, I would say the viability of this pocket is questionable. The pocket is relatively 
large (surface area = 1700 Å2, volume = 950 Å3) and the highly hydrophobic nature of the pocket means 
that specific interactions would be difficult to achieve. As such, binding molecules must depend on a 
number of non-specific hydrophobic interactions spread across a large surface area. Therefore, it is 




In the next section, I will discuss how I used an alternate approach for developing inhibitors of activin 







             
Peptide Approach 





In addition to a small molecule approach, a peptide-based approach was also attempted to achieve 
inhibition of activin A signalling. The generation of peptide inhibitors has certain advantages when 
compared to small molecule, especially with regards to protein-protein interactions. As larger 
molecules, peptides can take advantage a number of weak interactions across a wide surface area to 
create high affinity binding. Additionally, due to the large number of interactions, interactions can be 
tuned at specific sites to create highly specific binding. Thus, peptides are less likely to suffer from off-
target interactions and events. This is highly desirable in the case of the TGF-β family where the 
structural and sequence similarity of the ligands and ligand promiscuity make high specificity a 
requirement of any inhibitor. However, issues can arise from peptides’ lack of membrane permeability 
and susceptibility to proteolysis.234,235  
The TGF-β family ligands are good candidates for peptide-based inhibition. As they are extracellular 
proteins, there are no requirements for an inhibitor to cross the cell membrane. Furthermore, as only 
the mature growth factor is required for signalling, the TGF-β family has a natural starting point for 
designing peptide inhibitors – the pro-domains. Each dimeric TGF-β ligand is made up of two pro-
domains and two mature domains. After expression, the pro-domains are cleaved from the mature 
domains but remain in association.94 Though important for solubility, stability, and storage, pro-
domains are not believed to be actively involved in signalling, dissociating to allow receptor binding 
to occur.95,104,106 Pro-domains usually bind their mature growth factor with high affinity and it has been 
shown that for several members of the family the pro-domain can also inhibit signalling, though the 
potency of this inhibition is highly dependent on the growth factor in question.99,108 Pro-domains have 
already been used as inhibitors with pro-domain-based ligand traps being used to inhibit activin A 
signalling (See “1.6 Inhibitors of TGF-β Family Signalling”) (Figure 4).236 Makanji et al. also developed a 
chimeric inhibitor through fusing the α1-helix-loop-α2-helix motif of activin A to the shoulder region 
of the TGF-β1 pro-domain. This inhibitor inhibited activin A signalling with an IC50 of 2.6 nM.188 Peptide 
inhibitors based on the N-terminal region of myostatin pro-domain have been shown to successfully 
inhibit myostatin signalling. Takayama et al. developed inhibitors based on the mouse pro-domain, 
identifying a minimal binding peptide with an IC50 value of 3.5 μM in a cell-based assay and a Kd value 
of 30 nM for the mature domain obtained via surface plasmon resonance (SPR).  Since then the 
peptide has been optimised through increased interactions with the mature domain and introduction 
of a staple. This has led to an approximately 13-fold increase in inhibitor potency with an IC50 value of 
260 nM for the most potent inhibitor.189,190 
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The region that all these inhibitors are based on is N-terminal segment of the pro-domains. This region 
is of particular interest as it contains the α1-helix-loop-α2-helix motif that was discussed previously 
(see “1.4 The Structural Features of the TGF-β Family and Activin A”). Analysis of the individual 
residues in this region show the region is highly hydrophobic, with residues being conserved across 
the family. The currently available pro-domain structures also show how residues in this region form 
the majority of contacts with the mature domains (Figure 14A). The pro-domain of activin A has a high 
affinity for the mature growth factor (5 nM measured via BLI) and it is likely that the affinity is due to 
the interactions in this motif. 104 Therefore, I decided to use the α1-helix-loop-α2-helix motif of the 
activin A pro-domain to develop inhibitors for activin A signalling.  
3.2 Design of Peptide Fusions 
In order to generate inhibitors for activin A based on its pro-domain, it was first important to identify 
the key motifs that were vital for mature domain binding. Analysis of the structure of the activin A 
pro-mature complex shows the majority of the interacting pro-domain residues occurs between Q51-
E104 (Figure 14). This sequence contains the α1-helix-loop-α2-helix motif typical of TGF-β family pro-
domains along with the highly conserved hydrophobic residues present across the pro-domains of all 
TGF-β family members. In this epitope, the 1-helix binds to the putative type I receptor binding site 
on the concave face of the mature domain and the 2-helix binds to the convex face in the vicinity of 
the type II receptor binding site. A β-hairpin that follows the 2-helix also appears to make a number 
of contacts on the convex face. Based on this, five peptides were designed incorporating motifs that 
















Figure 14: Pro-domain derived peptides of activin A. A) The structure of the pro-mature complex of activin A. 
Here one of the pro-domains (light pink) has been made transparent and the α1-helix, loop, α2-helix and the β-
Hairpin of the other (magenta) highlighted. The mature domains are shown in yellow and grey B) Representations 
of the peptides used in this project based on the pro-mature structure. Here H1LH2β is shown in blue, H1LH2 in 
green, LH2β in orange, H2β in gold, and H1L in red. C) Representations of the peptides used in this project based 
on the pro-mature structure bound to mature activin A. 
 
Table 5: Pro-domain derived peptides of activin A.  
Peptide Features Residue Range 
H1LH2β α1-helix-loop-α2-helix-β-hairpin Q51-E104 
H1LH2 α1-helix-loop-α2-helix Q51-H91 
LH2β loop-α2-helix-β-hairpin K69-E104 
H2β α2-helix-β-hairpin Q76-E104 
H1L α1-helix-loop Q51-Q76 
 
Due to the length of the designed peptides (26-74 amino acids) it would be uneconomical and 
inefficient to purchase them commercially or synthesise them via solid phase peptide synthesis. I 
therefore decided that the peptides would be generated as fusion proteins with an N-terminal B1 
domain from streptococcal protein G (GB1). GB1 is well characterised as a fusion partner and its C-
terminus is positioned such that the peptide inhibitors are left exposed for interactions in solution. In 
addition, an N-terminal His-tag and C-terminal StrepTag II were incorporated to allow a two-step 
purification where the protein is first purified by Ni affinity chromatography followed by StrepTactin 
affinity chromatography.237 The exposed nature of the pro-domain epitopes means that proteolytic 
degradation by cellular proteases during the expression phase is likely. Therefore the dual purification 
system allows for any product that has undergone degradation at the N-terminus to be removed in 
the first step and any that has undergone degradation at the C-terminus to be removed in the second 
step, allowing for the isolation of the desired full-length peptide fusion only (for full construct 
sequences, see Appendix 2). 
3.3 Cloning of Peptide Fusions 
To generate the peptide fusions desired, it was first necessary to obtain a vector that incorporated the 
desired tags and fusions partners. The vector pOP5BP, used already in the Hyvönen Group, contained 
DNA encoding an N-terminal His-tag, GB1 domain multiple cloning site, and a C-terminal Avi tag, 
however lacked the desired C-terminal Strep-tag II. Thus, pOP5BP was restriction digested to remove 
the Avi-tag. Primers encoding Strep-tag II with 5  and 3  restriction sites for incorporation into pOP5BP 
were the directly annealed and phosphorylated before being ligated into digested pOP5BP to generate 
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pOP4BP (Figure 15). The success of the ligation for this step and all subsequent ligation steps was 
determined via Sanger sequencing. 
 
Figure 15: The pOP4BP vector. Here, the design of the pOP4BP vector employed in this study is shown. The 
multiple cloning site has been expanded so the restriction enzyme cutting sites are displayed. 
Once the vector was generated. It was necessary to generate the peptide fusions themselves. DNA 
encoding the sequences for the peptides was amplified via polymerase chain reaction using 
appropriate primers with 5  and 3  restriction sites for incorporation into pOP4BP, and a template of 
pHAT2-activin A (residues 21-426, Uniprot P08476). Amplified DNA was then ligated into pOP4PBP. All 
subsequent peptide fusions described in this section were generated in the same manner.  
3.4 Expression and Purification of Peptide Fusions 
Successfully cloned peptide fusions and doubly tagged GB1 were transformed into chemically 
competent E. coli BL21 (DE3) cells for expression. In order to determine the optimal temperature for 
expression, test expressions were conducted at 37 °C, 25 °C and 16 °C (Figure 16). Analysis of the 
subsequent polyacrylamide gel revealed prominent bands in the soluble fraction of each sample at 25 
°C corresponding to the approximate molecular weight of the desired products. Though higher 
amounts of expression are observed for GB1-LH2β at 37 °C, expression appears lower in the majority 
of cases with the amounts of GB1-H1LH2 and GB1-H2β being significantly lower than that observed at 
25 °C. Samples grown at 16 °C show similar expression to those grown at 25 °C, however due to the 
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quicker expression time, 25 °C was selected as the expression temperature. Based on this, expression 
in 1 l cultures was then conducted at 25 °C. 
 
Figure 16: Expression tests of pro-domain derived peptide fusions. Expression tests conducted in BL21 (DE3) cells 
of the peptide fusions at 16 °C (A), 25 °C (B), and 37 °C (C). Here we see prominent bands in the soluble fraction 
for all peptides at 25 °C. 
After expression,  the peptide fusions were successfully purified via a two-step Ni-affinity-StrepTactin 
affinity purification. Analysis of the SDS-PAGE gels of the Ni-affinity purification shows that all the 
peptide fusions were successfully expressed however significant degradation products are present in 
each sample at lower molecular weights (Figure 17). To isolate the desired product from this mixture, 
each Ni-affinity purified sample was further purified via StrepTactin affinity purification. Here there is 
a single prominent band in each sample at the expected molecular weight indicating each protein had 
been successfully purified. To confirm the identity of the peptide fusions, each sample was analysed 
via intact MALDI-Tof mass spectrometry (Table 6). The molecular weight of each sample determined 
via mass spectrometry compares well with that of the calculated mass, differing only in each case by 
2 Da (likely due to protonation and deamidation). Therefore, it was determined that each peptide 






Figure 17: Purification of the peptide fusions via Ni-affinity and StrepTactin affinity purification. Here, SDS-PAGE  
gels are shown of the Ni-affinity and StrepTactin affinity purifications of each peptide. In each case we see the 
degradation product present after Ni-affinity purification is removed after StrepTactin affinity purification. 
 
Table 6: Molecular weights of peptide fusions as determined via mass spectrometry. 
Peptide Fusion Calculated MW / Da Observed MW (Mass Spec) / Da 
GB1 11508.47 11510.20 
GB1-H1LH2β 16837.82 16840.22 
GB1-H1LH2 15463.30 15465.14 
GB1-LH2β 14725.24 14727.64 
GB1-H2β 13900.26 13902.21 
GB1-H1L 13840.28 13842.89 
 
3.5 Identification of the Key Binding Motifs in the Activin A Pro-
domain 
To determine which pro-domain motifs were vital for mature domain binding, the purified peptide 
fusions were analysed via biolayer interferometry (BLI). Peptide fusions were immobilised on anti-His 
tips and immersed in solutions of mature activin A at 100 nM and 1 μM. Doubly tagged GB1, was 
deemed to have a small but non-zero interaction with mature activin A, however this was at a 
significantly lower value than interacting motifs. As such, it was used as a reference to confirm binding 
was specific and all fusions were normalised to this (Figure 18 – Raw data: A, Normalised data: B).  
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Figure 18: Identification of the key binding motifs of the activin A pro-domain via BLI. A) Unnormalized BLI traces 
of the peptide fusions at binding to 100 nM mature activin A. B) Normalized BLI traces of the peptide fusions 
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binding to 100 nM and 1 μM of mature activin A. Here the association phase occurs between 0-300 s and the 
dissociation phase between 300-600 s. 
Analysis of the binding traces shows that GB1-H1LH2β, GB1-H1LH2 and GB1-H1L showed significant 
binding relative to the GB1 control whereas GB1-LH2β and GB1-H2β did not, demonstrating the α1-
helix and possibly the loop are important for mature domain binding. This compares well with 
observations made for myostatin and that the α1-helix and the initial residues of the loop are vital for 
mature domain binding.189 The data reveals also that the β-hairpin does not appear to make a 
significant contribution to binding, with the binding profiles of GB1-H1LH2β and GB1-H1LH2 showing 
minimal, if any, difference. Additionally, though the α2-helix does not to bind to mature activin A 
alone, it does appear to contribute towards binding, with the response magnitude and dissociation 
rates of GB1-H1LH2β and GB1-H1LH2 being larger and slower than that of GB1-H1L. Overall, this 
indicates that the α1-helix and the loop are the key motifs of the pro-domain for binding to the mature 
activin A.  
Interestingly, closer inspection of the BLI data showed that plateau was not reached in the association 
phase for any of the peptides. Instead the response increased at an apparent constant rate. In 
addition, full dissociation of activin from the peptides did not occur in any instance, with signals not 
returning to the baseline in the dissociation phase. When the raw data is analysed, both observations 
are still present, only more severely. Initial attempts at determining the Kd of GB1-H1LH2 and GB1-H1L 
proved successful however, the kinetic model poorly fit the data (Figure 19A and B). There are two 
major possibilities for this. The first is that the anti-His antibodies used to immobilise the peptide 
fusions are holding two peptides in close spatial proximity, thus creating an avidity effect. As such, 
two association and dissociation events are being observed, the binding of one peptide fusion to 
activin A followed by a second. These interactions will have different kinetic rates and thus the 
measured change in response will be a combination of these two kinetic events resulting in the drift 
in the association phase and lack of return to baseline in the dissociation phase. To see if this was 
indeed the case, an additional BLI experiment was performed where biotinylated activin A was 
immobilised to streptavidin tips and immersed in a solution of GB1-H1L (Figure 19C). As GB1-H1L is 
monomeric with only one site of interaction for activin A, the drift in the association phase and lack of 
return to baseline in the dissociation phase should not be observed. However, this was not the case 









Figure 19: Kd determination of GB1-H1LH2 and GB1-H1L for mature activin A via BLI and ITC. A) The binding profiles 
generated for the interaction between GB1-H1LH2 and mature activin A from BLI (top) and ITC (bottom). B) The 
binding profiles generated for the interaction between GB1-H1L and mature activin A from BLI (top) and ITC 
(bottom). In both cases the processed data along with the fitting is shown. C) The binding profiles generated for 
the interaction between GB1-H1L and mature activin A from BLI. This time mature activin A is immobilised on 
streptavidin tips and immersed in a solution of GB1-H1L D) The binding profiles generated for the interaction 
between GB1-H1L and mature activin A from BLI. This time mature activin A is directly immobilised onto AR2G 
tips and immersed in a solution of GB1-H1L E) Binding profile of double tagged GB1 to mature activin A. Here we 
see there is no significant binding observed. 
The second possibility is that the peptide fusions or activin A undergo a secondary non-specific 
interaction with either the antibodies to which they are immobilised or the dextran matrix at the end 
of the fibre optic cable, thus resulting in a second kinetic event. To test if this was the case, activin A 
was directly immobilised onto AR2G tips and immersed into a solution of GB1-H1L (Figure 19D). As 
there are no antibodies present, if a secondary kinetic event is still observed it is likely due to 
interactions between the peptide fusions or activin A and the matrix. Again, this time there was a 
continuous upward drift throughout the experiment making it likely that either the peptide fusions or 
activin A interact non-specifically with the dextran matrix. As such, I decided though BLI may be 
appropriate for qualitative experiments, alternative methods should be used for quantitative 
experiments.  
The alternate method chosen was isothermal titration calorimetry (ITC). Unlike BLI which uses kinetic 
methods to determine Kd, ITC determines the thermodynamic parameters of an interaction, from 
which Kd can be calculated. Furthermore, it is an in-solution measurement that requires no additional 
antibodies or dextran matrices. Peptide fusions at a concentration of 100 μM were injected into an 
experimental cell containing solution of mature activin A at 4 μM (here all mature activin A 
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concentrations refer to the mature activin A dimer and not a single protomer chains). From this, the 
heats of interaction were measured and a binding profile generated (Figure 19A and B). If the 
stoichiometry determined from this profile was within 10 % of a whole number, the ligand 
concentration was adjusted such that the stoichiometry was a whole number and Kd was calculated 
accordingly. Doubly tagged GB1 was again used as a control and it was determined that there was no 




Table 7: Dissociation constants determined for the interaction between mature activin A and peptide fusions. 
 
* For GB1- H1LH2, the Kd and N value obtained is an average of three identical ITC experiments. 
Analysis of the Kd values determined from ITC shows a stark difference to those determined via BLI 
(Table 7). The values obtained for GB1-H1LH2 and GB1-H1L from ITC are over 100-fold lower affinity 
than those obtained via BLI (640 nM and 900 nM vs 1.25 nM and 3.11 nM). Affinity measured for GB1-
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H1LH2 (640 nM) is slightly stronger than that measured for GB1-H1L (900 nM) with the additional 
affinity possibly arising from increased interactions with the mature domain due to the presence of 
the α2-helix. However, the similarity in values confirms what was observed via BLI, that the α2-helix 
only contributes weakly towards binding. The stoichiometries determined for both fusions also show 
that in both cases, two moles of peptide fusion interact with every mole of activin A. This is expected 
due to the dimeric nature of activin A meaning two peptide binding sites are present on every 
molecule of protein.   
Comparison of the Kd values obtained from ITC with the reported Kd value of the pro-domain is poor 
(5 nM – obtained via BLI).104 This disparity may be due to additional interactions resulting in a higher 
affinity between the pro-domain and mature domain or due to the difference in methodology. 
Incidentally, the Kd values obtained via BLI compare very well with that reported for the pro-domain 
(1.3 nM and 3.1 nM vs 5.0 nM). Therefore, unless a Kd value for the pro-domain is obtained via ITC it 
is difficult to make a full comparison of the system. Interestingly, the Kd values obtained via ITC do 
compare well with the predicted Kd as reported in Walton et al. (100 nM) however this value is 
obtained from projections made based on inhibition data and no kinetic or thermodynamic 
experiments were performed.238 
3.6 Effect of Chemical Stapling on Binding of Synthetic Peptides to 
Mature Activin A (In Conjunction with Sam Rowe) 
In addition to the peptide fusions described so far, the effect of chemical stapling on the binding of 
synthetic peptides to activin A was also investigated. These synthetic peptides were based on H1L, 
lacking only the two C-terminal residues. The staple that was chosen for this work is N-(4,6-divinyl-
1,3,5-triazin-2-yl)-N-methylglycine. This molecule contains two alkenes which can undergo a Michael 
addition with cysteine residues to form thioethers, therefore by including two cysteine residues in the 
peptide sequence a staple can be introduced (Figure 20A). To select which residues should be mutated 
to cysteines, a structural analysis was performed (Figure 20B). Analysis of the structure of the pro-
mature activin A complex reveals that the residues that could likely be stapled with minimum 
disruption to interactions between the pro- and mature domains were residues 54 and 61 in an i+7 
stapling. This was supported by modelling performed by Tan Yaw Sing (A*STAR, Singapore, 
unpublished data),239 that also suggested the most optimal residues for introducing a staple to be M54 
and H61. Additionally, this analysis also suggested that the mutations V58I and H61F (assuming 
residues 61 is not the site of stapling) may improve the affinity of the peptides for activin through an 




Figure 20: Stapling of synthetic activin A derived peptides. A) Stapling of a peptide through the Michael addition 
of N-(4,6-divinyl-1,3,5-triazin-2-yl)-N-methylglycine to two cysteine residues (Figure provided by Sam Rowe). B) 
Structural analysis of the pro-mature activin A complex using a representation of the full-length peptide sequence 
(blue) with residues M54 and H61 highlighted. In the right picture, a possible surface for the staple to interact 
with activin A is highlighted with shading. In the below picture, potential interacting residues on mature activin 




Table 8: Synthetic peptides screened against mature activin A (synthesised by Sam Rowe). Here X denotes the 
site of stapling (highlighted in red), and all mutations are highlighted in cyan. Kd values were determined via 
ITC. 
 
In total, five peptides were provided by Sam Rowe (Department of Chemistry, University of 
Cambridge) at >95 % purity, of which three contained a chemical staple (Table 8). The binding of these 
peptides to mature activin A was then analysed via ITC (Table 8, Appendix 4). The Kd values obtained 
for Ac-H1ΔLmut (190 nM) and Ac-H1ΔL (400 nM) are slightly lower than that of GB1-H1L (900 nM), 
binding to mature activin A with approximately 2-fold/ 4-fold higher affinity. This may be due to a 
reduced conformational change afforded by the smaller peptide upon binding. The Kd observed Ac-
H1ΔLmut compared to Ac-H1ΔL supports the modelling data suggesting that the mutations V58I and 
H61F increase interactions between the peptide and mature activin A through a more spatially 
optimised fit. However, caution must be taken when drawing conclusions from all these values due to 
their similarity. Interestingly, the addition of staples to Ac-H1ΔLmut appear to reduce its ability to 
interact with the mature domain. Of the three stapled peptides tested, no significant binding was 
observed for two of them, with the third Ac-H1ΔL-56St, showing a 10-fold decrease in affinity (2.1 μM). 
Surprisingly Ac-H1ΔL-54St shows no binding to the mature domain despite the structural analysis and 
computational modelling identifying residues M54 and H61 as the optimal sites for stapling. This 
suggests that additional factors that were not considered in these analyses must be present, such as 
the presence of steric clashes between the staple and mature domain that are not adequately 
modelled using the pro-mature structure. In addition, no binding was seen for the second stapled 
peptide Ac-H1ΔL-53St. The pro-mature structure suggests in this peptide, the staple would be highly 
solvent exposed, which given the hydrophobic nature of the staple, may be energetically unfavourable 
and hinder binding. The only observed binder of the three, Ac-H1ΔL-56St,  shows a reduced affinity 
which again could be due to steric clashes between the staple and C-terminal residues of the peptide, 
reducing its ability to bind. Another possibility is that the staple introduces a conformation constraint 
that significantly hinders binding. Indeed, this is a possibility for all three peptides though further 
experimentation would be required to determine if this is the case. Overall however, stapling with N-
(4,6-divinyl-1,3,5-triazin-2-yl)-N-methylglycine results in a destabilisation of the interaction between 
the peptide and mature activin A compared to the unstapled peptide.  
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In addition to the ITC experiments, co crystallisation was attempted with all the peptides discussed in 
this section (both stapled and unstapled). However, these experiments failed to produce any crystals 
of a peptide-mature activin A complex.  
3.7 Determination of the Minimal Binding Peptide of the Activin A 
Pro-domain 
Previously, I have shown that the α1-helix and the loop are the key motifs for high affinity binding. 
However, this was the shortest peptide used that contained both these epitopes. In order to 
determine what the minimal binding peptide for high affinity binding to mature activin A was, a series 
of N-terminal and C-terminal truncations were generated (Table 9). 




GB1-H1L    QPEMVEAVKKHILNMLHLKKRPDVTQ 
GB1-P52-Q76     PEMVEAVKKHILNMLHLKKRPDVTQ 
GB1-E53-Q76      EMVEAVKKHILNMLHLKKRPDVTQ 
GB1-M54-Q76       MVEAVKKHILNMLHLKKRPDVTQ 
GB1-V55-Q76        VEAVKKHILNMLHLKKRPDVTQ 
GB1-E56-Q76         EAVKKHILNMLHLKKRPDVTQ 
GB1-Q51-T75    QPEMVEAVKKHILNMLHLKKRPDVT 
GB1-Q51-V74    QPEMVEAVKKHILNMLHLKKRPDV 
GB1-Q51-D73    QPEMVEAVKKHILNMLHLKKRPD 
GB1-Q51-P72    QPEMVEAVKKHILNMLHLKKRP 
GB1-Q51-R71    QPEMVEAVKKHILNMLHLKKR 
GB1-H1    QPEMVEAVKKHILNMLHL 
 
In addition, to confirm whether the α1-helix alone bound to mature activin A, an additional construct 
corresponding to the residues Q51-H67 (GB1-H1) was also used.  These peptide fusions, along with 
GB1-H1L, were then analysed via biolayer interferometry using solutions of 100 nM and 1 μM of 
mature activin A (Figure 21). Analysis of the binding profiles of the C-terminal deletions reveals a 
significant loss in affinity at R71, with P72 being observed to be the last residue that results in high 
affinity binding. As P72 is present in the loop rather than the α1-helix, this indicates that the initial 
loop residues are required for binding to mature activin A. This is further supported by the binding 
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profile of GB1-H1 which shows no significant binding to the mature domain. As such, it was decided 
that the C-terminal residue of the minimum peptide should be P72.  
 
Figure 21: Determination of the minimal binding peptide of the activin A pro-domain via BLI. A) Binding profiles 
for the C-terminal deletion peptides to 100 nM and 1 μM mature activin A as determined via BLI. B) Binding 
profiles for the N-terminal deletion peptides to 100 nM and 1 μM mature activin A as determined via BLI. 
The binding profiles of the N-terminal deletions are more difficult to interpret. Of the five peptides, 
GB1-P52-Q76 and GB1-E53-Q76 show a similar binding profile to GB1-H1L (albeit with a slightly higher 
signal) in both 100 nM and 1 μM of mature activin A. By contrast, the shortest peptide GB1-E56-Q76 
shows very low binding at both concentrations. It is the two next shortest peptides however, GB1-
M54-Q76 and GB1-V55-Q76, that make determining the minimal peptide challenging. GB1-M54-Q76 
shows binding to mature activin A at both concentrations, however the association response is lower 
and the dissociation quicker than observed for the longer peptides. GB1-V55-Q76 on the other hand 
shows very low binding at 100 nM however this binding shows an increase at 1 μM. This indicates that 
the loss of E53 and to a lesser extent M54 does not prevent the peptide from being able to bind to 
mature activin A, however it does likely reduce the affinity. Thus, as GB1-E53-Q76 was the shortest 
peptide that closely mimicked the binding of GB1-H1L, it was decided that the minimal peptide should 
be designated as E53-P72.  
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To confirm if GB1-E53-P72 was indeed the minimal high affinity binding peptide, this peptide fusion 
was then generated and binding to mature activin A was confirmed via ITC as described previously. 
From this a Kd was determined of 580 nM (Table 10,). This value compares well with that of GB1-H1L 
(900 nM) and the unmutated synthetic peptide Ac-Q51-V74-NH2 (395 nM). This therefore suggests 
that E53-P72 is the minimal binding peptide for binding to mature activin A.  
Table 10: Dissociation constant determined for mature activin A and the minimal binding peptide as 
determined via ITC. 
Peptide 
Fusion 
Sequence Kd / nM Stoichio
-metry 
ΔH / kcal 
mol-1 
ΔS / cal 
mol-1 K-1 




Figure 22: Determination of the Kd for the minimal binding peptide.. A) Representation of E53-P72 (purple) 
interacting with mature activin A (yellow and grey) based on the structure of the pro-mature activin A complex. 







Figure 23: End-of- α1-helix arginine in TGF-β family members. Arginine residues at the terminus of the α1-helix 
of activin A, myostatin, BMP9, and TGF-β1. Apart from activin A, the other TGF- β family members have no 
aspartate or glutamate residues in their immediate vicinity to form a salt bridge with. In each case, the α1-helix 
and the initial loop residues of the pro-domain have been extracted. Nearby residues are also represented as 
sticks. 
In addition to determining the minimal binding peptide, the C-terminal truncations also revealed that 
the initial loop residues are vital for binding, with truncations not containing residue P72 showing a 
large drop in affinity for mature activin A. Analysis by Tan Yaw Sing (A*STAR, unpublished data) of the 
energetic contributions to binding of each residue in the α1-helix-loop-α2-helix region indicated that 
contribution  comes from the formation of a salt bridge between R71 and D337. Therefore, it is 
possible that the loss of P72 may affect the orientation of these two residues thus resulting in 
destabilisation of the salt bridge and loss of binding. The presence of an arginine residue at the end of 
the α1-helix or start of the loop is not uncommon for TGF-β family members, however an arginine-
aspartate salt bridge interaction appears to be relatively unique to activin A (Figure 23).The structures 
of pro-TGF-β1 (PDB ID: 3RJR102), pro-BMP9 (PDB ID: 4YCG107) and pro-myostatin (PDB ID: 5NTU108) 
show the presence of an arginine residue at the end of the α1-helix that is either not proximal to an 
aspartate / glutamate residue to form a salt bridge or oriented away from the mature domain. 
Alignment of the α1-helix-loop-α2-helix region of activin A with other TGF-β family members shows 
that an arginine residue at the end of the α1-helix is conserved across the activins and many BMPs. 
Due to the high sequence similarity of the activins and ability of H1LH2 to interact with activin B in a 
similar manner to activin A, it is likely this interaction is preserved here. However, with lack of 
structures or alanine scanning for more of the BMPs, it is difficult to say whether this interaction 
occurs. As such this salt bridge may be a unique interaction to the activins that facilitates interactions 
between their pro- and mature domains. 
3.8 Mutagenesis of the Minimal Binding Peptide of the Activin A 
Pro-domain 
To test if the minimal binding peptide could be optimised further, a structural analysis was performed. 
This was to determine whether mutations could be introduced that optimise the spatial fit of the 
peptide into its binding groove and maximise interactions. Analysis of residues E53-P7Z of the pro-
mature complex structure identified three sites for optimisation – The presence of a relatively flat 
hydrophobic surface adjacent to M54, a large channel adjacent to V55, and hydrophobic pocket that 
may not be spatially optimized adjacent to V58 (Figure 24). Based on this, five mutant constructs were 




Figure 24: Selected residues for mutation in the activin A minimal peptide. A structural Analysis of the pro-mature 
activin A complex using only pro-domain residues E53-P72. Here we see the three sites proposed for optimisation 
highlighted. Here, residues selected are shown in cyan. Sites for optimisation on the mature domain are also 
shown in cyan (carbon), red( oxygen) and blue (nitrogen) respectively. In the below figures, carbon atoms in the 
mature domain are shown as black to distinguish them from those in the mutated peptide. 
 
Table 11: Dissociation Constants determined for mature activin A and mutant minimal binding peptides via 
ITC. 
Mutation Sequence Kd / nM Stoichio-
metry 
ΔH / kcal 
mol-1 
ΔS / cal 
mol-1 K-1 
GB1-E53-P72 EMVEAVKKHILNMLHLKKRP 581 ± 68.8 2 -14.0 ± 0.2 -18.6 
M54Y EYVEAVKKHILNMLHLKKRP 1590 ± 338 2 -14.4 ± 0.5 -21.7 
M54W EWVEAVKKHILNMLHLKKRP 1360 ± 131 2 -11.8 ± 0.2 -12.8 
V58I EMVEAIKKHILNMLHLKKRP 654 ± 85.0 2 -14.1 ± 0.2 -19.0 
V58L EMVEALKKHILNMLHLKKRP 585 ± 43.3 2 -12.2 ± 0.1 -12.3 




These mutants were then screened via ITC as described previously (Table 11, Appendix 4). Analysis of 
the resulting binding profiles shows that the mutation of methionine 54 to tyrosine or tryptophan 
appeared to destabilise peptide binding, with an approximate three-fold reduction in affinity. This 
suggests that this surface is not as available for the large aromatic groups as our analysis suggested. 
By contrast, the Kd values observed for the mutations V55Y, V58I, and V58L were highly similar to that 
of the original peptide (690 nM, 650 nM, and 590 nM vs 580 nM). The similarity means the mutations 
introduced do not significantly optimise interactions. However, it may be the case that combinations 
of mutations would have a greater impact on affinity. 
Incidentally, the mutation V58I is one of the two mutations present in the synthetic peptide Ac-Q51-
V74-NH2*‡ which had a Kd value of 190 nM. This peptide had a two-fold higher affinity for mature 
activin A than the equivalent native sequence. As there is no significant difference between the 
mutant V58I and the native sequence in this experiment, this suggests that it may be the mutation 
H61F that contributes the most to the observed higher affinity of the synthetic peptide. However, it is 
difficult to say due to the common observation that the interactions of multiple mutations accumulate 
to produce a more pronounced effect on affinity, which may also be the case here. Due to the time 
constraints of the project it was not possible to test the mutation H61F in the GB1 fusion format. 
3.9 GB1-H1LH2 and GB1-H1L Inhibit Activin A Signalling with 
Micromolar Efficacy 
Based on the binding data, it was decided to investigate whether GB1-H1LH2, GB1-H1L and the 
synthetic peptide Ac-H1ΔLmut could inhibit mature activin A signalling. As these peptides correspond 
to the key binding motifs of the pro-domain and bind in the vicinity of the receptor binding sites, they 
should compete with the type I and II receptors for mature domain binding. Therefore, these peptides 
may be able to inhibit activin A signalling.  
To evaluate the ability of these peptides to inhibit activin A signalling, I used an activin A responsive 
luciferase assay in HEK293T cells. In this assay the cells were transfected with plasmids encoding a 
Smad 2/3 responsive firefly luciferase and a constitutively expressed Renilla luciferase gene. As activin 
A signals through the Smad 2/3 pathway the expression levels of firefly luciferase are dependent on 
the level of activin A signalling, allowing for the effect of the pro-domain fragments to be investigated 
quantitively. Constitutive expression of Renilla luciferase allows normalisation of the data and takes 
into account variations in cell numbers and transfection efficiency. The assay was performed at the 
EC80 concentration of 100 pM as determined by Wang et al. for the same system, 104 and a range of 
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concentrations of GB1-H1LH2, GB1-H1L and doubly tagged GB1 were used from 20 μM – 0.9 nM (for 
Ac-H1ΔLmut, a concentration range of 100 μM – 0.9 nM was used). 
Analysis of the inhibition profile of GB1-H1LH2 and GB1-H1L shows a general inhibitory trend for both 
(Figure 25), however IC50 values could only be approximated as the full inhibition curve could not be 
obtained (cell death occurred at higher concentrations of peptide). These profiles show GB1-H1LH2 
and GB1-H1L inhibit with low micromolar efficacy with IC50 values of approximately 4.4 μM and 3.8 μM 
respectively (Table 12). By contrast, doubly tagged GB1 lacking activin A peptide showed no change in 
activin A response, as expected. This indicates that the His-tag, Strep-tag II, and GB1 domain do not 
contribute towards inhibition and that inhibition was solely due to H1LH2 and H1L sequences, thus 
confirming that the pro-domain derived peptides inhibit activin A signalling. In the case of Ac-H1ΔLmut, 
a general inhibitory trend was observed, however it was not possible to obtain an IC50 value with any 
accuracy. Furthermore, analysis of the normalised responses for each concentration of Ac-H1ΔLmut 
suggests it appears to be a much weaker inhibitor of activin A signalling than GB1-H1LH2 or GB1-H1L. 




Figure 25: Luciferase Assays of GB1, GB1-H1LH2, and GB1-H1L. A) The inhibitory profile of doubly tagged GB1 
inhibiting mature activin A signalling in HEK293T cells. B) The inhibitory profile of Ac-H1ΔLmut  inhibiting mature 
activin A signalling in HEK293T cells. C) The inhibitory profiles of GB1-H1LH2, and GB1-H1L inhibiting mature 
activin A signalling in HEK293T cells. In both cases the log10 of the concentration in nM is plotted against the 
normalised ratios of firefly luminescence: renilla luminescence. Inhibitory profiles are generated from three 
technical repeats. Error bars correspond to one standard deviation of uncertainty. 
Table 12: IC50 values determined for GB1-H1LH2 and GB1-H1L inhibiting activin A signalling. 
Inhibitor Log10 (IC50 / nM) IC50 / nM 
GB1-H1LH2 3.64 ± 0.14 4,400 
GB1-H1L 3.58 ± 0.16 3,800 
 
The similarity between the IC50 values of GB1-H1LH2 and GB1-H1L suggests that the α2-helix 
contributes little towards inhibition. Taking this into account, it is likely that inhibition occurs through 
the α1-helix of the peptides preventing the type I receptors from binding to the type II-ActA complex. 
This is due to the binding site of the α1-helix and the putative binding site of ALK4 overlapping on the 
mature domain. The observation that the main inhibitory motifs are the α1-helix and the loop 
compares well with the previous observation that the motifs required for high affinity binding are the 
same epitopes. This indicates that these motifs must be present to achieve inhibition when designing 
inhibitors based on the pro-domain. Overall, this data shows that peptides derived from the pro-
domain can inhibit activin A signalling, and the key motif responsible for this inhibition is the α1-helix 
and the loop.  
Incidentally, the IC50 values of GB1-H1LH2 and GB1-H1L may be a good approximation of that of activin 
A’s pro-domain. Previous attempts to measure IC50 values for the pro-domain have failed with no 
inhibitory trend often being reported. This is despite evidence suggesting the pro-domain can inhibit 
the downstream effects of activin A. The limitation in both attempts has been the highest 
concentration of pro-domain (10 nM and 100 nM respectively).236,240 Wang et al. has shown that the 
pro-domain alone is likely monomeric.104 As GB1-H1LH2 and GB1-H1L are both monomeric and contain 
the key interacting pro-domain residues, it is likely that the IC50 value of the pro-domain is similar to 
that obtained for these peptides (4.4 μM and 3.8 μM).  
3.10 Conclusions 
In this section I have described the generation of a series of peptide fusions based on the α1-helix-
loop-α2-helix-β-hairpin motif of activin A’s pro-domain and characterised their binding affinity for 
mature activin A. From this I have determined that the α1-helix and the loop play a crucial role allowing 
the pro-domain to bind the mature domain with high affinity whereas the α2-helix and the β-hairpin 
appear to contribute little. I then tested a series of stapled peptides based on the α1-helix and the 
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loop, finding that stapling appeared to have a negative effect on binding, before determining the 
minimal binding peptide to be residues E53-P72. Finally, I tested the effect of two of the original 
peptide fusions, GB1-H1LH2 and GB1-H1L, on activin A signalling. From this I found that they both show 
an inhibitory trend, appearing to inhibit activin signalling with micromolar affinity (approximately 4.4 
μM and 3.8 μM respectively). This therefore shows that pro-domain derived peptides are a viable 
strategy for developing inhibitors of activin A signalling. 
There are multiple ways in which the optimisation of these peptides could be attempted. However, in 
the next section I will discuss how dimerization impacts the inhibitory properties of these peptide 
fusions. I will test both covalent and non-covalent optimisations based on GB1-H1LH2 and GB1-H1L 
before going on to investigate the specificity of the one of the peptide fusions against other members 
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In the previous section I looked how peptide fusions based on the key interacting epitopes of the 
activin A pro-domain bound to and inhibited mature activin A signalling. However, this inhibition was 
observed only at low micromolar level in cellular assays. One reason for this low efficacy may be due 
to the monomeric nature of the peptides. In “3.5 Identification of the Key Binding Motifs in the Activin 
A Pro-domain”, it was shown that both GB1-H1LH2 and GB1-H1L interact monomerically with mature 
activin A, with a stoichiometry of 2. As these peptides are thought to bind mature activin A in the 
vicinity of its type I and type II receptors binding sites, it may be the case that they have difficulty 
competing with the multiple receptors on the cell surface for activin A binding due to an avidity effect 
created by receptor clustering. Therefore, dimerization of the peptides may moderate this difficulty. 
It has long been demonstrated that for molecules with multiple binding sites, increasing the valency 
of a binding partner can result in an increase in affinity due to avidity, and in the case of the pro-
domain derived peptides, this may also lead to an increase in inhibitor efficacy. Therefore,  to improve 
the efficacy of the peptides, I decided to explore further optimisation through dimerization.  
The use of dimeric inhibitors to inhibit activin A signalling has been reported in a number of instances. 
Pro-domain ligand traps such as those reported in Chen et al. are dimeric due to the dimeric Fc 
fragment to which the pro-domain is fused (IC50 value of most potent ligand trap = 5 nM).236 
Furthermore, Makanji et al. achieved highly potent inhibition of activin A signalling through the fusion 
of the N-terminal helices of the activin A pro-domain to the covalently dimeric TGF-β1 shoulder region 
(IC50 = 10.3 nM).188 Outside of activin A inhibition, dimeric inhibitors have also been demonstrated to 
be efficacious inhibitors for the related TGF-β family ligand, myostatin. Jiang et al. observed that GST-
fused peptides based on myostatin pro-domain showed similar inhibitory activity to that of myostatin 
pro-domain (IC50 value of the pro-domain = 0.9 nM, no IC50 value was reported for the GST-fused 
peptide).108,206 This contrasts with Takayama et al. whose monomeric peptide inhibitors of myostatin 
were significantly weaker than the pro-domain (IC50 value of the original mouse derived peptide = 3.5 
μM).189 Therefore, optimisation through dimerization may present a viable strategy for increasing 
inhibitor efficacy for activin A. 
There are several possible ways to induce dimerization, both covalently and non-covalently. One such 
way is to create a fusion with a protein or motif that dimerizes. The dimerization and docking domain 
of the cAMP-dependent protein kinase type II-α regulatory subunit (PKADD domain) is one such 
potential fusion. This small domain dimerizes with a second regulatory subunit and binds to the PKA 
binding motif of A-kinase anchor proteins. This localises the regulatory subunits and the inactive 
protein kinase A complex in the cell for signalling.241,242 PKADD domain consists of a disordered region 
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followed by two helices linked by a short linker, each with a highly hydrophobic and highly hydrophilic 
face. In solution, these helices dimerize to form an X-type four helical bundle. This dimerization is 
facilitated by the formation of a hydrophobic core by the hydrophobic faces of the helices.243 This X-
type helical arrangement means the two N-termini of the PKADD domain subunits are oriented 
towards the opposite direction, thus making the system ideal for connecting two peptides that are 
also oriented in opposite directions. Furthermore, with this region only corresponding to 45 residues, 
the PKADD domain represents a relatively small fusion that can be added to proteins to induce 
dimerization. 
Another strategy to induce dimerization is to introduce a disulfide bridge between the two molecules. 
This can be generated through the addition of a cysteine residues to a peptide and placing it in 
oxidising conditions. This strategy has been shown to have success in the case of HIV-1, where 
facilitating dimerization through the introduction of a disulfide bond resulted in an increase in anti-
HIV-1 activity.244 One common problem when introducing cysteines is the potential for multiple 
products due to disulfide formation with other cysteines in the protein. However, in the case of the 
activin peptide fusions, neither GB1-H1LH2, GB1-H1L or the PKADD contain any cysteine residues and 
therefore disulfide mediated dimerization should be very feasible.  
In this section I will look at the optimisation of the peptide fusions as inhibitors of activin A signalling 
through dimerization before testing specificity of the most potent inhibitors against other TGF-β family 
members. 
4.2 Design of PKADD Domain Fused Peptides 
In order to investigate the effect of dimerization on inhibitor potency, the two peptides GB1-H1LH2 
and GB1-H1L first needed to be dimerized. The method selected for this was to introduce the PKADD 
domain to the C-terminus of the peptide fusions (for mock model, see Figure 26). Fusions were 
designed such that residues 2-46 of the PKADD domain (Uniprot P13861) consisting of an eight-residue 
linker region and the two helices that form an X-helical bundle were inserted between the pro-domain 
derived peptide and the C-terminal purification tag. Due to the vector employed, the termini of the 
purification tags were swapped such that the N-terminal tag was Strep-tag II and the C-terminal tag a 
His-tag. The resulting peptides were subsequently named GB1-H1LH2-PKADD and GB1-H1L-PKADD (for 




Figure 26: PKADD domain fused peptides. A) The PKADD domain dimer (PDB ID: 2DRN). B) A schematic mock 
model of H1LH2-PKADD generated from the pro-mature activin A structure (PDB ID: 5HLZ) and PKADD domain 
dimer. Here mature activin A is shown in yellow and grey, H1LH2 in green, and the PKADD domain in teal. 
4.3 Cloning of PKADD Domain Fused Peptides 
To generate the PKA fused peptides, an appropriate vector was first generated. This vector was 
designed as discussed in “4.2 Design of PKADD Domain Fused Peptides” with an N-terminal Strep-tag 
II, followed by a GB1 domain, a multiple cloning site, the PKADD domain and a C-terminal His-tag 
(Figure 27). Generation of the vector was achieved through modification to the vector pOP2H (used 
in the Hyvönen Group). Primers were designed with appropriate 5  and 3  restriction site to generate 
DNA encoding the Strep-tag II, GB1 domain and the PKADD domain. DNA was then amplified via PCR 
using pOP4BP and pGEX-PKADD as a template. The resulting PCR products were subsequently ligated 
into pOP2H to generate the vector pOP6BPA. DNA encoding H1LH2 and H1L was generated in a similar 




Figure 27: The pOP6BPA vector. Design of the pOP4BP vector employed in this study. Here the multiple cloning 
site has been expanded so the restriction enzyme cutting sites are displayed. 
 4.4 Expression and Purification of PKADD Domain Fused Peptides 
Like with the monomeric peptide fusions, expression tests were first conducted to determine the 
optimal temperature for expression. Expression tests on chemically competent BL21(DE3) cells 
containing DNA encoding for GB1-PKADD, GB1-H1L-PKADD, and GB1-H1LH2-PKADD revealed 
significant soluble expression of the peptide fusions occurred at 37 °C. Large scale expression was thus 
conducted at 37 °C and the peptide fusions were purified using the same dual purification system as 
described before (see 3.4 Expression and Purification of Peptide Fusions) with similar results being 
observed (Figure 28). Subsequent analysis via mass spectrometry shows molecular weights were 
observed for all three fusions at 130 Da lower than expected. This is most likely due to the loss of the 




Figure 28: Purification of PKADD domain fused peptides. A) SDS-PAGE of GB1-H1LH2-PKADD after metal affinity 
purification with Ni-NTA beads (left) and StrepTactin Beads (right). B) SDS-PAGE of GB1-H1L-PKADD after metal 
affinity purification with Ni-NTA beads (left) and StrepTactin Beads (right). After, StrepTactin affinity purification 
we now see only one prominent band corresponding to the PKADD fused peptides indicating the purification has 
been successful. 
 4.5 PKADD Domain Fused Peptides are Dimers in Solution 
In order to confirm whether the PKA fused peptides were dimeric in solution, SEC-MALS analysis was 
performed. Each sample was loaded onto a Superdex 75 increase 10/300 column (GE Healthcare) and 
the light scattering and refractive index change was measured.  From the light scattering, the 
molecular mass of each species was calculated (Table 13, Figure 29). Analysis of the resulting 
chromatograms for GB1-PKADD and GB1-H1L-PKADD both show single peaks with masses of 34 kDa 
and 40 kDa, respectively, indicating both exist as dimers in solution. The chromatogram of GB1-H1LH2-
PKADD shows the elution of three peaks with assigned molecular weight values of 51 kDa, 31 kDa, and 
13 kDa. In this instance it is likely that these three peaks correspond to the dimer, monomer and a 
lower weight degradation product that does not dimerize. This suggests GB1-H1LH2-PKADD may be 
less stable as a dimer than either GB1-PKADD and GB1-H1L-PKADD, though it is not clear as to why this 
may be the case. Overall this data shows that GB1-PKADD, and GB1-H1LH2-PKADD and GB1-H1L-PKADD 




Table 13: Mass spectrometry and SEC-MALS analysis of PKADD fused peptides. 









GB1-PKADD 16853.9 16724.3 34500 ± 25.5 34410 ± 25.5 1.003 ± 0.001 
GB1-H1LH2-PKADD 20978.6 20848.6 51030 ± 354.1 
30810 ± 515.8 
13390 ± 203.5 
50950 ± 356.1 
30780 ± 515.3 
13390 ± 203.7 
1.002 ± 0.001 
1.001 ± 0.024 
1.000 ± 0.022 
GB1-H1L-PKADD 19355.6 19225.9 40070 ± 42.3 39940 ± 42.3 1.003 ± 0.002 
 
 
Figure 29: SEC-MALS analysis of the PKADD domain fused peptides. The chromatograms of doubly tagged GB1 
(A), GB1-H1L (B), and GB1-H1LH2 (C) generated via SEC MALS. Here the refractive index is shown in blue, the light 
scattering in red, and the absorbance at 280 nm in green. The molecular weight analysis of the eluted peaks is 
shown as dotted black lines. 
4.6 PKADD Domain Fused Peptides are More Effective Inhibitors 
than the Monomeric Peptide Fusions 
In order to determine if the PKA fused peptides were better than their monomeric counterparts at 
binding to and inhibiting mature activin A signalling, ITC experiments and luciferase assays were 
performed as described previously on GB1-H1LH2-PKADD and GB1-H1L-PKADD (Table 14, Figure 30). 
Similar to the previous experiments, an ITC experiment and luciferase assay was performed on doubly 
tagged GB1-PKADD as a control. No significant binding to mature activin A or inhibitory properties 
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were observed suggesting the PKADD had no significant effect on the system apart from dimerizing 
the pro-domain derived peptides. 
Table 14: Dissociation constants and IC50 values for PKADD domain fused GB1-H1LH2 and GB1-H1L with mature 
activin A.  
Peptide 
Fusion 
Kd / nM Stoichio
-metry 
ΔH / kcal mol-
1 
ΔS / cal 
mol-1 K-1 
Log10 (IC50 / 
nM) 
IC50 / nM 
GB1-H1LH2 642 ± 76.1* 2 -13.8 ± 0.2* -18.2* 3.64 ± 0.14 4400 
GB1-H1L 909 ± 112 2 -7.85 ± 0.14 1.32 3.58 ± 0.16 3800 
GB1-H1LH2-
PKADD 
58.6 ± 10.6* 1 -24.0 ± 0.5* -49.2* 2.58 ± 0.06 380 
GB1-H1L-
PKADD 
156 ± 33.9 1 -29.4 ± 0.4 -65.4 3.56 ± 0.09 3600 





Figure 30: The binding and inhibitory profiles of the PKADD fused peptides. A) The binding profile generated via 
ITC for the interaction between GB1-H1LH2-PKADD and mature activin A (left) and the inhibition profile of GB1-
H1LH2 and GB1-H1LH2-PKADD (right). B) The binding profile generated via ITC for the interaction between GB1-
H1L-PKADD and mature activin A (left) and the inhibition profile of GB1-H1L and GB1-H1L-PKADD (right). C) The 
binding profile generated via ITC for the interaction between GB1-PKADD and mature activin A (left) and the 
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inhibition profile of GB1 -PKADD (right). All inhibitory profiles are generated from three technical repeats. Error 
bars correspond to one standard deviation of uncertainty. 
Analysis of the ITC data for GB1-H1LH2-PKADD reveals a stoichiometry of 1, meaning the fusion binds 
to mature activin A in a 1:1 ratio. This suggests GB1-H1LH2-PKADD occupies both binding sites on 
mature activin A, thus interacting as a dimer. The approximate 10-fold increase in affinity observed 
for GB1-H1LH2-PKADD compared to GB1-H1LH2 (58.6 nM vs 642 nM) is likely due to this dimeric 
binding, with the increase in affinity resulting from the increase in avidity. Inhibition data shows a 
similar story with activin A signalling. A similar approximate 10-fold increase in inhibitor potency is 
observed in cell-based reporter assay upon dimerization, with IC50 values of 380 nM and 4.4 μM for 
the dimeric and monomeric constructs, respectively. This shows that non-covalent dimerization, as 
predicted, is a valid method of optimising the inhibition of activin A signalling with pro-domain derived 
peptide fusions.  
The observations made for GB1-H1L-PKADD interactions with mature activin A are more complex. The 
ITC data shows an increase in affinity compared to the monomeric version (156 nM and 909 nM) with 
a stoichiometry of 1 however there is no significant difference between the IC50 values obtained for 
GB1-H1L and GB1-H1L-PKADD (3.8 μM vs 3.6 μM). The structure of the pro-mature complex indicates 
a large distance between the two C-terminal residues of the loop, 72.2 Å, with them being oriented 
away from each other on different faces of the mature dimer (Figure 31). This contrasts with the 
distance between the C-terminal residues of H1LH2, 30.1 Å, and their orientation towards one another. 
As such, the large distance and suboptimal orientation of GB1-H1L-PKADD may weaken the interaction 
between the two PKADD domains resulting in a partial monomeric and partial dimeric character. This 
would explain the similarity between the IC50 values of GB1-H1L and GB1-H1L-PKADD as well as the Kd 




Figure 31: Interhelical distance of H1LH2. The inter-residue distance between Cα of the C-terminal residues of 
H1LH2 and H1L based on the structure of pro-mature activin A. Here mature activin A is shown in yellow and grey, 
H1LH2 in green, and H1L in red.   
Overall this section has demonstrated for the H1LH2 containing fusion, dimerization results in both an 
increase in affinity and inhibitor potency for activin A, confirming the validity of a dimeric approach. 
4.7 Continuous Fused Helix Peptides Behave in a Similar Manner to 
GB1-H1LH2-PKADD 
GB1-H1LH2-PKADD inhibits activin A signalling with the highest affinity observed so far (380 nM) 
representing approximately a 10-fold increase in potency compared to the other three peptides 
fusion. However, it is desirable to optimise this peptide further. The target selected for this 
optimisation was the linker between the α2-helix and the PKADD. The length of linker (eight residues) 
means that the α2-helix-α2-helix distance between the dimeric subunits may be large when the 
PKADD domain is taken into account. Therefore, this may have a negative effect on affinity and 
potency as the avidity affect may be reduced due to distance and conformational changes being 
required for mature activin A binding. Thus, in order to try to spatially optimise GB1-H1LH2-PKADD and 
increase its structural rigidity, I decided to eliminate the linker and fuse the C-terminus of the α2-helix 
directly to the N-terminal helix of PKADD. In order to achieve this, the C-terminal residue of the α2-
helix and the N-terminal residue of the PKADD domain first needed to be identified. Analysis of the 
respective pro-mature activin A complex and PKADD domain structures revealed these residues to be 
L90 of the α2-helix (L90H2) and L10 of the PKADD domain (L10PKADD). Next, additional alternating serine 
and alanine spacer residues were added to allow for the testing of whether the relative geometry of 
the α2-helix and PKADD to each other had an impact on either affinity or efficacy. From this, three 
peptide fusions were generated – GB1-H1LH2-S-PKADDF, GB1-H1LH2-AS-PKADDF, and GB1-H1LH2-SAS-
PKADDF. Of these, GB1-H1LH2-S-PKADDF contained one serine residue as a spacer between L90H2 and 
L10PKADD, GB1-H1LH2-AS-PKADDF an alanine followed by a serine, and GB1-H1LH2-SAS-PKADDF a serine 
followed by an alanine and a serine. JPred4 and Spider2 secondary structure prediction software was 
used to predict whether helicity would be retained throughout the fused helix which it did in all 
cases.245,246  Each peptide was then expressed and purified and ITC experiments and luciferase assays 




Table 15: Dissociation constants and IC50 values obtained for the Fused Helix peptides with mature activin A.  
Peptide Fusion Kd / nM Stoichio-
metry 
ΔH / kcal 
mol-1 
ΔS / cal 
mol-1 K-1 
Log10 (IC50 / 
nM) 
IC50 / nM 
GB1-H1LH2-
PKADD 



















The ITC data obtained for these fusions shows that all three exhibit similar binding properties to that 
of GB1-H1LH2-PKADD binding both in a dimeric manner (stoichiometry = 1 in all instances) with similar 
affinities (Kd = 33.3 nM, 69.9 nM, and 45.7 nM vs 58.6 nM) (Figure 32). Analysis of the luciferase assays 
of GB1-H1LH2-S-PKADDF and GB1-H1LH2-AS-PKADDF show a similar story, with both inhibiting signalling 
in a similar manner to GB1-H1LH2-PKADD (IC50 = 254 nM and 294 nM vs 380 nM). These similarities 
suggest that fusing the α2-helix directly to the N-terminal helix of the PKADD domain has a positive 




Figure 32: Binding and inhibitory profiles of the continuous fused helix peptides. A) The binding and inhibition 
profiles generated for GB1-H1LH2-S-PKADDF with mature activin A via ITC and luciferase assay. B) The binding 
and inhibition profiles generated for GB1-H1LH2-AS-PKADDF with mature activin A via ITC and luciferase assay. C) 
The binding and inhibition profiles generated for GB1-H1LH2-SAS-PKADDF with mature activin A via ITC and 
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luciferase assay. All inhibitory profiles are generated from three technical repeats. Error bars correspond to one 
standard deviation of uncertainty. 
Interestingly, the IC50 value obtained for GB1-H1LH2-SAS-PKADDF is significantly lower than that of GB1-
H1LH2-S-PKADDF and GB1-H1LH2-AS-PKADDF. This may be due to the position of the X-helical bundle of 
PKA relative to the α2-helix, causing it to clash sterically with the mature domain of activin A, leading 
to a partial monomeric character similar to that suggested for GB1-H1L-PKADD however again, 
evidence is currently weak and further investigation would be required. Overall, this data shows that 
eliminating the linker between the PKADD domain and the α2-helix and fusing the two helices 
together results in a small increase in potency for  GB1-H1LH2-S-PKADDF and GB1-H1LH2-AS-PKADDF. 
4.8 Design of Covalently Linked Dimeric Peptide Fusions 
The effect of dimerization on inhibitor potency so far has been positive, with non-covalent 
dimerization resulting in a 10-20-fold decrease in IC50 values depending on the peptide in question. 
However, the non-covalent nature of this dimerization may be a limitation. The Kd of dimerization for 
PKADD is unknown, however it is possible at the lower inhibitor concentrations used in the luciferase 
assays, the PKADD fused peptides monomerise thus reducing the efficacy of the inhibitor. Therefore, 
to overcome this I decided to adopt a covalent dimerization approach. For this, two constructs were 
designed – GB1-H1LH2-SS and GB1-H1LH2-PKADDSS. 
To generate GB1-H1LH2-SS, three residues containing one cysteine were added to GB1-H1LH2 between 
the α2-helix and the Strep-tag II such that a single disulfide could be formed. Though the combined 
average chain length of these six additional residues is likely less than that of the interhelical distance 
of 30.1 Å (assuming each residue has an end to end distance of between 3.6-4.0 Å), however activin A 
has been observed to be flexible about its dimerization cysteine so this should not prevent dimeric 
binding. An equivalent GB1-H1L-SS was not generated due to the observation that GB1-H1L-PKADD did 
not show a significant increase in inhibitor potency compared to GB1-H1L. 
GB1-H1LH2-PKADDSS was generated through introduction the mutation L14C into the PKADD domain 
of GB1-H1LH2-PKADD. Residue L14 is an interfacial residue in the N-terminal helix of the PKADD domain 
that interacts hydrophobically with the corresponding L14 residue on the N-terminal helix of the other 
monomer. Therefore, only one mutation is required to generate the desired disulfide product, thus 
eliminating the problem of potential by-products associated with introducing multiple cysteine 
mutations. Measuring the distance between the Cαs of the two residues in the PKADD structure 
reveals they are 8.6 Å apart (Figure 33). This distance is longer than most disulfide bonds, which usually 
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fall in the range 4.3-6.4 Å. As such, some amount of conformational change may be required to 
facilitate bond formation, however it was decided to proceed non the less. 
 
Figure 33: Selected site for disulfide formation in the PKADD domain. The interatomic distance between Cα of 
residues L14 on both PKADD domain chains. Here L14 is highlighted in magenta. 
Unlike the other peptide fusions, GB1 H1LH2-SS and GB1-H1LH2-PKADDSS were purified via Ni affinity 
purification using an increasing concentration of imidazole. As dimerization forms a covalent link 
between two monomers, the resulting dimer will contain two His-tags rather than one. Due to the 
increase in avidity, the dimer should therefore interact more strongly with the resin than the 
monomer. Therefore, the monomeric and dimeric forms should elute at different concentrations of 
imidazole. Analysis of the chromatogram of GB1 H1LH2-SS shows the elution of two clear broad peaks 
at much higher absorbance than that of the increasing the imidazole between approximately 70-100 
mL (Fractions A7-C2) (Figure 34). SDS-PAGE of these fractions shows that both the dimer and 
monomer are successfully expressed in large amounts and elute at different enough concentrations 
of imidazole that the products can be separated easily via this purification. As such, the fractions 
containing the dimer were then pooled and purified further with StrepTactin beads. Analysis of this 
purification shows the presence of a prominent band at the expected molecular weight for GB1-H1LH2-
SS, however there are fainter bands at higher molecular weights. Analysis via mass spectrometry (data 
not shown) revealed that only monomeric and dimeric GB1-H1LH2-SS were detected indicating these 
bands correspond to oligomerisation, though how this occurs is unclear. These higher molecular 
weight species could not be adequately separated from dimeric GB1-H1LH2-SS thus the sample was 




Figure 34: The purification of GB1-H1LH2-SS. A) Chromatogram of the metal affinity purification of GB1-H1LH2-SS 
with increasing concentration of imidazole. B) SDS-PAGE of the metal affinity purification of GB1-H1LH2-SS. C) 
StrepTactin affinity purification of the pooled fractions of GB1-H1LH2-SS containing the covalent dimer. 
In the case of GB1-H1LH2-PKADDSS, analysis of the StrepTactin affinity purification reveals the presence 
of both the covalent and non-covalent forms after expression with the non-covalent form being more 
prevalent. Lu et al. has shown the ability of Cu (ii) ions to catalyse the formation of disulfide bonds in 
denatured human granulocyte colony-stimulating factor resulting in protein folding.247 Therefore, in 
order to maximise covalent dimerization rapidly, the sample was incubated with 1 mM CuSO4 at 4 °C 
overnight. Analysis of the subsequent SDS PAGE shows that after 16 hours most of the sample had 




Figure 35: Cu (ii) catalysed linkage of GB1-H1LH2-PKADDSS. A) SDS-PAGE of GB1-H1LH2-PKADDSS before and after 
treatment with CuSO4. Here we see that the addition of CuSO4 results in almost complete formation of the 
covalent dimer. B) Chromatogram of the metal affinity purification of GB1-H1LH2-PKADDSS with increasing 
concentration of imidazole (top). SDS-PAGE of the metal affinity purification of GB1-H1LH2- PKADDSS. Here we see 
the presence of a single band corresponding to the covalent dimer (bottom). 
The sample was then purified in a similar manner to GB1-H1LH2-SS. The purification was performed in 
6 M urea to monomerise any non-covalently linked GB1-H1LH2-PKADDSS which should exhibit a 
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different elution profile to covalently linked GB1-H1LH2-PKADDSS due to the difference in the number 
of His-tags. In addition, the absorbance at 580 nm was measured due to the absorbance of Cu (ii) ions 
at this wavelength (Figure 35B). Analysis of the chromatogram shows zero absorbance at 580 nm in 
the elution phase suggesting all the Cu (ii) ions have been removed (here the sharp spikes likely 
correspond to air in the column). A perturbation of the increasing absorbance at 280 nm associated 
with the increasing imidazole concentration occurs at approximately 90 – 110 mL (Fractions B14-B2). 
SDS-PAGE of these fractions revealed the presence of a single band at the molecular weight of the 
dimer. Thus, these fractions were pooled, concentrated and taken forward for luciferase assays. 
4.9 Introduction of a Disulfide Bridge Results in an Increase in 
Inhibitor Efficacy 
To determine the effect covalent dimerization has on inhibitor potency, luciferase assays were 
performed on both GB1-H1LH2-SS and GB1-H1LH2-PKADDSS (Table 16, Figure 36). Analysis of the 
inhibition curves generated for each peptide fusion shows a marked increase in inhibitor potency 
compared with GB1-H1LH2 and GB1-H1LH2-PKADD. Here the IC50 values for GB1-H1LH2-SS and GB1-
H1LH2-PKADDSS are 45.2 nM and 71.5 nM. This is around 5-10-fold more potent than the non-covalent 
dimer GB1-H1LH2-PKADD and 50-100-fold more potent than the monomeric GB1-H1LH2. This therefore 
suggests that covalent dimerization is the best method of improving inhibitor potency through 
dimerization. An additional ITC titration was also performed with GB1-H1LH2-SS as described 
previously. The Kd value obtained from this experiment is around 2-fold stronger than that of GB1-
H1LH2-PKADD with a stoichiometry of 1 confirming GB1-H1LH2-SS interacts as a dimer with mature 
activin A.  
Table 16: Dissociation constants and IC50 values obtained for the covalently dimerized peptide fusions with 
mature activin A. 
Peptide 
Fusion 
Kd / nM Stoichiometry ΔH / kcal 
mol-1 
ΔS / cal 
mol-1 K-1 
Log10 (IC50 / 
nM) 
IC50 / nM 
GB1-H1LH2-
PKADD 
58.6 ± 10.6 1 -24.0 ± 0.5 -49.2 2.58 ± 0.06 380 
GB1-H1LH2-SS 30.5 ± 12.0 1 -39.0 ± 0.8* -96.3* 1.66 ± 0.04 45.2 
GB1-H1LH2-
PKADDSS 






Figure 36: Inhibitory profiles of covalently dimerized peptide fusions. A) The inhibition profiles of GB1-H1LH2-SS 
(left) and GB1-H1LH2-PKADDSS (right) generated via luciferase assays. Inhibitory profiles are generated from three 
technical repeats. Error bars correspond to one standard deviation of uncertainty. B) The binding profile of GB1-
H1LH2-SS to mature activin A generated via ITC.  
4.10 Screening of GB1-H1LH2-PKADDSS against Other TGF-β 
Superfamily Members 
The covalent dimerization of peptide fusions through a disulfide bond generated two highly potent 
inhibitors of activin A signalling, GB1-H1LH2-SS and GB1-H1LH2-PKADDSS. However, due to the high 
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structural and sequence similarity of TGF-β ligands and receptor promiscuity within the family, it was 
important to test one of these fusions against other ligands to determine specificity.  
The first step of the determining specificity was to select which members of the TGF-β family would 
be screened. To provide a robust screen, three ligands were selected of varying sequence similarity to 
activin A and that signal through two different Smad pathways. The first two were activin B and 
myostatin. Both these ligands are commonly used for specificity screens on activin A due to their 
similarities with activin A.188 Like activin A, activin B and myostatin signal through the ActRIIA / B and 
ALK4 receptors, triggering the Smad 2/3 pathway (though they can also signal through ALK7 and ALK5 
respectively).248,249 Furthermore, the sequences of the mature domains of activin B and myostatin 
have a high similarity with that of activin A. Activin B shares 82.8 % similarity (63.8 % identity) with the 
key receptor interacting residues being conserved and myostatin 49.6 similarity. Functional studies 
have also implicated activin B and myostatin as acting in concert with activin A in tissues such as the 
sex organs and skeletal muscle thus making distinguishing their specificity highly important for 
therapeutics.7,250 
The final ligand selected for screening was BMP2. BMP2 is a more distant relative of activin A, 
appearing to have diverged from a common ancestor much earlier than either activin B or myostatin. 
As such, BMP2 primarily signals through the Smad 1/5/8 pathway and appears not to interact with 
ALK4, interacting with other type I receptors instead (however BMP2 does interact with ActRIIA and 
ActRIIB as well as the type II receptor BMPRII).251 Therefore, this ligand was selected to increase the 
broadness of the screen. 
To confirm the appropriateness of this selection, the similarity of the α1-helix-loop-α2-helix region 
between the three selected ligands and activin A was compared. Alignment was performed using 
ClustalX (Figure 37).252 The minimal binding peptide for activin A obtained in this thesis (see 3.7 
Determination of the Minimal Binding Peptide of the Activin A Pro-domain) tells us the key interacting 
residues of H1LH2 are in the region E53-P72. This region includes a crucial salt bridge formed by residue 
R71, as well as a number of hydrophobic residues in the α1-helix (V55, V58, I62, L63, L66 and L68), 
that appear to form the majority of contacts between the peptide and the mature domain. Analysis 
of the alignment reveals that these hydrophobic residues are highly conserved across activin B, 
myostatin, and BMP2, however subtle differences exist and substitution of similar aliphatic amino 
acids is common. However, in the case of BMP2 the differences are larger with substitution to 
phenylalanine occurring at two of these positions. This suggests larger, more hydrophobic binding 
pockets may be present on the mature BMP2 surface, thus making inhibition by H1LH2 less likely. R71, 
which forms the crucial salt bridge in activin A, is conserved in activin B however not in myostatin, 
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meaning it is likely H1LH2 will have a higher specificity for activin B over myostatin.† Furthermore, 
comparison of the aligned sequences reveals activin B to have a much higher similarity to activin A 
than myostatin or BMP2 (sequence similarity activin B = 82.1 %, myostatin = 47.7 %, BMP2 = 46.3 %). 
As such is it is likely H1LH2 will have discernible differences in specificity for these three ligands. 
 
Figure 37: Alignment of the α1-helix-loop-α2-helix region of activin A, human activin B, xenopus activin B, 
myostatin, and BMP2. Here highly conserved hydrophobic residues are shown in blue, aromatic residues in 
turquoise, acidic residues in purple, basic residues in red and polar residues in green. Glycine and proline residues 
are also shown in orange and yellow respectively. Above the residue numbers are shown for activin A along with 
the helix boundaries. 
Analysis of the α2-helix  of activin A and B reveals sequence conservation is high. However, compared 
to the α1-helix, there is significantly lower conservation between family members and a greater 
degree of sequence variation is seen. Though this region of  H1LH2 was not crucial for mature domain 
binding, it still forms contacts with the mature domain in the pro-mature ActA structure and as such 
may also contribute towards specificity of the peptide.  
To test specificity, inhibitory luciferase assays were performed on activin B, myostatin and BMP2 using 
GB1-H1LH2-PKADDSS as the inhibitor (Table 17, Figure 38). As both activin B and myostatin signal 
through the Smad 2/3 pathway, the assays could be performed as described previously. However, this 
is not the case for BMP2, which usually signals through the Smad 1/5/8 pathway. As such, HEK293T 
cells containing a BMP responsive element (BRE), which expresses firefly luciferase upon signalling 
through the Smad 1/5/8 pathway, were used. 
The three assays were all performed at the EC80 of each respective ligand (activin B = 80 pM, myostatin 
= 250 pM, BMP2 = 2.5 nM). The activin B used here was not the human sequence, rather Xenopus. 
However, the human and Xenopus sequence is highly conserved with 96.5% identity and 98.3% 
similarity and thus likely to behave in a similar manner. Both the myostatin and BMP2 used were 
 
† R71 is also conserved in BMP2, however due to the phylogenetic distance between BMP2 and activin A, it is 
difficult to predict whether it forms a salt bridge. 
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human. An additional positive control was used in the BMP2 assay – the extracellular BMP inhibitor 
gremlin.  
 
Figure 38: Specificity screen of GB1-H1LH2-PKADDSS. The inhibitory profile of GB1-H1LH2-PKADDSS against activin 
A, activin B, myostatin and BMP2 as determined via luciferase assay. Inhibitory profiles are generated from three 
technical repeats. Error bars correspond to one standard deviation of uncertainty. 
 
Table 17: Specificity screen of the TGF-β family. 
Ligand Log10 (IC50 / nM) IC50 / nM 
Activin A 1.85 ± 0.06 71.5 
Activin B 1.94 ± 0.08 88.0 
Myostatin 3.88 ± 0.11 7600 
BMP2 – – 
 
Analysis of the inhibition curves shows that GB1-H1LH2-PKADDSS inhibits activin B with an IC50 value of 
88.0 nM. This value is highly similar to that obtained for activin A with the same inhibitor (71.5 nM), 
suggesting GB1-H1LH2-PKADDSS inhibits both proteins in a similar manner. This is to be expected due 
to the sequence similarity of the α1-helix-loop-α2-helix motif of activins A and B (82.1 %) and the 
similarity of the mature domains (82.8 %). The inhibitory trend for myostatin is weaker, with a full 
inhibition not being obtained within the concentration range of the experiment. Extrapolation of an 
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IC50 value from this data yields a value of approximately 7.6 μM, meaning GB1-H1LH2-PKADDSS is 
around 100-fold more selective for activin A and B than myostatin. The curve obtained for BMP2 
shows maximum signal throughout with the signal being significantly higher at all concentration points 
than that obtained for gremlin. As such GB1-H1LH2-PKADDSS does not inhibit BMP2 signalling. 
Therefore, GB1-H1LH2-PKADDSS, and thus the H1LH2 motif of activin A’s pro-domain, is a specific 
inhibitor of activin A and B signalling.  
4.11 Conclusions 
In this section I described the optimisation of the inhibitory peptides described in the section “Peptide 
Approach” through dimerization. I described the generation and characterisation of non-covalent 
PKADD domain fusions based on GB1-H1LH2 and GB1-H1L and show that both are dimeric in solution. 
I then showed that their affinity for mature activin A is higher than that of their monomeric 
counterparts (58.6 nM and 156 nM vs 642 nM and 909 nM), likely due to the increase in avidity. I 
demonstrated that a similar effect is observed for GB1-H1LH2 on the inhibition of activin A signalling 
(380 nM vs 4.4 μM) but not for GB1-H1L (3.6 μM vs 3.8 μM). I then attempted to optimise GB1-H1LH2 
through the design of a fused helix system, however these fusions showed no great increase in either 
affinity for mature activin A or inhibition of mature activin signalling. I designed two covalent 
constructs – one directly fusing two GB1-H1LH2 at the C-terminus through a disulfide bond, and one 
introducing a disulfide into the PKADD domain of GB1-H1LH2-PKADD. These molecules had significantly 
higher inhibitory activity compared to both the monomeric and non-covalent dimeric peptides (GB1-
H1LH2-SS = 45.2 nM, GB1-H1LH2-PKADDSS = 71.5 nM). Finally, I established the specificity of GB1-H1LH2-
PKADDSS against 3 other members of the TGF-β family – activin B, myostatin, and BMP2. From this I 
determined GB1-H1LH2-PKADDSS inhibited activin B in a similar manner to activin A, whereas it had 










             
Discussion 





Activin A signalling has been implicated as a key mechanism in the pathology in several diseases. As 
well as driving the proliferation and epithelial-mesenchymal transitions in a number of breast and 
prostate cancers, activin A signalling has been identified as the main cause of fibrodysplasia ossificans 
progressiva.159,167,253 Furthermore, it plays a crucial role in muscular homeostasis as a major negative 
regulator of muscle growth.7 As such, activin A is an important therapeutic target. However, specific 
inhibition of activin A signalling has often been difficult to achieve, due to structural and sequence 
similarity between activin A and other TGF-β family members and ligand promiscuity in TGF-β family 
signalling. Indeed, commonly used methods either target activin’s receptors or utilise non-specific 
extracellular inhibitors resulting in convoluted phenotypes and side effects associated with the 
inhibition of multiple TGF-β ligands.186,210 In this project, I aimed to develop inhibitors that specifically 
target activin A and its signalling.  
In order to achieve this, two approaches were attempted in parallel – a small molecule approach and 
a peptide approach. The small molecule approach used XChem fragment screening to identify 13 
molecules that bound to mature activin A, of which four were analysed further. Validation through a 
second crystallographic screen led me to focus on the molecule NM466, and a number of NM466 
derivatives were designed. Of these derivatives, only one, TR17, was validated as an activin A binding 
molecule. The in-solution binding of NM466 and TR17 was then analysed through ligand-based NMR, 
however the data were inconclusive. 
In parallel to the small molecule approach, the peptide approach succeeded in the generation of 
potent activin A inhibitors. First the structure of the pro-mature activin A complex was analysed to 
identify key motifs for the interaction between activin A’s pro- and mature domains. Peptide fusions 
based on these motifs were then generated and their interactions with mature activin A investigated. 
From this, it was determined that the α1-helix and the loop were the key interacting motifs. It was 
then found that two peptide fusions containing these motifs, GB1-H1LH2 and GB1-H1L, inhibited activin 
A signalling with IC50 values of approximately 4.4 μM and 3.8 μM respectively. Optimisation of these 
fusions through non-covalent C-terminal dimerization utilising the dimerization and docking domain 
of the PKA RIIα subunit resulted in an approximate 12-fold increase in inhibitor potency for H1LH2  to 
380 nM.  Finally, stabilisation of the H1LH2 dimers through the introduction of either a C-terminal 
disulfide bond or a disulfide linkage in the PKADD domain resulted in further increases in inhibitor 
potency to 45.2 nM for GB1-H1LH2-SS, and 71.5 nM for GB1-H1LH2-PKADDSS. The specificity of GB1-
H1LH2-PKADDSS was assessed through screening against three other TGF-β family members, activin B, 
myostatin, and BMP2.  I showed that GB1-H1LH2-PKADDSS inhibited both activin A and activin B in a 
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similar manner (71.5 nM  vs 88.0 nM) with a 100-fold specificity over myostatin ( approximately 7.6 
μM). No inhibition was observed for BMP2 signalling. 
5.2 The Putative Type I Receptor Binding Site as a Target for Small 
Molecule Inhibition 
Due to their importance in activin A signalling, the type I and type II receptor binding sites make 
obvious targets for developing inhibitors. The type II binding site has been structurally identified by 
Greenwald et al. and Thompson et al. to exist on the convex face of the monomeric subunit of activin 
A, in the fingertip region.103,254 Conversely the site of the type I receptor is believed to be within a 
hydrophobic groove on the concave face of the monomeric subunit. Though there is currently no 
structural data available for the interaction between ALK4 and activin A, structural data for the related 
family member GDF11 and ALK5 shows this hydrophobic groove is the site of interaction, thus 
increasing confidence in the case of activin A.76 It was in this site that Zhu et al. designed several small 
molecule binders via in silico screening, of which the most potent, NUCC-555, inhibited activin A 
signalling with an IC50 value of  5.3 μM.193  
Incidentally, the XChem screen reported in this thesis identified 12 fragment hits that bound in this 
same groove, by far the most commonly occupied site. One of these hits NM466 and its derivative 
TR17 were found to interact with mainly through hydrophobic interactions with residues W335, I339, 
F368, T371, M401, Y403, I415, and M418 forming one hydrogen bond with W338 (Figure 39A). 
Modelling of these residues found that several of these residues also form the majority of hydrophobic 
interactions with NUCC-555 (W335, W338, F368, Y403, and I415) with only additional hydrogen 
bonding interactions with K413 and N417 being observed. NUCC-555 was observed to compete with 




Figure 39: The putative type I receptor binding site as a target for inhibitors. A) Comparison of the binding site of 
TR17 (left, here shown as an example) with that modelled for NUCC-555 with activin A (right) by Zhu et al. (Figure 
of modelled NUCC-555 structure adapted from Zhu et al.193). Note mature domain numbering is shown in the 
part of the figure adopted from Zhu et al. B) The structure of TR17 bound to mature activin A with residues K413, 
Q416 and N417 highlighted. Here, the amide designated “α” of TR17 highlighted. 
Many of the derivatives of NM466 screened were not observed to bind to activin A. Most of these 
molecules aimed to spatially optimise the weak hydrophobic interactions in NM466’s binding. 
However, due to the small number of derivatives that bound, it may be prudent look beyond the 
immediate binding site of NM466 and try to form new electrostatic and hydrogen bonding 
interactions. As such interactions beyond the immediate vicinity of NM466’s binding site may need to 
be utilised for optimisation. The hydrogen bonding interactions of NUCC-555 could be used as a guide 
for this. The two key hydrogen bonding interactions between NUCC-555 and activin A occur at residues 
K413 and N417.193 Analysis of the crystal structure of NM466 and TR17 reveals the carbonyl of amide 
α is oriented towards K413, 8.2 Å away, appearing to undergo no obvious interactions with any residue 
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of activin A. As such replacing this group with an alkyl chain containing hydrogen bonding groups (such 
as alcohols and carboxylic acids ) would allow for hydrogen bonding with K413 to occur. Due to the 
positioning of F58 upon NM466/ TR17 binding, N417 is significantly less accessible than in the NCC-
555-activin A model and thus it is not a reasonable target for interactions. However, Q416 is proximal 
to NM466/ TR17 (11.1 Å away) and more accessible than N417 meaning further derivatisation of the 
chain may also allow for hydrogen bonding to occur with this residue (Figure 39B). These increased 
interactions of a NM466/TR17 derivative will likely increase affinity for activin A and as such become 
a useful next step in inhibitor development. 
5.3 Pro-domain Derived Peptides as Inhibitors of Activin A and the 
Wider TGF-β Family 
The inhibitors generated in this project represent a new chapter in the inhibition of activin A. Current 
methods that either utilise or target activin receptors or follistatin usually have specificity issues due 
to ligand promiscuity.186,210 Antibodies overcome this problem, as do full pro-domain-based inhibitors, 
and both are highly specific, however they are synthesised using mammalian expression systems 
which are significantly more expensive than E. coli-based systems.188,198,236 Thus, the most potent 
peptides reported in this thesis represent a happy medium, with relatively high specificity (100-fold 
more specific for activin A / B than myostatin) compared to receptor and follistatin approaches, yet 
utilising a rapid, low cost production method that results in a high inhibitor yield. 
Compared to the AT pro-peptide (the α1-helix-loop-α2-helix motif of activin A fused to the shoulder 
region of TGF-β1) and pro-domain ligand traps reported in Makanji et al. and Chen et al., the two 
covalently dimerised peptide inhibitors have a lower potency – up to 14-fold lower than that of the 
most potent ligand trap (IC50 GB1-H1LH2-SS = 45.2 nM, GB1-H1LH2-PKADDSS = 71.5 nM, AT peptide = 
10.3 nM, most potent ligand trap = 5 nM).188,236 Interestingly, the Fc fusion reported in Chen et al. is 
specific for activin A signalling, showing a ~100-fold specificity over activin B, whereas the AT pro-
peptide and GB1-H1LH2-PKADDSS are not (4-fold and approximately the same specificity over activin 
B respectively). This indicates that additional epitopes in the C-terminus of the pro-domain of activin 
A may be important in determining its specificity for activin A and not activin B. However, the 
identity of these epitopes is yet to be elucidated. 
To my knowledge, this thesis represents the first attempt to use peptides derived from activin A’s pro-
domain to inhibit activin A signalling. However, it is not the first reported peptide-based approach to 
inhibit TGF- family ligands, with pro-domain derived peptides also being reported for myostatin, 
inhibin A and B, and GDF11.106,189,191  
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The trends observed for both binding and inhibition by the peptide fusions generated in this project 
mirror those observed by Takayama et al. for peptides based on myostatin’s pro-domain.189 Two 
peptides developed by Takayama et al. based on the murine pro-domain inhibited human myostatin 
signalling with IC50 values of 4.1 μM and 3.5 μM respectively, highly similar to the IC50 values obtained 
for GB1-H1LH2 and GB1-H1L of ~4.4 μM and ~3.8 μM. This is not where the similarities end. The minimal 
binding peptide that I determined for activin A is the 19mer GB1-E53-P72 whereas the minimal binding 
peptide identified by Takayama for myostatin is a 23mer. Sequence alignment of the two sequences 
shows that the majority of the highly conserved hydrophobic residues across TGF-β family members 
are present in both (Figure 40A). Analysis of the structures of human pro-mature activin A and human 
pro-mature myostatin with the minimal peptides highlighted reveals that both correspond to the 
majority of the α1-helix and initial loop residues, however the surface area of interaction on the 
mature domain is slightly higher for myostatin (activin A = 1845 Å2, myostatin = 2046 Å2) and the 
myostatin α1-helix has a higher number of interacting hydrophobic residues (activin A = 6 hydrophobic 
residues, myostatin = 9) (Figure 40B). These differences may be the explanation behind the differences 
in measured affinities, with the affinities for GB1-H1LH2 and GB1-H1L being ~10-fold weaker than that 
of the myostatin peptides (642 nM and 909 nM vs 35.9 nM and 29.7 nM). Dimerization has not been 
employed with the myostatin peptides and the most potent inhibitor to date is a monomeric stapled 
peptide that inhibits myostatin signalling with an IC50 value of 260 nM.190 This is still significantly less 
potent than the dimeric inhibitors developed in this thesis, GB1-H1LH2-SS and GB1-H1LH2-PKADDSS, 





Figure 40: Comparison of the activin A and myostatin minimal binding peptides. A) Alignment of the activin A 
and myostatin minimal binding peptides performed using ClustalX2. Here hydrophobic residues are shown in 
blue. Polar residues are shown in green, basic residues in red and proline residues in yellow. Here “*” denotes 
identical residues whereas “:” denotes highly similar residues. B) Representations of the minimal binding peptide 
of the activin A pro-domain (left, purple) and myostatin pro-domain (right, green) bound to their respective 
mature domains. 
Similar trends are seen in terms of specificity for the activin and myostatin systems as well. In Ohsawa 
et al., Fc fusions of a 29mer containing the humanised version of  the peptides reported in Takayama 
et al. preferentially inhibited myostatin and GDF11 over TGF-β1 and activin A signalling (though no 
IC50 values were reported so this specificity is difficult to quantify).205 Similarly, GB1-H1LH2-PKADDSS 
had a 100-fold specificity for activin A and B over myostatin. This therefore suggests, pro-domain 
derived peptides are a good approach for generating TGF-β family inhibitors with a high specificity 
compared to other methods. 
In addition to myostatin, pro-domain derived peptides have also been reported for inhibin.191 Walton 
et al. describe the generation of a 43mer peptide based on the inhibin α subunit that specifically 
inhibited inhibin A and B signalling with IC50 values of 255 and 150 nM respectively. These IC50 value 
are significantly higher than those reported for unmodified monomeric activin A and myostatin 
peptides, however it is likely due to the inhibin derived peptide preventing association of inhibin A/B 
to the co-receptor betaglycan rather than a type I receptor, thus the values are not directly 
comparable. Incidentally, it is possible that the inhibitors reported in this thesis may also have an 
inhibitory effect on inhibin signalling due to their interactions with the βA and βB subunits, however 
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the efficacy of this inhibition is likely to be similar to that observed for the monomeric peptides GB1-
H1LH2 and GB1-H1L due to the inhibin being a heterodimer of α and β subunits.  
In contrast to activin A, inhibin and myostatin pro-domain derived peptides, Pepinsky et al. observed 
that a sequence corresponding to the α1-helix-loop-α2-helix motif of GDF11 had no inhibitory effect 
on GDF11 signalling at the concentrations tested.106 This is unexpected as, like myostatin, the pro-
mature GDF11 is a latent and the pro-domain of GDF11 is a known antagonist of GDF11 signalling (IC50 
value unreported). However, the peptide concentrations used in this study were significantly lower 
than those used in this thesis or Takayama et al. Interestingly, it was observed that this GDF11 derived 
peptide, PDP60-114, was able to improve the solubility of mature GDF11, especially at neutral pH. This 
was not tested with the peptide fusions described in this thesis for activin A but given the similarity 
between the two systems, it is possible that the activin A derived peptides may also be able to aid the 
solubility mature activin A. Like mature GDF11, mature activin A has poor solubility at physiological 
pH. As such, this could have applications in experimental biology, such as in biochemical assays and 
animal studies, where the presence of soluble activin A for an extended period of time is required. 
5.4 Future Directions of Peptide Inhibitors of Activin A 
In this thesis, I have demonstrated the optimisation of pro-domain derived peptide inhibitors of activin 
A through covalent dimerization, resulting in an approximately 50-100-fold increase in inhibitor 
potency compared to the monomeric form. However, to improve their viability as chemical tools it is 
still desirable to optimise these inhibitors further. 
So far, I have shown the key pro-domain epitopes for the inhibition of activin A signalling to be the α1-
helix and the loop. Furthermore, it is within this region where the key residues for interaction with the 
mature domain are contained. Consequently, the α2-helix does not contribute significantly to 
inhibition or binding, however it is present in the two most potent peptide inhibitors, GB1-H1LH2-SS 
and GB1-H1LH2-PKADDSS. Therefore, increasing interactions between this region and the mature 
domain may lead to a more potent inhibitor of activin signalling. One way of achieving this would be 
to mimic the interactions of follistatin with mature activin A. Like the α2-helix, the primary interactions 
between follistatin and mature activin A occur in the vicinity of the type II receptor binding site, with 
interactions in the type I site not being necessary to achieve inhibition.77 Follistatin is a much more 
potent inhibitor of activin A signalling with an IC50 value of 90 pM (FS288 isoform). As such, mimicking 
the crucial interactions between follistatin and the type II site could increase the potency of H1LH2 
inhibitors. Harrington et al. identifies one of the crucial interactions in the Fs2 domain to be the 
interaction between R192 of follistatin with D337 and Y404. Alignment of the structure of the Fs12-
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ActA complex (PDB ID: 2ARP) to the pro-mature complex reveals residue of K80 of the α2 helix to be 
occupy a similar spatial position to R192 relative to Y404 of the mature domain (Figure 41). Thus, the 
most promising mutation would be K80R. It is however important to note that D337 forms a key salt 
bridge with R71 and thus these mutations may also destabilise the peptide-activin A complex. 
A second potential mechanism for optimising inhibition would be to reduce the conformational 
flexibility of the peptide. Inspiration for this comes from Chen et al. who incorporated fastener 
residues into the pro-domain of activin A. Highly conserved across the latent TGF-βs, fastener residues 
occur in the α1-helix, shoulder region and mature domains that, through a network of interactions 
with one another, reduce the conformational flexibility of the α1-helix. This stabilises binding of the 
pro-domain to the mature domain. Though H1LH2 does not contain the region where the majority of 
these residues lie, “locking” H1LH2 through another mechanism may result in an increase in inhibitor 
potency. The most promising site to do this would be between the α1-helix and the loop. This is the 
region in which most of the crucial interactions between H1LH2 and mature activin A occur, so 
conformationally restricting these residues may minimise the entropic penalty to binding. The most 
obvious method of “locking” the conformation would be the use of a chemical staple. Stapling has 
already been shown to improve potency in the myostatin system with the most potent peptide 
inhibitor of myostatin to date containing a diester staple.190 Though stapling resulted in a reduction in 
affinity when attempted in this thesis, this is likely due to the position or nature of the staple and more 
work is needed to explore the feasibility and benefit of stapling for activin-derived peptides. Analysis 
of the crystal structure suggests that K60 and K70 are the most promising sites to introduce a staple 
due to spatial proximity and lack of obvious interactions with the mature domain (Figure 41B). Thus, 
introducing a staple here may represents the next avenue for optimisation of the dimeric peptide 




Figure 41: Potential optimisations of H1LH2. A) Alignment of the Fs12-ActA structure to the representation of 
H1LH2 bound to mature activin A based on the pro-mature ActA complex. Here the Fs-ActA complex is shown in 
green/ white (mature activin A), and light brown (Fs2). B) The α2-helix of pro-activin A bound to mature activin 
A with residues K80, D337, and Y404 highlighted (left). H1LH2 bound to mature activin A with potential sites for 
stapling, K60 and K70, highlighted (right). 
5.5 Potential Applications of TGF-β Family Pro-domain Derived 
Peptides 
Overall, this project has demonstrated a rational method for designing and generating specific 
inhibitors of activin A and B signalling via a peptide approach, using the interacting motifs of activin 
A’s pro-domain as a basis for inhibitor design. To date, this represents only the third member of the 
TGF-β family for which a pro-domain derived peptide approach has been thoroughly investigated, 
along with myostatin and inhibin (the concentrations tested for the GDF11 derived peptide were 
significantly lower than those reported in this thesis or Takayama et al. for pro-domain derived 
peptides).106,189,191 As such, there is potential for expansion of this methodology to other members of 
the family. In the case of the myostatin, inhibin and activin A, specificity was high with only very closely 
related ligands being inhibited in each case. It is still highly difficult to generate specific inhibitors for 
TGF-β family signalling, so this approach represents a viable means of achieving this. Expansion to the 
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wider TGF-β family could result in therapeutic applications. TGF-β signalling has been reported to have 
oncogenic effects in a number of cancers, facilitating epithelial-mesenchymal transitions, suppressing 
immune response, and aiding distal metastasis, and is thus an important clinical target.255 
Furthermore, though activin signalling is the main causative agent of FOP, the ossifying TGF-β proteins 
BMP2 and BMP4 have been observed to have elevated levels in FOP.256 Thus, using a pro-domain 
based peptide method to develop inhibitors for these proteins, combined with the H1LH2 activin 
peptides reported here could be a viable approach for developing FOP therapeutics. 
Furthermore, to the best of the author’s knowledge, this thesis represents the first reported 
application of the PKADD domain as a fusion partner to induce dimerization in a system outside of the 
PKA RIIα subunit itself. This could be especially important in developing inhibitors of other protein 
targets that contain two sites of interest that are appropriately spaced and oriented away from each 
other, including other TGF-β family members. Therefore, the work described here may aid in a greater 
understanding of TGF-β family signalling and represent a new approach for targeting multivalent 
systems.  
Comparing the two approaches taken in this thesis, It is clear that the peptide approach was much 
more successful than the small molecule approach. Whereas the small molecule approach failed to 
identify any molecules that bound to activin A with high affinity, the peptide approach not only 
identified peptides that bind activin A with high affinity but can also inhibit its signalling with 
nanomolar potency. Furthermore, due to the structural and sequence similarity between the mature 
domains TGF-β family members,  a peptide approach is much more likely to yield a specific inhibitor 
due to the larger number of interactions that can be fine-tuned for specificity. As such, based on the 
evidence presented here, I believe it would be much more prudent for a peptide-based approach to 
be taken rather than a small molecule approach when designing inhibitors that target other ligands in 










             
Material and Methods 




6.0  Materials 
All materials described in this thesis were obtained from the communal stocks of the Hyvönen Lab, 
University of Cambridge unless stated otherwise. All solutions and buffers were made from these 
stocks. 
6.1 Crystallisation of Mature Activin A 
Purified mature activin A for all experiments was kindly provided by Mrs Katharina Ravn. Screens were 
performed around the original conditions as described in Harrington et al. in a 24-well format.71 
Lyophilised mature activin A was resuspended in 20 % acetonitrile and pipetted onto a glass cover slip 
in a 1 μL : 1 μL with well solution. The slips were then placed over the wells of an XRL pater (Molecular 
Dimensions) 24 well plate containing 1 mL well solution and sealed with high vacuum grease (Dow 
Corning). Crystals of activin A of grew best in 1.65 M (NH4)2SO4, 4 % PEG 300, 100 mM Hepes pH 7.4, 
2 % DMSO, 3.6 mg/mL activin A. 
For crystals grown in a 96-well format, lyophilised mature activin A was resuspended in 20 % 
acetonitrile to a concentration of 3.6 mg/mL. The protein was then crystallised in 1.55 M (NH4)2SO4, 
100 mM Hepes pH 7.4, 4 % PEG 300, 8 % DMSO at a ratio of 200 nl well solution : 200 nl protein using 
a Mosquito Crystal (TTP Labtech) crystallization robot. Crystal drops were either set up in MRC 2 Well 
Crystallization Plates in UVP (Jena Bioscience) or 96-well 3-drop Swissci plates (Molecular Dimensions) 
for soaking at XChem facility.  
For crystals containing no PEG 300, a microseed stock was generated from mature activin A crystals 
grown as previously described. A crystal drop containing 5 or fewer crystals was added to 50 μL well 
solution in a tube containing a single Microseed Bead (Molecular Dimensions). The mixture was then 
vortexed in 3 × 30 s intervals with incubation on ice for 30 s in between. 96 well plates were then set 
up using a Mosquito Crystal (TTP Labtech) crystallization robot with a ratio of 200 nl protein (3.3 
mg/mL): 150 nl well solution (1.55 M (NH4)2SO4, 100 mM Hepes pH 7.4, 8% DMSO) : 50 nl microseed 
stock.  
In all cases crystals were allowed to grow for a minimum of 3 days at 18 °C before being flash cooled 
in liquid nitrogen at 98 K for storage before data collection. 
6.2 Structural determination of mature activin A crystals 
All crystals were shot using either the i03, i04-1, or i24 beamlines at the Diamond Light Source, 
Harwell, UK. Diffraction data was processed using the autoProc257 (Global Phasing) automatic data 
processing pipeline within IsPyB.258 All data was managed using CCP4i. Structures were solved using 
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molecular replacement with either 2ARV (DMSO structure) or the DMSO-containing  structure (all 
other datasets) as search model in using Phaser MR.259 Models were refined using refmac5260 and 
Coot.261 Ligands were modelled using Grade (Global Phasing). All crystals belonged to the space group 
I222.  
6.3 XChem Screening  
Crystals of mature activin A were soaked at with fragments of the DSPL, Kidd3D and Edelris Keymical 
Fragment libraries at concentrations of 25 mM/ 50 mM (library dependent) in DMSO using an ECHO 
acoustic liquid handler (Labcyte). Crystals were then allowed to equilibrate at 18 °C for 1 hour before 
being vitrified in liquid nitrogen at 98 K. Diffraction data  was then collected on the i04-1 beamline at 
the Diamond Light Source, Harwell, UK. Data was managed using XChemExplorer and the apo 
structure of mature activin A grown in 2 % DMSO was used as the model reference. Data was then 
processed using PanDDA Analyse as described in Pearce et al.142 and models refined using PanDDA 
Inspect.  
6.4 Fragment soaking of mature activin A 
Compounds for fragment soaking were dissolved to a final concentration of 40 mM in 1.55 M 
(NH4)2SO4, 100 mM Hepes pH 7.4, 8% DMSO. 5 μL of this solution was added to wells containing 
mature activin A crystals and the crystals allowed to equilibrate for 1 hour at 18 °C. Crystals were then 
harvested and vitrified in liquid nitrogen at 98 K. 
6.5 Cloning of Peptide Fusions and Vectors 
To generate the vectors required in this project primers were designed such as to generate the DNA 
encoding the relevant tags and dimerization domains with appropriate 5  and 3  restriction sites 
(Appendix 3).  
pOP4BP was generated from the pOP5BP vector (http://hyvonen.bioc.cam.ac.uk/pOP-vectors/) with 
the C-terminal Avi Tag being replaced by a Strep-tag II. To achieve this, pOP5BP was restriction 
digested with XhoI and HindIII (New England Biolabs) to remove the Avi Tag from the vector, before 
being dephosphorylated with shrimp alkaline phosphatase (GE Healthcare) and purified using Gel 
Extraction (ThermoScientific). Primers encoding the Strep Tag II with appropriate 5  and 3  restriction 
sites were then mixed and heated to 98 °C for 60 s before allowing to cool to room temperature. The 
annealed primers were then phosphorylated using polynucleotide kinase and  ligated into the digested 
vector using Quick ligase (New England Biolabs). The resulting ligation mixture was transformed into 
50 μL of DH5α E.coli competent cells. Cells were grown overnight at 37 °C on agar plates containing 
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100 μg/mL ampicillin before a single colony from each plate was removed and added to 5 mL LB with 
100 μg/mL ampicillin. This mixture was then grown overnight at 37 °C with shaking.  Plasmid DNA was 
extracted from the pellet using a Miniprep Kit (ThermoScientific). DNA concentration was determined 
by measuring the absorbance at 260 nm using a NanoDrop 2000 (Thermoscientific). 
In the case of pOP6BPA and all peptide fusions, DNA encoding the various tags, fusion partners and 
pro-domain derived sequences were generated via PCR. Primers were designed containing 
appropriate 5  and 3  restriction sites (Restrictions sites used are listed alongside the primers in 
Appendix 3). PCR was performed using a template of pOP4BP (Strep-tag II + GB1 domain) and pGEX-
PKADD (PKADD domain) (provided by Dr. Katherine Stott) for pOP6BPA. To confirm the identity of PCR 
products, 5 μL product was analysed on a 1% agarose gel at 80 V for 50 minutes. PCR products were 
then purified via a PCR Purification Kit (ThermoScientific) before being ligated into appropriately 
digested pOP2H and transformed as described above. 
Similarly, PCR for the amplification of DNA encoding the peptides was performed using a template of  
pHAT2-pro-activin A (provided by Dr. Xuelu Wang,  Department of Biochemistry, University of 
Cambridge). Continuous fused helix peptides PCR was performed according to in vitro assembly 
cloning protocol described in García-Nafría et al. using pHAT2-pro-activin A and pOP6BPA as a 
template.262 Identity was confirmed, and the purified products were ligated into appropriately 
digested pOP4BP or pOP6BPA  depending on whether they were PKADD domain fusions or not. Again, 
transformation was performed as described above.  
All constructs were verified by DNA sequencing at Source Bioscience.  
6.6 Expression Tests 
Plasmids encoding the peptide fusions were  transformed into BL21 (DE3) cells and added to 4 mL LB 
with 100 μg/mL ampicillin before growing for 3 hours. 900 μL of each sample was then added to 100 
μL 80% glycerol and mixed thoroughly to generate glycerol stocks before storing at -80 °C. The 
remaining culture was then split into 3 × 1 mL samples and IPTG was added to a concentration of 400 
μM. The individual samples were then grown shaking at 16 °C overnight, 25 °C for 4 hours, and 37 °C 
for 3 hours respectively. 500 μL aliquots of each sample were then centrifuged at 17,000 × g for 3 mins 
and the supernatant removed. 50 μL of a lysis master mix (1 mL BugBuster, 5 μL Lysonase (Novagen)) 
was then added to each sample and vortexed thoroughly before being incubated at room temperature 
for 10 minutes. Samples were then centrifuged at 17,000 × g for 3 mins and the supernatant removed 
and kept for further analysis. The pellets were then resuspended in 20% lysis master mix and 
centrifuged at 17,000 × g for 3 mins and the supernatant removed. The pellets were then resuspended 
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in 20% lysis master mix taken forward for analysis via SDS-PAGE along with the initial supernatant 
after lysis. 
6.7 SDS-PAGE 
All proteins samples were analysed via SDS-PAGE using 15 % polyacrylamide gels (acrylamide : 
bisacrylamaide = 37.5 : 1). Gel solution (5 ml) was polymerised (240) 10 % w/v ammonium persulfate 
(240 μl) in water and Tetramethylethylenediamine (150 μl). A 5 % stacking gel was similarly 
polymerised atop the 15% polyacrylamide gel to allow for sample loading. Samples were diluted 1:1 
with either non-reducing (125 mM Tris-HCl pH 6.8, 20% glycerol, 4% SDS, 0.02% bromophenol blue) 
or reducing (+ 8% β-mercaptoethanol) loading dye and heated to 95 °C for 5 minutes before 10 μL of 
each sample was loaded onto the gel and run for 55 minutes in 1× Laemmli Running Buffer (25 mM 
Tris HCl, 192 mM glycine, 0.1% w/v SDS) at 200 V, 400 mA. The gels were then stained for 60 minutes 
with Coomassie Blue Stain (0.1% w/v Coomassie Brilliant Blue R, 10% ethanol, 10% mL acetic acid) 
before destaining with 10% acetic acid. 
6.8 Large Scale Expression 
To express fusion proteins on a large scale, glycerol stocks of each fusion was streaked on ampicillin 
agar plates and incubated overnight at 37 °C. A single colony from each plate was then added to 10 
mL LB with 100 μg/mL ampicillin before being incubated at 37 °C shaking overnight. 10 mL of culture 
was then added to 1 L 2×YT with 100 μg/mL ampicillin and incubated shaking at 37 °C until an optical 
density of 0.7-1.0 was reached. IPTG was added to a final concentration of 400 μM IPTG and each 
sample was grown at 25 °C/ 37 °C shaking for a further 3/4 hours or overnight depending on the 
optimal temperature determined in the expression test. Cultures were then centrifuged at 4000 × g 
for 20 minutes at 4 °C and the supernatant removed. The pellet of each sample was then resuspended 
in 25 mL Resuspension Buffer (50 mM NaPi pH 7.0, 300 mM NaCl, 10 mM imidazole, 0.5 cOmplete 
mini EDTA free protease inhibitor cocktail tablet) and passed through a French press (Avestin) six times 
at approximately 5 MPa. Samples were then centrifuged at 16,600 × g for 30 minutes at 4 °C and the 
supernatant collected for purification. 
6.9 Metal Affinity Purification 
To purify the fusion proteins from the supernatant, the supernatant was then incubated with Ni-NTA 
agarose beads (Cube Biotech) at 4 °C for 1 hour. Beads were then loaded onto gravity flow columns 
and washed with 2 × 10 mL of Ni Wash Buffer (50 mM NaPi pH 7.0, 300 mM NaCl, 10 mM imidazole) 
followed by a further 3 mL wash. The protein was then eluted with 10 mL Ni Elution Buffer (50 mM 
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NaPi pH 7.0, 300 mM NaCl, 250 mM imidazole) and the sample was analysed via SDS-PAGE. Protein 
concentration was calculated by measuring absorbance at 280 nm using a NanoDrop 2000 
(ThermoScientific). Concentration was then determined via the Beer Lambert law using extinction 
coefficients as calculated by ProtParam (ExPASy).263 
Metal affinity purification was also performed GB1-H1LH2-SS and GB1-H1LH2-PKADDSS using a gravity 
flow column assembled as described above with an ÄKTApurifier (GE Healthcare). Samples loaded 
onto the column was purified using two buffers, Buffer A (50 mM NaPi pH 7.0, 300 mM NaCl, 10 mM 
imidazole) and Buffer B (50 mM NaPi pH 7.0, 300 mM NaCl, 500 mM imidazole), where an increasing 
concentration of Buffer B was used from 0% - 100%. 1 mL fractions were collected and the absorbance 
at 280 nm was measured. In the case of GB1-H1LH2-PKADDSS both Buffer A and Buffer B contained 6 
M urea and absorbance at 580 nm was also measured. Fractions were then analysed via SDS-PAGE. 
6.10 StrepTactin Affinity Purification 
Pooled elution fractions from the metal affinity purification (5 mL) were then added to 1 mL of 
StrepTactin Sepharose High Performance beads (GE Healthcare) suspended in 10 mL StrepTactin Wash 
Buffer (100 mM Tris HCl pH 8.0, 300 mM NaCl) and incubated for 1 hour at room temperature. The 
beads were then loaded onto gravity flow columns and washed with 2 × 10 mL of StrepTactin Wash 
Buffer before eluting with 5 mL StrepTactin Elution Buffer (100 mM Tris HCl pH 8.0, 300 mM NaCl, 2.5 
mM d-desthiobiotin). Samples were then buffer exchanged into 100 mM Tris HCl pH 8.0, 5 mM EDTA 
using a PD-10 column (GE Healthcare) and concentrated using an Amicon Ultra-15 centrifugal filter 
MWCO 3k or 10k (Millipore) as appropriate. 
6.11 Biolayer Interferometry 
Biolayer Interferometry experiments were performed using an Octet RED96 instrument (ForteBio). 
Anti-penta-HIS biosensors were regenerated 3 times in 10 mM glycine pH 1.7 followed by Kinetic 
Buffer (PBS, 0.1% BSA, 0.02% Tween 20) and baselined in Kinetic Buffer for 60 s. Peptide fusions at a 
concentration of 1 μg/mL in Kinetic Buffer were then loaded onto the sensors for 90 s. The loaded 
biosensors were then immersed in Kinetic Buffer for 60 s to establish a baseline before being 
immersed in a solution of mature activin A at 100 nM or 1 μM in Kinetic Buffer for 300 s to determine 
the association rate. The sensors were then moved back to the baseline position for 300 s to determine 
the dissociation rate. All experiments were performed at 30 °C. The data was then analysed using 
Prism 8 software (GraphPad) according to the equations as described by Motulsky.264 
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6.12 Isothermal Calorimetry 
Isothermal Calorimetry Experiments were performed using a Microcal iTC200 instrument (GE 
Healthcare). Peptide Fusions were exchanged into 100 mM Tris HCl pH 8.0, 5 mM EDTA to a 
concentration of approximately 100 μM for monomeric peptides or 50 μM for dimeric peptides. 
Lyophilised activin (250 μg) was resuspended in 100 μL of 10 mM HCl before being diluted to a 
concentration of approximately 4.5 μM in 400 μL of 100 mM Tris HCl pH 8.0, 5 mM EDTA, 3.2 μM BSA. 
The 200 μL of activin solution was then loaded into the cell and bubbles removed before loading the 
peptide 50 μL of cell solution into the syringe. The cell was then set to 25 °C and the stirring speed set 
to 750 rpm. The syringe was placed into the cell and the cell was allowed to equilibrate until the 
measured power difference between the experimental and references cells was > 0.4 μcal/s. The 
experiment was then run according to the following protocol. 
Injection Volume / μL Spacing / s 
1 0.2 240 
2-20 2 240 
Data analysis was performed using Origin 7.0 software (Origin). After initial analysis, ligand 
concentration was adjusted to give a stoichiometry of the nearest whole number if the original 
stoichiometry was within 0.2 of that number. Kd was then determined from these adjusted values. 
In the case of synthetic peptides, the syringe and cell solutions also contained 2% DMSO. 
6.13 Luciferase Assays 
In order to measure IC50 values of the peptides, luciferase assays were performed. HEK293T cells were 
cultured in DMEM (Life Technologies) + 10% v/v Foetal Calf Serum (Life Technologies) in a 37 °C in a 
humidified incubator with 5% CO2 until a confluency of 80% was achieved. The cells were then diluted 
to a density of 8 × 104 cells and 100 μL was added to every well of a polylysine (Sigma Aldrich) treated 
Nunc Microwell 96F plate (ThermoScientific) and incubated overnight as previously described. After 
24 hours, 33 ng of pGL3-CAGA (carrying the activin A responsive firefly luciferase gene) and 17 ng of 
pRL-SV40 (Promega) (with constitutively expressed renilla luciferase) were added to every well with 
200 nl of FuGENE HD (Promega) to transfect the cells. After a further 24 hours each well was washed 
with 100 μL PBS (Sigma Aldrich) and cultured in DMEM containing 0.5 % FCS and 100 pM activin. Each 
well contained peptide fusion with concentrations ranging from 90 pM to 20 μM and each fusion was 
analysed in triplicate. Three wells were additionally cultured using 100 pM activin A without inhibitor 
and three wells were cultured without activin or inhibitor. The cells were then incubated for 8 hours 
before washing with 100 μL PBS and lysed with shaking using 20 μL of Passive Lysis Buffer (Promega) 
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for 15 minutes. 5 μL from each well was then added to a 384 well low volume assay plate (Corning). 
Each well was injected with 25 μL of either firefly or renilla luciferase substrate using a Pherastar plate 
reader (BMG Labtech) and luminescence was recorded. The ratio of firefly to renilla response was then 
determined and this ratio was normalised to the average ratio in 3 wells that contained 100 pM activin 
A only and 3 wells that contained no activin A. Data was then analysed using Prism 8 (GraphPad) 
For activin B, myostatin, and BMP2, concentrations of 80 pM, 250 pM, and 2.5 nM were used 
respectively.  
6.14 SEC-MALS analysis 
SEC-MALS analysis was performed using a Superdex 75 increase 10/300 column (GE Healthcare), 
connected to the DWAN Helios light scattering detector (Wyatt Technology) and the Optilab T-rEX 
refractive index detector (Wyatt technology). The system was equilibrated overnight in StrepTactin 
Wash Buffer (100 mM Tris pH 8.0, 300 nM NaCl) and calibrated using BSA (Sigma Aldrich). After 
calibration, 50 μL of protein sample at a concentration of 2.5 mg/mL were analysed and the 
experimental data was processed using ASTRA (Wyatt Technology) software. 
6.15 CuSO4 catalysed disulfide formation of GB1-H1HL2 -SS and GB1-H1HL2-PKADDSS 
5 mL StrepTactin purified protein was incubated with 1 mM CuSO4 at 4 °C with exposure to air 
overnight. Urea was then added to the samples to a final concentration of 6 M. Samples were then 
purified using metal affinity purification via an ÄKTApurifier (GE Healthcare) as described above.  
6.16 Mass Spectrometry 
All mass spectrometry experiments described in this thesis were performed via MALDI-ToF by Dr. Mike 
Deery or Dr. Anja Andrejeva at the Cambridge Centre for Proteomics, Cambridge Systems Biology 
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8.1 Appendix 1: Crystallographic Statistics from Data Collection and 
Refinement 
The statistics generated from the crystallographic data collection and structural refinement of the 
DMSO, PEGless, and NM466 and TR17 soaked structures reported in this thesis (Table 18). All 
beamlines used were at the Diamond Light Source, Harwell, UK. Values in parentheses denote the 
high-resolution shell. 
Table 18: Data collection and refinement statistics for all structures reported in this thesis (excluding those 
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63.43 96.41 118.11 / 90 90 90 





















63.21 95.35 117.98 / 90 90 90 




















64.25 96.95 120.27 / 90 90 90 




















64.05 96.94 117.24 / 90 90 90 







8.2 Appendix 2: Expression Construct Protein Sequences 
Here are listed the protein sequences of all peptide fusions described and used in this thesis. For 
clarity, His-tags are highlighted in cyan, GB1 domains in pink, activin derived peptides in green, PKADD 
domains in teal, and Strep-tag IIs in grey. Cysteine residues are highlighted in yellow. The extinction 










































































































































ε280 = 36900 mol-1dm3cm-1  
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8.3 Appendix 3: PCR Oligonucleotide Sequences 
Here are listed the DNA sequences of the primers used to generate all vectors and constructs used in 
this thesis. In each case, all primers are shown 5 -3 . The restriction enzyme used for restriction digest 
is also included in parentheses and the restriction site highlighted in yellow. In some cases primers 
from a previous section will have been used to amplify the desired sequence. For, clarity primer 
combinations will be listed at the bottom (Table 19). 



































































































Table 19: Primer combinations.  
Construct Forward Primer Reverse Primer Additional Primers Vector 
Cloned 
into 
Strep-tag II ST2_FP ST2_RP  pOP5BP 
H1LH2β 4Q51_FP 4E104_RP  pOP4BP 
H1LH2 4Q51_FP 4H91_RP  pOP4BP 
LH2β 4K69_FP 4E104_RP  pOP4BP 
H2β 4Q76_FP 4E104_RP  pOP4BP 
H1L 4Q51_FP 4Q76_RP  pOP4BP 
H1 4Q51_FP 4H67_RP  pOP4BP 
P52-Q76 4P52_FP 4Q76_RP  pOP4BP 
E53-Q76 4E53_FP 4Q76_RP  pOP4BP 
M54-Q76 4M54_FP 4Q76_RP  pOP4BP 
V55-Q76 4V55_FP 4Q76_RP  pOP4BP 
E56-Q76 4E56_FP 4Q76_RP  pOP4BP 
Q51-R71 4Q51_FP 4R71_RP  pOP4BP 
Q51-P72 4Q51_FP 4P72_RP  pOP4BP 
Q51-D73 4Q51_FP 4D73_RP  pOP4BP 
Q51-V74 4Q51_FP 4V74_RP  pOP4BP 
Q51-T75 4Q51_FP 4T75_RP  pOP4BP 
E53-P72 4E53_FP 4P72_RP  pOP4BP 
E53-P72M54Y 4E53_M54Y_FP 4P72_RP  pOP4BP 
E53-P72M54W 4E53_M54W_FP 4P72_RP  pOP4BP 
E53-P72V58I 4E53_V58I_FP 4P72_RP  pOP4BP 
E53-P72V58L 4E53_V58L_FP 4P72_RP  pOP4BP 
E53-P72V55Y 4E53_V55Y_FP 4P72_RP  pOP4BP 
Strep-tag II – 
GB1  
ST2GB1_FP GB1_RP  pOP2H 
PKADD PKADD_FP PKADD_RP  pOP2H 
H1LH2 6Q51_FP 6H91_RP  pOP6BPA 


































H1LH2-SS 4Q51_FP 4H91_GSCGS_RP   






8.4 Appendix 4: ITC Isotherms and Thermograms for the Interaction 
between the Synthetic Peptides / Mutant Minimal Peptide 
Fusions with Activin A 
Here are shown all the isotherms and thermograms for the binding of the interaction between mature 
activin A and the synthetic peptides and the mutant peptides based on GB1-E53-P72, as determined 
via ITC. Here mut corresponds to the mutations V58I and H61F. St corresponds to a N-(4,6-divinyl-
1,3,5-triazin-2-yl)-N-methylglycine staple. 
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